<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">84566</article-id><article-id pub-id-type="doi">10.7554/eLife.84566</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Multi-centre analysis of networks and genes modulated by hypothalamic stimulation in patients with aggressive behaviours</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-131787"><name><surname>Gouveia</surname><given-names>Flavia Venetucci</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0029-1269</contrib-id><email>fvenetucci@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-131788"><name><surname>Germann</surname><given-names>Jurgen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0995-8226</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-314548"><name><surname>Elias</surname><given-names>Gavin JB</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-260449"><name><surname>Boutet</surname><given-names>Alexandre</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-271202"><name><surname>Loh</surname><given-names>Aaron</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-297249"><name><surname>Lopez Rios</surname><given-names>Adriana Lucia</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-297250"><name><surname>Torres Diaz</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-297251"><name><surname>Contreras Lopez</surname><given-names>William Omar</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-131799"><name><surname>Martinez</surname><given-names>Raquel Chacon Ruiz</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-111883"><name><surname>Fonoff</surname><given-names>Erich Talamoni</given-names></name><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-297253"><name><surname>Benedetti-Isaac</surname><given-names>Juan Carlos</given-names></name><xref ref-type="aff" rid="aff14">14</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-297254"><name><surname>Giacobbe</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="aff" rid="aff16">16</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-297255"><name><surname>Arango Pava</surname><given-names>Pablo M</given-names></name><xref ref-type="aff" rid="aff17">17</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-297256"><name><surname>Yan</surname><given-names>Han</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff18">18</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-271191"><name><surname>Ibrahim</surname><given-names>George M</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff18">18</xref><xref ref-type="aff" rid="aff19">19</xref><xref ref-type="aff" rid="aff20">20</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-297257"><name><surname>Lipsman</surname><given-names>Nir</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-314561"><name><surname>Lozano</surname><given-names>Andres</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-297258"><name><surname>Hamani</surname><given-names>Clement</given-names></name><email>clement.hamani@sunnybrook.ca</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04374qe70</institution-id><institution>Neuroscience and Mental Health, Hospital for Sick Children Research Institute</institution></institution-wrap><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff2"><label>2</label><institution>Sunnybrook Research Institute</institution><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r5mk904</institution-id><institution>Division of Neuroscience, Sírio-Libanês Hospital</institution></institution-wrap><addr-line><named-content content-type="city">São Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042xt5161</institution-id><institution>Division of Neurosurgery, Department of Surgery, University Health Network</institution></institution-wrap><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dbr7087</institution-id><institution>Division of Neurosurgery, Department of Surgery, University of Toronto</institution></institution-wrap><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dbr7087</institution-id><institution>Joint Department of Medical Imaging, University of Toronto</institution></institution-wrap><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02d61wv82</institution-id><institution>Department of Functional and Stereotactic Neurosurgery, University Hospital San Vicente Fundación</institution></institution-wrap><addr-line><named-content content-type="city">São Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff8"><label>8</label><institution>Department of Functional and Stereotactic Neurosurgery, San Vicente Fundación</institution><addr-line><named-content content-type="city">Barranquilla</named-content></addr-line><country>Colombia</country></aff><aff id="aff9"><label>9</label><institution>Department of Neurosurgery, University Hospital La Princesa</institution><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00gkhpw57</institution-id><institution>Nemod Research Group, Universidad Autónoma de Bucaramanga</institution></institution-wrap><addr-line><named-content content-type="city">Bucaramanga</named-content></addr-line><country>Colombia</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wnzzd87</institution-id><institution>Division of Functional Neurosurgery, Department of Neurosurgery, FOSCAL Clinic</institution></institution-wrap><addr-line><named-content content-type="city">Bucaramanga</named-content></addr-line><country>Colombia</country></aff><aff id="aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036rp1748</institution-id><institution>LIM 23, Institute of Psychiatry, School of Medicine, University of São Paulo</institution></institution-wrap><addr-line><named-content content-type="city">São Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036rp1748</institution-id><institution>Department of Neurology, Integrated Clinic of Neuroscience, School of Medicine, University of São Paulo</institution></institution-wrap><addr-line><named-content content-type="city">São Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff14"><label>14</label><institution>Stereotactic and Functional Neurosurgery Division of the International Misericordia Clinic</institution><addr-line><named-content content-type="city">Barranquilla</named-content></addr-line><country>Canada</country></aff><aff id="aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03wefcv03</institution-id><institution>Harquail Centre for Neuromodulation, Sunnybrook Health Sciences Centre</institution></institution-wrap><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dbr7087</institution-id><institution>Department of Psychiatry, University of Toronto</institution></institution-wrap><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff17"><label>17</label><institution>Servicio de Neuocirugia Funcional y Esterotaxia, Clinica Comuneros Bucaramanga, Clinica Desa y Clinica Dime Neurocardiovascular de Cali; Clinica Nueva del Lago</institution><addr-line><named-content content-type="city">Bucaramanga</named-content></addr-line><country>Colombia</country></aff><aff id="aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04374qe70</institution-id><institution>Division of Neurosurgery, The Hospital for Sick Children</institution></institution-wrap><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dbr7087</institution-id><institution>Institute of Biomedical Engineering, University of Toronto</institution></institution-wrap><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dbr7087</institution-id><institution>Institute of Medical Science, University of Toronto</institution></institution-wrap><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Forstmann</surname><given-names>Birte U</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04dkp9463</institution-id><institution>University of Amsterdam</institution></institution-wrap><country>Netherlands</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Frank</surname><given-names>Michael J</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05gq02987</institution-id><institution>Brown University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>22</day><month>05</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e84566</elocation-id><history><date date-type="received" iso-8601-date="2022-10-29"><day>29</day><month>10</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-05-14"><day>14</day><month>05</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-11-01"><day>01</day><month>11</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.10.29.22281666"/></event></pub-history><permissions><copyright-statement>© 2023, Gouveia, Germann et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Gouveia, Germann et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-84566-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-84566-figures-v2.pdf"/><abstract><p>Deep brain stimulation targeting the posterior hypothalamus (pHyp-DBS) is being investigated as a treatment for refractory aggressive behavior, but its mechanisms of action remain elusive. We conducted an integrated imaging analysis of a large multi-centre dataset, incorporating volume of activated tissue modeling, probabilistic mapping, normative connectomics, and atlas-derived transcriptomics. Ninety-one percent of the patients responded positively to treatment, with a more striking improvement recorded in the pediatric population. Probabilistic mapping revealed an optimized surgical target within the posterior-inferior-lateral region of the posterior hypothalamic area. Normative connectomic analyses identified fiber tracts and functionally connected with brain areas associated with sensorimotor function, emotional regulation, and monoamine production. Functional connectivity between the target, periaqueductal gray and key limbic areas – together with patient age – were highly predictive of treatment outcome. Transcriptomic analysis showed that genes involved in mechanisms of aggressive behavior, neuronal communication, plasticity and neuroinflammation might underlie this functional network.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>deep brain stimulation</kwd><kwd>hypothalamus</kwd><kwd>aggressive behaviour</kwd><kwd>imaging connectomics</kwd><kwd>imaging transcriptomics</kwd><kwd>magnetic resonance imaging</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Canadian Institutes for Health Research</institution></institution-wrap></funding-source><award-id>72484</award-id><principal-award-recipient><name><surname>Gouveia</surname><given-names>Flavia Venetucci</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundacao de Amparo a Pesquisa do Estado de Sao Paulo</institution></institution-wrap></funding-source><award-id>13/20602-5</award-id><principal-award-recipient><name><surname>Gouveia</surname><given-names>Flavia Venetucci</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundacao de Amparo a Pesquisa do Estado de Sao Paulo</institution></institution-wrap></funding-source><award-id>17/10466-8</award-id><principal-award-recipient><name><surname>Gouveia</surname><given-names>Flavia Venetucci</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>Canadian Institutes for Health Research</institution></institution-wrap></funding-source><award-id>471913</award-id><principal-award-recipient><name><surname>Germann</surname><given-names>Jurgen</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundacao de Amparo a Pesquisa do Estado de Sao Paulo</institution></institution-wrap></funding-source><award-id>11/08575-7</award-id><principal-award-recipient><name><surname>Martinez</surname><given-names>Raquel Chacon Ruiz</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Integrated imaging analysis of a large multi-center dataset showed that treatment of refractory aggressive behavior with hypothalamic deep brain stimulation is highly effective with specific clinical and neuroimaging features associated with treatment success.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Aggressive behaviors are highly prevalent among psychiatric patients, presenting a major obstacle to patient care. In addition to suffering, these symptoms constitute a leading cause for institutionalization <xref ref-type="bibr" rid="bib44">Gouveia et al., 2021a</xref>; <xref ref-type="bibr" rid="bib12">Brentani et al., 2013</xref>; <xref ref-type="bibr" rid="bib42">Gouveia et al., 2019</xref>. Standard treatments for aggressive behaviors involve behavioral and pharmacological therapies that mainly act on the dopaminergic and serotonergic systems (e.g. serotonin reuptake inhibitors, antipsychotics) <xref ref-type="bibr" rid="bib44">Gouveia et al., 2021a</xref>; <xref ref-type="bibr" rid="bib12">Brentani et al., 2013</xref>; <xref ref-type="bibr" rid="bib42">Gouveia et al., 2019</xref>⁠. Despite their efficacy, a substantial proportion (30%) of patients fail to respond and are considered to be treatment refractory <xref ref-type="bibr" rid="bib1">Adler et al., 2015</xref>; <xref ref-type="bibr" rid="bib43">Gouveia et al., 2020</xref>; <xref ref-type="bibr" rid="bib45">Gouveia et al., 2021b</xref>. For these patients, neuromodulation therapies, such as deep brain stimulation (DBS), have been investigated <xref ref-type="bibr" rid="bib42">Gouveia et al., 2019</xref>; <xref ref-type="bibr" rid="bib46">Gouveia et al., 2021c</xref>; <xref ref-type="bibr" rid="bib17">Contreras Lopez et al., 2021</xref>; <xref ref-type="bibr" rid="bib10">Benedetti-Isaac et al., 2015</xref>; <xref ref-type="bibr" rid="bib96">Torres et al., 2020</xref>; <xref ref-type="bibr" rid="bib75">Micieli et al., 2017</xref>; <xref ref-type="bibr" rid="bib68">López Ríos et al., 2023</xref>. DBS is a neurosurgical therapy in which implanted electrodes are used to adjustably deliver electrical current to specific brain targets <xref ref-type="bibr" rid="bib57">Jakobs et al., 2019</xref>. It is an established therapy for Parkinson’s Disease, dystonia, essential tremor, epilepsy <xref ref-type="bibr" rid="bib88">Salanova et al., 2021</xref> and obsessive-compulsive disorder <xref ref-type="bibr" rid="bib51">Hamani et al., 2014</xref>; <xref ref-type="bibr" rid="bib66">Li et al., 2020</xref>, showing promising results for the treatment of several other neuropsychiatric disorders, including Alzheimer’s disease <xref ref-type="bibr" rid="bib40">Germann et al., 2021a</xref>; <xref ref-type="bibr" rid="bib70">Lozano et al., 2016</xref>, depression, anorexia nervosa, addiction, and posttraumatic stress disorder <xref ref-type="bibr" rid="bib27">Elias et al., 2021</xref>; <xref ref-type="bibr" rid="bib69">Lozano et al., 2008</xref>; <xref ref-type="bibr" rid="bib22">De Vloo et al., 2021</xref>; <xref ref-type="bibr" rid="bib29">Elias et al., 2022</xref>; <xref ref-type="bibr" rid="bib52">Hamani et al., 2022</xref>; <xref ref-type="bibr" rid="bib19">Davidson et al., 2022</xref>.</p><p>To date, DBS for refractory aggressive behavior has primarily targeted the posterior hypothalamic region <xref ref-type="bibr" rid="bib42">Gouveia et al., 2019</xref>; <xref ref-type="bibr" rid="bib46">Gouveia et al., 2021c</xref>; <xref ref-type="bibr" rid="bib17">Contreras Lopez et al., 2021</xref>; <xref ref-type="bibr" rid="bib10">Benedetti-Isaac et al., 2015</xref>; <xref ref-type="bibr" rid="bib96">Torres et al., 2020</xref>; <xref ref-type="bibr" rid="bib75">Micieli et al., 2017</xref>; <xref ref-type="bibr" rid="bib68">López Ríos et al., 2023</xref>. The hypothalamus is a diencephalic structure with well-established roles in the control of homeostasis and motivated behaviors and is a key area in a broader neurocircuitry regulating aggressive behavior that also involves the orbitofrontal cortex, hippocampus, amygdala and periaqueductal gray <xref ref-type="bibr" rid="bib23">Dudás, 2013</xref>; <xref ref-type="bibr" rid="bib11">Blair, 2016</xref>; <xref ref-type="bibr" rid="bib77">Miczek et al., 2007</xref>. Along the anterior-posterior axis, the hypothalamus can be divided into three regions (i.e. supraoptic or anterior, tuber cinereum or medial and supramamillary or posterior) with distinct cell types, projections and functions <xref ref-type="bibr" rid="bib23">Dudás, 2013</xref>; <xref ref-type="bibr" rid="bib9">Beattie et al., 1930</xref>. While the anterior region is mainly involved in thermoregulation and the control of circadian rhythms, the medial region regulates feeding and sexual behavior and plays a critical role in several endocrine and autonomic processes <xref ref-type="bibr" rid="bib23">Dudás, 2013</xref>; <xref ref-type="bibr" rid="bib55">Hoff, 1950</xref>; <xref ref-type="bibr" rid="bib33">Flament-Durand, 1980</xref>. The posterior hypothalamus (pHyp) is an ergotropic area involved in the generation of sympathetic responses <xref ref-type="bibr" rid="bib54">Hess, 1945</xref>. It provides robust projections to the midbrain and reticular formation via the hypothalamotegmental tract, thus being critical in the regulation of wakefulness and stress responses <xref ref-type="bibr" rid="bib9">Beattie et al., 1930</xref>; <xref ref-type="bibr" rid="bib64">Lechan and Toni, 2016</xref>; <xref ref-type="bibr" rid="bib91">Saper and Lowell, 2014</xref>. Indeed, lesions (e.g. hamartomas and gliomas) located at the pHyp have been reported to cause apathetic and somnolent symptoms, while the selective neurosurgical ablation of a small portion of the pHyp has been successfully used to treat patients with severe treatment-resistant aggressive behavior (for a detailed review, see <xref ref-type="bibr" rid="bib42">Gouveia et al., 2019</xref>; <xref ref-type="bibr" rid="bib89">Sano et al., 1966</xref>; <xref ref-type="bibr" rid="bib90">Sano and Mayanagi, 1988</xref>).</p><p>More recently, DBS of the pHyp (pHyp-DBS) has also been shown to reduce aggressive symptoms in humans, with variable outcomes <xref ref-type="bibr" rid="bib46">Gouveia et al., 2021c</xref>; <xref ref-type="bibr" rid="bib17">Contreras Lopez et al., 2021</xref>; <xref ref-type="bibr" rid="bib10">Benedetti-Isaac et al., 2015</xref>; <xref ref-type="bibr" rid="bib96">Torres et al., 2020</xref>; <xref ref-type="bibr" rid="bib38">Franzini et al., 2010</xref>; <xref ref-type="bibr" rid="bib95">Torres et al., 2013</xref>; <xref ref-type="bibr" rid="bib68">López Ríos et al., 2023</xref>. At present, only 21patients diagnosed with autism spectrum disorder (ASD), intellectual disability, obsessive-compulsive disorder, epilepsy and schizophrenia with ages ranging from 10 to 51 years have been reported, mostly as individual cases or small case series. In these patients, long-term improvement (up to several years of follow-up) in aggressive behaviors was in the order of 38–100% compared to baseline <xref ref-type="bibr" rid="bib46">Gouveia et al., 2021c</xref>; <xref ref-type="bibr" rid="bib17">Contreras Lopez et al., 2021</xref>; <xref ref-type="bibr" rid="bib10">Benedetti-Isaac et al., 2015</xref>; <xref ref-type="bibr" rid="bib96">Torres et al., 2020</xref>; <xref ref-type="bibr" rid="bib75">Micieli et al., 2017</xref>; <xref ref-type="bibr" rid="bib68">López Ríos et al., 2023</xref>. Although case studies and small series provide valuable insight into the safety and therapeutic impact of pHyp-DBS in individual patients, they do not allow the characterization of clinical phenotypes, optimal stimulation targets or brain networks underlying treatment.</p><p>In this work, we gathered data from the largest international multi-centre dataset of patients treated to date with pHyp-DBS for aggressive behaviors to retrospectively investigate possible neurobiological mechanisms of action. Combining a well-documented electrode localization and volume of activated tissue (VAT) modeling pipeline (<ext-link ext-link-type="uri" xlink:href="https://www.lead-dbs.org/">https://www.lead-dbs.org/</ext-link>) with probabilistic sweet-spot mapping <xref ref-type="bibr" rid="bib27">Elias et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Dembek et al., 2017</xref>, normative connectomics <xref ref-type="bibr" rid="bib37">Fox, 2018</xref>; <xref ref-type="bibr" rid="bib26">Elias et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Germann et al., 2021b</xref>, and transcriptomics analysis <xref ref-type="bibr" rid="bib44">Gouveia et al., 2021a</xref>; <xref ref-type="bibr" rid="bib79">Mroczek et al., 2021</xref> (<ext-link ext-link-type="uri" xlink:href="https://alleninstitute.org/">https://alleninstitute.org/</ext-link>), we delineated a potentially ‘optimized’ surgical target and identified the brain networks and underlying neurobiological processes that might underpin successful pHyp-DBS. Demographic data, pre-and post-operative magnetic resonance imaging (MRI) and computed tomography (CT) scans were obtained from each participant for DBS lead localization, followed by an estimation of the VAT and the determination of the most effective region of stimulation. The VATs were further processed for connectomic analyses to investigate the structural (i.e. fiber tracts) and functional (i.e. brain areas) maps associated with symptom improvement. Using demographics and individual functional connectivity, we tested a predictive model of improvement following pHyp-DBS. Finally, we investigated genes with a spatial pattern of distribution similar to the functional connectivity map to explore associated biological processes. A graphical summary of the methodology used in this study can be found in <xref ref-type="fig" rid="fig1">Figure 1</xref> and in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Illustration of the methodologies applied in this study.</title><p>Preoperative MRI scans were co-registered with the postoperative MRI/CT scan, followed by normalization to standard MNI152 space (<ext-link ext-link-type="uri" xlink:href="https://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009">https://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009</ext-link>). Individual DBS leads were manually localized in the posterior hypothalamic area (pHyp) in the patient space and normalized to MNI152 space. The estimation of the volume of activated tissue (VAT) was calculated based on individual stimulation parameters using Lead-DBS (<ext-link ext-link-type="uri" xlink:href="https://www.lead-dbs.org/">https://www.lead-dbs.org/</ext-link> See <xref ref-type="table" rid="table1">Table 1</xref> for individual stimulation parameters). The patients’ VATs were further investigated for the analysis of the Voxel Efficacy Map (determination of the optimal stimulation site), Imaging Connectomics using Structural Connectivity Map (determining the streamlines involved in symptom improvement) and Functional Connectivity Map (determining the functionally connected areas involved in symptom improvement). For imaging Transcriptomics, we applied a Threshold Free Cluster Enhancement (TFCE) to the functional connectivity map. Functionally connected areas were averaged into the Harvard-Oxford Atlas (<ext-link ext-link-type="uri" xlink:href="http://www.cma.mgh.harvard.edu/">http://www.cma.mgh.harvard.edu/</ext-link>). Based on the human gene expression data from the Allen Human Brain Atlas (<ext-link ext-link-type="uri" xlink:href="https://alleninstitute.org/">https://alleninstitute.org/</ext-link>), genes with a spatial pattern distribution similar to the TFCE map were selected for further gene ontology analysis. 3D reconstruction of the DBS leads on a 100micron resolution, 7.0 Tesla FLASH brain (<ext-link ext-link-type="uri" xlink:href="https://openneuro.org/datasets/ds002179/versions/1.1.0">https://openneuro.org/datasets/ds002179/versions/1.1.0</ext-link>) in MNI152 space; the pHyp label was derived from a previously published high-resolution MRI atlas of the human hypothalamic region (<ext-link ext-link-type="uri" xlink:href="https://zenodo.org/record/3903588#.YHiE7pNKiF0">https://zenodo.org/record/3903588#.YHiE7pNKiF0</ext-link>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84566-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Method of generating functional connectivity maps.</title><p>This process involves the localization of the electrodes in each patient’s brain and the estimation of the volume of activated tissue (VAT) based on the stimulation parameters associated with symptom improvement. The VATs are then used as seeds for the generation of an individual r-map by correlating the BOLD time course of the VATs seed with the BOLD time course of all other voxels using the normative data of 1000subjects (Brain Genomics Superstruct Project dataset, <ext-link ext-link-type="uri" xlink:href="http://neuroinformatics.harvard.edu/gsp">http://neuroinformatics.harvard.edu/gsp</ext-link>). Individual r-maps are corrected for multiple comparisons to exclude voxels with potentially spurious correlations, resulting in an individual r-map that only included voxels surviving Bonferroni correction at the level of p&lt;0.05. Finally, to create group-level maps, a voxel-wise linear regression analysis is performed to investigate the relationship between the functional connectivity of the VATs and the individual clinical outcome, followed by permutation correction resulting in a significant group-level functional connectivity map (ppermute&lt;0.05). The MNI152 brain template was used for axial and three-dimensional brain images (<ext-link ext-link-type="uri" xlink:href="https://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009">https://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009</ext-link>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84566-fig1-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Patients included</title><p>In this retrospective study, we aggregated a large dataset of 33 patients from 5 centers treated with pHyp-DBS to alleviate intractable aggressive behaviors, characterized by self-injurious and extreme aggressive behaviors towards their surroundings and others (12 females and 21 males, 24.48±10.28 years of age ranging from 10 to 52y, <xref ref-type="fig" rid="fig2">Figure 2A–B</xref>). The most frequent diagnoses were epilepsy (pediatric: 50%, adult: 62%) and ASD (pediatric: 34%, adult: 24%). Intellectual disability was observed in all cases. This was described as severe in 82% of patients (pediatric: 75%, adult: 85%) and moderate in 18% of patients (pediatric: 25%, adult: 15%). <xref ref-type="table" rid="table1">Table 1</xref> presents demographic data. Clinical trials and individual cases were evaluated by the corresponding local ethics committee, and informed consent was obtained <xref ref-type="bibr" rid="bib46">Gouveia et al., 2021c</xref>; <xref ref-type="bibr" rid="bib17">Contreras Lopez et al., 2021</xref>; <xref ref-type="bibr" rid="bib10">Benedetti-Isaac et al., 2015</xref>; <xref ref-type="bibr" rid="bib96">Torres et al., 2020</xref>; <xref ref-type="bibr" rid="bib75">Micieli et al., 2017</xref>; <xref ref-type="bibr" rid="bib95">Torres et al., 2013</xref>; <xref ref-type="bibr" rid="bib68">López Ríos et al., 2023</xref>; . Surgical treatment was approved on a humanitarian basis, given the chronicity and severity of symptoms and the lack of response to conservative treatment.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Patient demographics and treatment outcome.</title><p>(<bold>A</bold>) Patients were divided in three main groups according to age: pediatric population (≤17years, 11 out of 33), young adults (18–30years, 14 out of 33) and older adults (31–52years, 8 out of 33). (<bold>B</bold>) Distribution of males (21 out of 33) and females (12 out of 33) in this study. (<bold>C</bold>) Patient distribution according to the percentage of symptomatic improvement (≤20: 3 out of 33; 21–40: 1 out of 33; 41–60: 7 out of 33; 61–80: 1 out of 33; 81–100: 21 out of 33). Note that the majority of individuals presented over 30% improvement following treatment (criteria for being considered a treatment responder), and a large proportion of patients presented an improvement greater than 80%. (<bold>D</bold>) Age at surgery was significantly negatively correlated with postoperative symptomatic improvement (<italic>R</italic>=–0.61; R2=0.38; *** p&lt;0.001). (<bold>E</bold>) There was no significant difference in the percentage of symptomatic improvement between male and female patients.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84566-fig2-v2.tif"/></fig><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Demographics.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="2">Case</th><th align="left" valign="bottom" rowspan="2">Sex</th><th align="left" valign="bottom" rowspan="2">Age range</th><th align="left" valign="bottom" rowspan="2">Improvement (%)</th><th align="left" valign="bottom" rowspan="2">Laterality</th><th align="left" valign="bottom" rowspan="2">DBS System</th><th align="left" valign="bottom" colspan="2">Stimulation Settings</th></tr><tr><th align="left" valign="bottom">Right</th><th align="left" valign="bottom">Left</th></tr></thead><tbody><tr><td align="left" valign="bottom">1</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">31–52</td><td align="left" valign="bottom">100</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3387</td><td align="left" valign="bottom">1.8V; 180Hz; 60msec</td><td align="left" valign="bottom">1.8V; 180Hz; 60msec</td></tr><tr><td align="left" valign="bottom">2</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">≤17</td><td align="left" valign="bottom">97</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3387</td><td align="left" valign="bottom">2.2V; 200Hz; 90msec</td><td align="left" valign="bottom">2.2V; 200Hz; 90msec</td></tr><tr><td align="left" valign="bottom">3</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">≤17</td><td align="left" valign="bottom">98</td><td align="left" valign="bottom">bilateral</td><td align="left" valign="bottom">Medtronic 3387</td><td align="left" valign="bottom">2.5V; 180Hz; 90msec</td><td align="left" valign="bottom">2.5V; 180Hz; 90msec</td></tr><tr><td align="left" valign="bottom">4</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">≤17</td><td align="left" valign="bottom">89</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3387</td><td align="left" valign="bottom">5.0V; 210Hz; 90msec</td><td align="left" valign="bottom">5.0V; 210Hz; 90msec</td></tr><tr><td align="left" valign="bottom">5</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">≤17</td><td align="left" valign="bottom">93</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3387</td><td align="left" valign="bottom">2.0V; 200Hz; 90msec</td><td align="left" valign="bottom">2.0V; 200Hz; 90msec</td></tr><tr><td align="left" valign="bottom">6</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">≤17</td><td align="left" valign="bottom">85</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3387</td><td align="left" valign="bottom">4.0V; 180Hz; 90msec</td><td align="left" valign="bottom">4.0V; 180Hz; 90msec</td></tr><tr><td align="left" valign="bottom">7</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">≤17</td><td align="left" valign="bottom">100</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3387</td><td align="left" valign="bottom">3.5V; 180Hz; 90msec</td><td align="left" valign="bottom">3.5V; 180Hz; 90msec</td></tr><tr><td align="left" valign="bottom">8</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">31–52</td><td align="left" valign="bottom">100</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3387</td><td align="left" valign="bottom">5.0V; 200Hz; 100msec</td><td align="left" valign="bottom">5.0V; 200Hz; 100msec</td></tr><tr><td align="left" valign="bottom">9</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">18–30</td><td align="left" valign="bottom">100</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3387</td><td align="left" valign="bottom">2.3V; 200Hz; 120msec</td><td align="left" valign="bottom">2.3V; 200Hz; 120msec</td></tr><tr><td align="left" valign="bottom">10</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">≤17</td><td align="left" valign="bottom">85</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3387</td><td align="left" valign="bottom">2.0V; 130Hz; 60msec</td><td align="left" valign="bottom">2.0V; 130Hz; 130msec</td></tr><tr><td align="left" valign="bottom">11</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">18–30</td><td align="left" valign="bottom">100</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3387</td><td align="left" valign="bottom">3.0V; 180Hz; 90msec</td><td align="left" valign="bottom">3.0V; 180Hz; 90msec</td></tr><tr><td align="left" valign="bottom">12</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">≤17</td><td align="left" valign="bottom">89</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3387</td><td align="left" valign="bottom">5.5V; 185Hz; 130msec</td><td align="left" valign="bottom">5.5V; 185Hz; 130msec</td></tr><tr><td align="left" valign="bottom">13</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">18–30</td><td align="left" valign="bottom">47</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3387</td><td align="left" valign="bottom">7.0V; 250Hz; 120msec</td><td align="left" valign="bottom">7.0V; 250Hz; 120msec</td></tr><tr><td align="left" valign="bottom">14</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">18–30</td><td align="left" valign="bottom">100</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3387</td><td align="left" valign="bottom">5.0V; 210Hz; 130msec</td><td align="left" valign="bottom">5.0V; 210Hz; 130msec</td></tr><tr><td align="left" valign="bottom">15</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">18–30</td><td align="left" valign="bottom">90</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3387</td><td align="left" valign="bottom">3.5V; 180Hz; 90msec</td><td align="left" valign="bottom">3.5V; 180Hz; 90msec</td></tr><tr><td align="left" valign="bottom">16</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">18–30</td><td align="left" valign="bottom">100</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3387</td><td align="left" valign="bottom">5.0V; 200Hz; 100msec</td><td align="left" valign="bottom">5.0V; 200Hz; 100msec</td></tr><tr><td align="left" valign="bottom">17</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">≤17</td><td align="left" valign="bottom">100</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3387</td><td align="left" valign="bottom">3.5V; 180Hz; 90msec</td><td align="left" valign="bottom">3.5V; 180Hz; 90msec</td></tr><tr><td align="left" valign="bottom">18</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">≤17</td><td align="left" valign="bottom">97</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3387</td><td align="left" valign="bottom">4.5V; 180Hz; 90msec</td><td align="left" valign="bottom">4.5V; 180Hz; 90msec</td></tr><tr><td align="left" valign="bottom">19</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">31–52</td><td align="left" valign="bottom">88</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3389</td><td align="left" valign="bottom">3.0V; 180Hz; 90msec</td><td align="left" valign="bottom">3.0V; 180Hz; 90msec</td></tr><tr><td align="left" valign="bottom">20</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">≤17</td><td align="left" valign="bottom">91</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3389</td><td align="left" valign="bottom">3.2V; 180Hz; 90msec</td><td align="left" valign="bottom">3.2V; 180Hz; 90msec</td></tr><tr><td align="left" valign="bottom">21</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">18–30</td><td align="left" valign="bottom">18</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3389</td><td align="left" valign="bottom">3.8V; 180Hz; 90msec</td><td align="left" valign="bottom">3.8V; 180Hz; 90msec</td></tr><tr><td align="left" valign="bottom">22</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">31–52</td><td align="left" valign="bottom">89</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3389</td><td align="left" valign="bottom">3.5V; 180Hz; 90msec</td><td align="left" valign="bottom">3.5V; 180Hz; 90msec</td></tr><tr><td align="left" valign="bottom">23</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">31–52</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3389</td><td align="left" valign="bottom">4.5V; 150Hz; 247msec</td><td align="left" valign="bottom">4.5V; 150Hz; 247msec</td></tr><tr><td align="left" valign="bottom">24</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">18–30</td><td align="left" valign="bottom">57</td><td align="left" valign="bottom">Unilateral</td><td align="left" valign="bottom">Medtronic 3389</td><td align="left" valign="bottom">0.3V; 150Hz; 450msec</td><td align="left" valign="bottom">Not applicable</td></tr><tr><td align="left" valign="bottom">25</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">31–52</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">Unilateral</td><td align="left" valign="bottom">Medtronic 3389</td><td align="left" valign="bottom">0.9V; 150Hz; 450msec</td><td align="left" valign="bottom">Not applicable</td></tr><tr><td align="left" valign="bottom">26</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">31–52</td><td align="left" valign="bottom">65</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3389</td><td align="left" valign="bottom">0.1V; 60Hz; 180msec</td><td align="left" valign="bottom">0.1V; 60Hz; 300msec</td></tr><tr><td align="left" valign="bottom">27</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">18–30</td><td align="left" valign="bottom">59</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3389</td><td align="left" valign="bottom">0.7V; 150Hz; 330msec</td><td align="left" valign="bottom">0.5V; 150Hz; 450msec</td></tr><tr><td align="left" valign="bottom">28</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">31–52</td><td align="left" valign="bottom">48</td><td align="left" valign="bottom">Unilateral</td><td align="left" valign="bottom">Medtronic 3389</td><td align="left" valign="bottom">0.1V; 150Hz; 450msec</td><td align="left" valign="bottom">Not applicable</td></tr><tr><td align="left" valign="bottom">29</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">18–30</td><td align="left" valign="bottom">100</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Medtronic 3387</td><td align="left" valign="bottom">2.0V; 180Hz; 120msec</td><td align="left" valign="bottom">2.0V; 180Hz; 120msec</td></tr><tr><td align="left" valign="bottom">30</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">18–30</td><td align="left" valign="bottom">50</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Boston, Vercise</td><td align="left" valign="bottom">1.0mA; 185Hz; 90msec</td><td align="left" valign="bottom">1.0mA; 185Hz; 90msec</td></tr><tr><td align="left" valign="bottom">31</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">18–30</td><td align="left" valign="bottom">50</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Boston, Vercise</td><td align="left" valign="bottom">1.2mA; 113Hz; 120msec</td><td align="left" valign="bottom">1.2mA; 113Hz; 120msec</td></tr><tr><td align="left" valign="bottom">32</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">18–30</td><td align="left" valign="bottom">36</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Boston, Vercise</td><td align="left" valign="bottom">1.0mA; 170Hz; 70msec</td><td align="left" valign="bottom">1.0mA; 170Hz; 70msec</td></tr><tr><td align="left" valign="bottom">33</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">18–30</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">Bilateral</td><td align="left" valign="bottom">Boston, Vercise</td><td align="left" valign="bottom">3mA; 185Hz; 60msec</td><td align="left" valign="bottom">3mA; 185Hz; 60msec</td></tr><tr><td align="left" valign="bottom" colspan="8">To preserve patients' anonymization, the diagnoses observed in this group are presented as the following list, from more to less frequent. Epilepsy, autism spectrum disorder, tuberous sclerosis, congenital rubella, intermittent explosive disorder, agenesia of the corpus callosum, schizophrenia, obsessive-compulsive disorder, West syndrome, Landau-Kleffner syndrome, Cri-du-chat syndrome, Lennox-Gastaut syndrome, Sotos syndrome, meningoencephalitis, perinatal hypoxia, periventricular leucomalacia, microcephaly, arteriovenous malformation.</td></tr></tbody></table></table-wrap><p>In all centers, patients were evaluated by a multidisciplinary healthcare team that reviewed all clinical and medication history. Patients were only considered for surgery when a consensus was reached that they indeed presented severe medication-resistant aggressive behavior (i.e. persistent severe symptomatology despite using multiple medications at well-established doses and duration). Whole-brain T1-weighted MRI was acquired preoperatively for surgical planning (1.5T MRI used in 14 cases at 3 centers, and 3T MRI used in 19 cases at 2 centers). Postoperative brain MRI and/or CT were obtained for confirmation of electrode localization. Aggressive behavior was assessed using standard questionnaires conducted by a neuropsychologist and answered by the parents/caregivers in all centers (i.e. Overt Aggressive Behaviour [OAS] used in 3 centers; Modified Overt Aggressive Behaviour [MOAS] used in 1 center; Inventory for Client and Agency Planning [ICAP] used in 1 center). Treatment response is reported as the percentage of improvement at the last follow-up relative to baseline (preoperative). Patients presenting more than 30% improvement were considered to be treatment responders.</p><p>pHyp-DBS was bilaterally implanted in 30 patients and unilaterally implanted in 3 using either Medtronic Activa (3387 leads in 19 cases and 3389 leads in 10 cases) or Boston Vercise DBS Systems (4 cases). Average stimulation parameters for the right hemisphere were 2.45V±1.76V (range 0.3–4.5V), 166.25Hz±18.87Hz (range 150–185Hz) and 219.25µsec ± 172.46µsec (range 60 to 450µsec). For the left hemisphere, average stimulation parameters were 3.17V±1.26V (range 2–4.5V), 171.67Hz±18.93Hz (range 150–185Hz) and 142.33µsec ± 95.48µsec (range 60 to 257µsec). Individual stimulation parameters are shown in <xref ref-type="table" rid="table1">Table 1</xref>.</p><p>After treatment, 91% (30 out of 33) of the patients were considered to be responders (&gt;30% decrease in validated scores compared to baseline) <xref ref-type="bibr" rid="bib1">Adler et al., 2015</xref>; <xref ref-type="bibr" rid="bib43">Gouveia et al., 2020</xref>; <xref ref-type="bibr" rid="bib45">Gouveia et al., 2021b</xref>; <xref ref-type="bibr" rid="bib10">Benedetti-Isaac et al., 2015</xref>. The average percentage of improvement was 75.25 ± 29.59% (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Younger patients were found to have a more pronounced benefit, with the pediatric population (patients ≤ 17 years of age) exhibiting greater symptom improvement compared to the adult population (93% vs 66%, <xref ref-type="fig" rid="fig2">Figure 2D</xref>). No differences were observed between males (75.57% ± 31.13%) and females (74.68% ± 28.00%; <xref ref-type="fig" rid="fig2">Figure 2E</xref>).</p></sec><sec id="s2-2"><title>Probabilistic sweet-spot mapping</title><p>To provide insight into the relationship between stimulation location and response to pHyp-DBS treatment, probabilistic maps of efficacious stimulation were generated using previously described methods <xref ref-type="bibr" rid="bib27">Elias et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Dembek et al., 2017</xref>. Briefly, preoperative MRI scans were co-registered to individual postoperative MRI/CT scans, normalized to standard MNI152 space for estimation of the VAT. Left-sided VATs were flipped at the sagittal plane, weighted by the corresponding percentage of improvement and the mean improvement of overlapping VATs was calculated at each voxel. These average maps were then thresholded for voxel-wise significance using a Wilcoxon signed rank test (p&lt;0.05). Additionally, to exclude outlier voxels, only those detected in&gt;10% of all maps were included. Finally, we performed nonparametric permutation testing, randomly assigning each clinical score to a VAT, as previously described <xref ref-type="bibr" rid="bib20">Dembek et al., 2017</xref>; <xref ref-type="bibr" rid="bib25">Eisenstein et al., 2014</xref>; <xref ref-type="bibr" rid="bib21">Dembek et al., 2019</xref>.</p><p>This analysis revealed greater symptom alleviation related to the stimulation of a more posterior-inferior-lateral region of the posterior hypothalamic area (<xref ref-type="fig" rid="fig3">Figure 3</xref>). This area encompassed 684 voxels associated with a behavioral improvement greater than 90%. The centroid of this highly efficacious area can be found at MNI152 space at the coordinates x=7.5, y=-15, z=−6.5 (<ext-link ext-link-type="uri" xlink:href="https://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009">https://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009</ext-link>) and in the Talairach-Tournoux space (<ext-link ext-link-type="uri" xlink:href="http://www.talairach.org/">http://www.talairach.org/</ext-link>) at coordinates x=6.5, y=-16, z=−1.5. The permutation test showed that this pattern indeed reflects the specific relationship of individual VATs with the individual outcome (p<sub>permute</sub> &lt;0.01).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Probabilistic Sweet-spot Mapping.</title><p>(<bold>A</bold>) The area of stimulation associated with greater symptomatic improvement (red) was located in the more posterior-inferior-lateral region of the posterior hypothalamic area (from left to right: sagittal, coronal and axial views). (<bold>B</bold>) The extent of the volumes of activated tissue (VATs) responsible for eliciting at least 50% improvement is shown in successive coronal MRI slices. All results are illustrated on slices of a 100micron resolution, 7.0 Tesla FLASH brain (<ext-link ext-link-type="uri" xlink:href="https://openneuro.org/datasets/ds002179/versions/1.1.0">https://openneuro.org/datasets/ds002179/versions/1.1.0</ext-link>) in MNI152 space (<ext-link ext-link-type="uri" xlink:href="https://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009">https://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009</ext-link>). The posterior hypothalamic nucleus (pHyp n.) label (shown in beige) was derived from a previously published high-resolution MRI atlas of the human hypothalamic region (<ext-link ext-link-type="uri" xlink:href="https://zenodo.org/record/3903588#.YHiE7pNKiF0">https://zenodo.org/record/3903588#.YHiE7pNKiF0</ext-link>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84566-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Localization of the probabilistic sweet spot mapping associated with at least 50% improvement in symptoms, in the posterior-inferior-lateral region of the posterior hypothalamic area, and in relation to the red nucleus and the subthalamic nucleus.</title><p>Note that a small portion of the map overlaps with the most superior part of the red nucleus, and no overlap with the subthalamic nucleus is observed. The labels for the Subthalamic nucleus and red nucleus are derived from a previously published high-resolution MRI atlas of the human hypothalamic region (<ext-link ext-link-type="uri" xlink:href="https://zenodo.org/record/3903588#.YHiE7pNKiF0">https://zenodo.org/record/3903588#.YHiE7pNKiF0</ext-link>), and illustrated in the MNI152 brain (<ext-link ext-link-type="uri" xlink:href="https://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009">https://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009</ext-link>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84566-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Comparison between two probabilistic sweet-spot maps performed considering amplitude (top panel, original analysis) and amplitude plus pulse width (bottom panel, additional analysis).</title><p>Note the striking similarity between maps, with the location and values of the peak corresponding to the most efficacious area for maximal symptom alleviation remaining unaltered, and only a few voxels on the periphery of the map changing in value by a couple of percentage points.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84566-fig3-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Normative connectomics analyses - structural and functional connectivity mapping</title><p>To investigate white matter tracts and brain networks associated with symptom improvement, normative structural and functional connectivity mapping were performed <xref ref-type="bibr" rid="bib37">Fox, 2018</xref>; <xref ref-type="bibr" rid="bib26">Elias et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Germann et al., 2021b</xref>. Structural connectivity mapping employed diffusion MRI-based tractography data sourced from Human Connectome Project subjects to identify streamlines that intersected individual VATs. Functional connectivity mapping used Genomics Superstruct Project-derived resting-state functional MRI information to generate voxel-wise correlation maps that reflected each VTA’s brain-wide functional connectivity. Subsequent statistical analyses were conducted to determine which streamlines and functional connectivity patterns were associated with positive treatment outcomes.</p><p>A variety of streamline bundles were identified by this analysis as being clinically relevant, such that VATs touching said streamlines corresponded to better outcomes than VATs that did not. These streamlines bundles may be divided into three main categories of function: I. Somatosensation (Medial Lemniscus and Spinothalamic Tract); II. Regulation of emotions (Amygdalofugal Pathway, Anterior Limb of the Internal Capsule, Medial Forebrain Bundle <xref ref-type="bibr" rid="bib84">Nieuwenhuys et al., 2007</xref>; <xref ref-type="bibr" rid="bib83">Nieuwenhuys et al., 1982</xref>); III. Motor Connections (Superior Cerebellar Peduncle, Rubrospinal tract, Frontopontine tract, Central Tegmental Tract, Medial-longitudinal Fasciculus, Motor Projections; <xref ref-type="fig" rid="fig4">Figure 4A–B</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Interestingly, when overlapping the voxel efficacy and the structural connectivity maps (<xref ref-type="fig" rid="fig4">Figure 4C</xref>), we observed that voxels associated with higher efficacy (in red) were more closely related to these fiber tracts.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Structural connectivity mapping.</title><p>(<bold>A</bold>) Magnetic resonance imaging (MRI) in the sagittal plane showing the fiber density of streamlines connected to the volumes of activated tissue (VATs) associated with significantly greater symptomatic improvement. (<bold>B</bold>) 3D reconstruction of the streamlines associated with significantly greater improvement illustrated on the MNI152 brain (<ext-link ext-link-type="uri" xlink:href="https://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009">https://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009</ext-link>); the posterior hypothalamic nucleus label (in red) was derived from a previously published high-resolution MRI atlas of the human hypothalamic region (<ext-link ext-link-type="uri" xlink:href="https://zenodo.org/record/3903588#.YHiE7pNKiF0">https://zenodo.org/record/3903588#.YHiE7pNKiF0</ext-link>). (<bold>C</bold>) MRI showing the relation between VATs responsible for eliciting at least 50% improvement and the fiber density map (from top to bottom: sagittal, coronal and axial views). The results presented in A and C are illustrated on a 100micron resolution, 7.0 Tesla FLASH brain (<ext-link ext-link-type="uri" xlink:href="https://openneuro.org/datasets/ds002179/versions/1.1.0">https://openneuro.org/datasets/ds002179/versions/1.1.0</ext-link>) in MNI152 space. Abbreviations: AFP: Amygdalofugal Pathway; ALIC: Anterior Limb of the Internal Capsule; CTT: Central-Tegmental Tract; FPT: Frontopontine Tract; MFB: Medial Forebrain Bundle; ML: Medial Lemniscus; MLF: Medial-Longitudinal Fasciculus; MP: Motor Projections; RBT: Rubrospinal Tract; SCP: Superior Cerebellar Peduncle; STT: Spino-Thalamic Tract.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84566-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Structural connectivity mapping.</title><p>Magnetic Resonance Imaging (MRI) in the sagittal (<bold>A</bold>), coronal (<bold>B</bold>) and axial (<bold>C</bold>) planes showing the fiber density of streamlines (pink scale) connected to the volumes of activated tissue (VATs) associated with significantly greater symptom improvement and voxels associated with at least 50% improvement in symptoms (spectrum scale), illustrated in the MNI152 brain (<ext-link ext-link-type="uri" xlink:href="https://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009">https://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009</ext-link>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84566-fig4-figsupp1-v2.tif"/></fig></fig-group><p>The functional connectivity analysis showed that the extent of VAT connectedness to several areas was significantly associated with clinical benefits. These areas are related to the production of monoamines (i.e. dorsal and medial raphe nuclei [serotonin]; substantia nigra [dopamine]; <xref ref-type="fig" rid="fig5">Figure 5</xref>) and are known to be components of the neurocircuitry of aggressive behavior (e.g. amygdala; nucleus accumbens, rostral anterior cingulate cortex; bed nucleus of the stria terminalis; hypothalamus; dorsal anterior cingulate cortex, insula, periaqueductal grey; <xref ref-type="fig" rid="fig5">Figure 5</xref>) <xref ref-type="bibr" rid="bib44">Gouveia et al., 2021a</xref>; <xref ref-type="bibr" rid="bib42">Gouveia et al., 2019</xref>; <xref ref-type="bibr" rid="bib43">Gouveia et al., 2020</xref>; <xref ref-type="bibr" rid="bib45">Gouveia et al., 2021b</xref>. Functional connectivity mapping after Threshold-Free Cluster Enhancement (TFCE) analysis FDR corrected at q&lt;0.0001 is presented in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Functional connectivity mapping.</title><p>Magnetic resonance imaging (MRI) in the axial plane showing areas found to have a positive (warm colors) or a negative (cold colors) correlation between clinical outcome and functional connectivity. Results are illustrated on a 100micron resolution, 7.0 Tesla FLASH brain in MNI152 space (<ext-link ext-link-type="uri" xlink:href="https://openneuro.org/datasets/ds002179/versions/1.1.0">https://openneuro.org/datasets/ds002179/versions/1.1.0</ext-link>). Abbreviations: ACC: Anterior Cingulate Cortex; BNST: Bed Nucleus of Stria Teminalis; LH: Lateral Hypothalamus; n.Acc: Nucleus Accumbens; OFC: Orbitofrontal Cortex; PAG: Periaqueductal Grey matter; Pe: Periventricular Hypothalamus; PVN: Paraventricular Hypothalamus; SN: Substantia Nigra; STN: Subthalamic Nucleus; VMH: Ventromedial Hypothalamus; ZI: Zona Incerta.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84566-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Threshold-free cluster enhancement functional connectivity mapping.</title><p>Magnetic resonance imaging (MRI) in the axial plane (<bold>A</bold>) and coronal plane (<bold>B</bold>) showing areas found to have a positive correlation between clinical outcome and functional connectivity (warm colors) or a negative correlation between outcome and functional connectivity (cold colors) FDR corrected at q&lt;0.0001. The results are illustrated in the MNI152 brain (<ext-link ext-link-type="uri" xlink:href="https://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009">https://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009</ext-link>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84566-fig5-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Estimation of clinical outcome</title><p>To investigate whether individual functional connectivity to particular hubs within the neurocircuitry of aggressive behavior could be used to estimate symptom improvement following pHyp-DBS, additive linear models were created. For this, we extracted individual connectivity values from the peak within each brain area where functional connectivity with the VATs was found to be significantly related to outcomes at the group level (as described in the Normative Connectomics Analyses, <xref ref-type="fig" rid="fig6">Figure 6A</xref>). The best-performing parsimonious model, which incorporated patient age as well as individual VAT functional connectivity, revealed the Periaqueductal Grey Matter (PAG) to be the only structure that, together with age, significantly predicted more than half of the variance in individual symptom improvement (<italic>R</italic>=0.72, R<sup>2</sup>=0.52, p=1.86e-05, <xref ref-type="fig" rid="fig6">Figure 6B</xref>, <xref ref-type="table" rid="table2">Table 2</xref>), retaining significance during leave-one-out cross-validation (LOOCV) (<italic>R</italic>=0.65, R<sup>2</sup>=0.42, p=4.406e-5; <xref ref-type="fig" rid="fig6">Figure 6C</xref>). Additionally, we investigated if functional connectivity of the VATs with any 2 brain areas, in addition to patient age, would improve the estimation of clinical outcome (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Indeed, connectivity with PAG and limbic structures, namely the amygdala (<italic>R</italic>=0.75, R<sup>2</sup>=0.57, p=4.20e-07), anterior cingulate cortex (rostral: <italic>R</italic>=0.76, R<sup>2</sup>=0.58, p=2.75e-07; dorsal: <italic>R</italic>=0.75, R<sup>2</sup>=0.57, p=3.96e-07), bed nucleus of the stria terminallis (<italic>R</italic>=0.76, R<sup>2</sup>=0.58, p=2.75e07), left nucleus accumbens (<italic>R</italic>=0.76, R<sup>2</sup>=0.58, p=8.51e-07), right orbitofrontal cortex (<italic>R</italic>=0.76, R<sup>2</sup>=0.58, p=2.75e-07) and right fusiform gyrus (<italic>R</italic>=0.75, R<sup>2</sup>=0.56, p=4.67e-07) was superior in predicting outcome.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Estimation of clinical outcome.</title><p>(<bold>A</bold>) Location of the peak extracted for each area found to have significant functional connectivity with the volume of activated tissue Illustrated in the coronal plane in MNI152 standard-space (<ext-link ext-link-type="uri" xlink:href="http://www.bic.mni.mcgill.ca/ServicesAtlases/HomePage">http://www.bic.mni.mcgill.ca/ServicesAtlases/HomePage</ext-link>). (<bold>B</bold>) A model using age and individual VAT connectivity to the periaqueductal gray significantly estimated individual symptom improvement in the whole dataset and (<bold>C</bold>) retained significance during leave-one-out cross-validation (LOOCV).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84566-fig6-v2.tif"/></fig><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Estimation of clinical outcome based on functional connectivity map and patient age.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Functionally connected brain area</th><th align="left" valign="top">Peak coordinate</th><th align="left" valign="top">R</th><th align="left" valign="top">R<sup>2</sup></th><th align="left" valign="top">p-value</th></tr></thead><tbody><tr><td align="left" valign="top">Periaqueductal Grey Matter</td><td align="left" valign="top">x=-1 y=-30 z=-10</td><td align="char" char="." valign="top">0.725</td><td align="char" char="." valign="top">0.525</td><td align="char" char="hyphen" valign="top">1.86e-06</td></tr><tr><td align="left" valign="top">Vermis</td><td align="left" valign="top">x=1 y=-49 z=-12</td><td align="char" char="." valign="top">0.702</td><td align="char" char="." valign="top">0.493</td><td align="char" char="hyphen" valign="top">5.21e-06</td></tr><tr><td align="left" valign="top">Medial Raphe nucleus</td><td align="left" valign="top">x=0 y=-25 z=-15</td><td align="char" char="." valign="top">0.689</td><td align="char" char="." valign="top">0.475</td><td align="char" char="hyphen" valign="top">9.11e-06</td></tr><tr><td align="left" valign="top">Right Subst. Nigra, Subthalamic n., Zona Incerta</td><td align="left" valign="top">x=16 y=-14 z=-7</td><td align="char" char="." valign="top">0.681</td><td align="char" char="." valign="top">0.464</td><td align="char" char="hyphen" valign="top">1.28e-05</td></tr><tr><td align="left" valign="top">Left Subst. Nigra, Subthalamic n., Zona Incerta</td><td align="left" valign="top">x=-14 y=-16 z=-7</td><td align="char" char="." valign="top">0.673</td><td align="char" char="." valign="top">0.453</td><td align="char" char="hyphen" valign="top">1.77e-05</td></tr><tr><td align="left" valign="top">Left Claustrum</td><td align="left" valign="top">x=-30 y=14 z=-2</td><td align="char" char="." valign="top">0.672</td><td align="char" char="." valign="top">0.451</td><td align="char" char="hyphen" valign="top">1.88e-05</td></tr><tr><td align="left" valign="top">Left Amygdala</td><td align="left" valign="top">x=-25 y=-8 z=-27</td><td align="char" char="." valign="top">0.672</td><td align="char" char="." valign="top">0.451</td><td align="char" char="hyphen" valign="top">1.88e-05</td></tr><tr><td align="left" valign="top">Right Fusiform Gyrus</td><td align="left" valign="top">x=37 y=-10 z=-34</td><td align="char" char="." valign="top">0.668</td><td align="char" char="." valign="top">0.447</td><td align="char" char="hyphen" valign="top">2.14e-05</td></tr><tr><td align="left" valign="top">Left Putamen</td><td align="left" valign="top">x=-33 y=-4 z=2</td><td align="char" char="." valign="top">0.656</td><td align="char" char="." valign="top">0.430</td><td align="char" char="hyphen" valign="top">3.41e-05</td></tr><tr><td align="left" valign="top">Left Dorsal Anterior Cingulate Cortex</td><td align="left" valign="top">x=-2 y=25 z=22</td><td align="char" char="." valign="top">0.654</td><td align="char" char="." valign="top">0.428</td><td align="char" char="hyphen" valign="top">3.65e-05</td></tr><tr><td align="left" valign="top">Right Superior Parietal Lobule</td><td align="left" valign="top">x=23 y=-62 z=63</td><td align="char" char="." valign="top">0.652</td><td align="char" char="." valign="top">0.425</td><td align="char" char="hyphen" valign="top">3.95e-05</td></tr><tr><td align="left" valign="top">Left Transition Orbitofrontal Cortex- Insula</td><td align="left" valign="top">x=-24 y=11 z=-18</td><td align="char" char="." valign="top">0.645</td><td align="char" char="." valign="top">0.416</td><td align="char" char="hyphen" valign="top">5.06e-05</td></tr><tr><td align="left" valign="top">Right Nucleus Accumbens</td><td align="left" valign="top">x=11 y=8 z=-7</td><td align="char" char="." valign="top">0.645</td><td align="char" char="." valign="top">0.416</td><td align="char" char="hyphen" valign="top">5.07e-05</td></tr><tr><td align="left" valign="top">Right Amygdala</td><td align="left" valign="top">x=-22 y=-6 z=-26</td><td align="char" char="." valign="top">0.645</td><td align="char" char="." valign="top">0.416</td><td align="char" char="hyphen" valign="top">5.14e-05</td></tr><tr><td align="left" valign="top">Left Anterior Insula</td><td align="left" valign="top">x=-39 y=18 z=-1</td><td align="char" char="." valign="top">0.642</td><td align="char" char="." valign="top">0.413</td><td align="char" char="hyphen" valign="top">5.59e-05</td></tr><tr><td align="left" valign="top">Right Rostral Anterior Cingulate Cortex</td><td align="left" valign="top">x=9 y=40 z=-5</td><td align="char" char="." valign="top">0.638</td><td align="char" char="." valign="top">0.407</td><td align="char" char="hyphen" valign="top">6.57e-05</td></tr><tr><td align="left" valign="top">Right Bed Nucleus Of The Stria Terminallis</td><td align="left" valign="top">x=7 y=8 z=-5</td><td align="char" char="." valign="top">0.638</td><td align="char" char="." valign="top">0.407</td><td align="char" char="hyphen" valign="top">6.57e-05</td></tr><tr><td align="left" valign="top">Left Bed Nucleus Of The Stria Terminallis</td><td align="left" valign="top">x=-6 y=8 z=-5</td><td align="char" char="." valign="top">0.638</td><td align="char" char="." valign="top">0.407</td><td align="char" char="hyphen" valign="top">6.57e-05</td></tr><tr><td align="left" valign="top">Left Nucleus Acuumbens</td><td align="left" valign="top">x=-11 y=8 z=-7</td><td align="char" char="." valign="top">0.638</td><td align="char" char="." valign="top">0.407</td><td align="char" char="hyphen" valign="top">6.57e-05</td></tr><tr><td align="left" valign="top">Right Transition Orbitofrontal Cortex- Insula</td><td align="left" valign="top">x=25 y=10 z=-15</td><td align="char" char="." valign="top">0.638</td><td align="char" char="." valign="top">0.407</td><td align="char" char="hyphen" valign="top">6.57e-05</td></tr><tr><td align="left" valign="top">Right Hypothalamus</td><td align="left" valign="top">x=5 y=-3 z=-11</td><td align="char" char="." valign="top">0.631</td><td align="char" char="." valign="top">0.398</td><td align="char" char="hyphen" valign="top">8.25e-05</td></tr><tr><td align="left" valign="top">Left Fusiform Gyrus</td><td align="left" valign="top">x=-34 y=-12 z=-33</td><td align="char" char="." valign="top">0.629</td><td align="char" char="." valign="top">0.396</td><td align="char" char="hyphen" valign="top">8.72e-05</td></tr><tr><td align="left" valign="top">Left Hypothalamus</td><td align="left" valign="top">x=-4 y=-3 z=-11</td><td align="char" char="." valign="top">0.621</td><td align="char" char="." valign="top">0.386</td><td align="char" char="hyphen" valign="top">1.13e-04</td></tr></tbody></table></table-wrap></sec><sec id="s2-5"><title>Imaging transcriptomics – Gene set analysis</title><p>Finally, to investigate neural phenotypes and possible neurobiological mechanisms of treatments, we performed imaging transcriptomics analysis using the abagen toolbox (<ext-link ext-link-type="uri" xlink:href="https://abagen.readthedocs.io/en/stable/index.html">https://abagen.readthedocs.io/en/stable/index.html</ext-link>) and the human gene expression data from the Allen Human Brain Atlas (<ext-link ext-link-type="uri" xlink:href="https://alleninstitute.org/">https://alleninstitute.org/</ext-link>). We investigated genes with a spatial distribution of expression that resembled the pattern of brain regions with clinically relevant (following TFCE correction) functional connectivity to the stimulation locus (q<sub>FDRcor</sub> &lt;0.0001). This type of analysis shows genes whose spatial pattern correlates with brain changes that are also found in post-mortem and large-scale GWAS studies of specific patient populations <xref ref-type="bibr" rid="bib5">Arnatkeviciute et al., 2022</xref>. This process resulted in an extensive list of candidate genes that were Bonferroni corrected (p&lt;0.005) before being investigated using the EnRichr Gene Ontology tool (<ext-link ext-link-type="uri" xlink:href="https://maayanlab.cloud/Enrichr/">https://maayanlab.cloud/Enrichr/</ext-link>) and a cell-specific aggregate gene set <xref ref-type="bibr" rid="bib92">Seidlitz et al., 2020</xref> to identify associated biological processes and cell types (<xref ref-type="fig" rid="fig7">Figure 7</xref>). We observed genes associated with clinically relevant brain areas considered to be at the core of the neurocircuitry of aggressive behavior (i.e. Hypothalamus, Amygdala, Prefrontal Cortex and Cingulate Cortex) <xref ref-type="bibr" rid="bib44">Gouveia et al., 2021a</xref>; <xref ref-type="bibr" rid="bib42">Gouveia et al., 2019</xref>; <xref ref-type="bibr" rid="bib43">Gouveia et al., 2020</xref>; <xref ref-type="bibr" rid="bib45">Gouveia et al., 2021b</xref>; <xref ref-type="bibr" rid="bib11">Blair, 2016</xref>, genes linked to oxytocin (a peptide hormone critically implicated in social behaviors) <xref ref-type="bibr" rid="bib81">Ne’eman et al., 2016</xref>; <xref ref-type="bibr" rid="bib58">Johansson et al., 2012</xref>; <xref ref-type="bibr" rid="bib82">Neumann, 2008</xref>; <xref ref-type="bibr" rid="bib72">Malik et al., 2012</xref>; <xref ref-type="bibr" rid="bib3">Amorim et al., 2018</xref> and to cell compartments related to neuronal communication and plasticity (e.g. neuron projection, synapse; axon guidance, long-term potentiation). Additionally, investigating the prevalence of cell types associated with the set of genes identified in our analysis, we found a significant overrepresentation of genes associated with oligodendrocytes and an underrepresentation of genes associated with astrocytes and microglia when compared to the expected distribution of genes per cell type (<xref ref-type="fig" rid="fig7">Figure 7</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Imaging transcriptomics-gene set analysis.</title><p>The gene set analysis was performed using the TFCE-corrected distribution of clinically relevant functionally connected areas (q<sub>FDR</sub>&lt;0.0001) along with whole brain three-dimensional expression patterns provided by the Allen Brain Atlas (<ext-link ext-link-type="uri" xlink:href="http://human.brain-map.org/">http://human.brain-map.org/</ext-link>) <xref ref-type="bibr" rid="bib53">Hawrylycz et al., 2012</xref>; <xref ref-type="bibr" rid="bib94">Sunkin et al., 2013</xref>; <xref ref-type="bibr" rid="bib93">Shen et al., 2012</xref> averaged into the Harvard-Oxford Atlas (<ext-link ext-link-type="uri" xlink:href="http://www.cma.mgh.harvard.edu/">http://www.cma.mgh.harvard.edu/</ext-link>). Genes with similar spatial pattern of distribution to the functional connectivity map were Bonferroni corrected at p&lt;0.005 and selected for further gene ontology analysis. Left panel: The EnRichr tool (<ext-link ext-link-type="uri" xlink:href="https://maayanlab.cloud/Enrichr/">https://maayanlab.cloud/Enrichr/</ext-link>) <xref ref-type="bibr" rid="bib62">Kuleshov et al., 2016</xref> was used to investigate associated biological processes, followed by specific tissue and compartment analysis provided by the Jensen Gene Ontology Tool (<ext-link ext-link-type="uri" xlink:href="https://jensenlab.org/resources/proteomics/">https://jensenlab.org/resources/proteomics/</ext-link>), the Kyoto Encyclopedia of Genes and Genomes (KEEG; <ext-link ext-link-type="uri" xlink:href="https://www.genome.jp/kegg/">https://www.genome.jp/kegg/</ext-link>) and the Allen Human Brain Atlas (<ext-link ext-link-type="uri" xlink:href="http://human.brain-map.org/">http://human.brain-map.org/</ext-link>). Right panel: A cell-specific aggregate gene set provided by <xref ref-type="bibr" rid="bib92">Seidlitz et al., 2020</xref> was used to determine the cell types associated with these genes. Results were confirmed to be non-random using permutation testing (1000 permutations, ** p&lt;0.01).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84566-fig7-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this work, we performed an integrated imaging analysis of a large, international multi-center dataset of patients treated with pHyp-DBS for severe refractory aggressive behavior. Overall, the response rate for pHyp-DBS was high, with 91% (30 out of 33) of patients qualifying as treatment responders. In addition, 64% of patients presented symptom improvement greater than 81% (<xref ref-type="fig" rid="fig2">Figure 2</xref>), and the average improvement across the whole pHyp-DBS cohort was 75%. These results are in line with previous work showing that symptom improvement following hypothalamic neurosurgery for the treatment of aggressive behavior is in the order of 90% <xref ref-type="bibr" rid="bib42">Gouveia et al., 2019</xref>. In our series, four patients were implanted with directional DBS electrodes. Outcomes in patients implanted with these systems or conventional electrodes were found to be comparable <xref ref-type="bibr" rid="bib17">Contreras Lopez et al., 2021</xref>. While analysis derived from retrospective clinical data is more prone to potential bias, this study included a collection of previously published prospective trials, where each center standardized the timeframe for data collection and the instruments used to evaluate symptom improvement.</p><p>Although we did not observe a difference in the main diagnosis between the pediatric and adult populations, the former presented the highest percentage of symptom improvement following pHyp-DBS treatment. Considering that the brain only fully achieves maturity in early adulthood <xref ref-type="bibr" rid="bib39">Gallagher et al., 2019</xref>, it is possible that treating dysfunctional circuitries while they are still being developed could induce beneficial and long-lasting plastic changes to restore functional normality. DBS is primarily used for the treatment of neurological and psychiatric disorders in adults and is emerging as an effective and safe therapy for neurological diseases in children <xref ref-type="bibr" rid="bib67">Lipsman et al., 2010</xref> such as childhood dystonia <xref ref-type="bibr" rid="bib30">Elkaim et al., 2018</xref>, drug-resistant epilepsy <xref ref-type="bibr" rid="bib100">Yan et al., 2018</xref> and Gilles de la Tourette syndrome <xref ref-type="bibr" rid="bib18">Coulombe et al., 2018</xref>.</p><p>Using patients’ pre and postoperative imaging, we performed a Voxel Efficacy Mapping investigation and were able to determine a specific area that, when stimulated, is associated with an improvement greater than 90% located in the more posterior-inferior-lateral aspect of the posterior hypothalamic area (coordinates are provided in Talairach-Tournoux space and MNI152 space in the Results section). In humans, DBS and lesions of the posterior hypothalamus have been consistently shown to reduce aggressive symptoms (for a detailed review, see <xref ref-type="bibr" rid="bib42">Gouveia et al., 2019</xref>). One of the most commonly targeted areas in those series lies along the midpoint of the line between the anterior and posterior commissures (AC-PC line), in a region anterior to the rostral end of the aqueduct, posterior to the anterior border of the mammillary body and superior to the red nucleus <xref ref-type="bibr" rid="bib90">Sano and Mayanagi, 1988</xref> (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref> shows the location of the sweet-spot in relation to the red nucleus and subthalamic nucleus).</p><p>Our connectomics analyses provided insight into the structural and functional networks that underlie the clinical efficacy of pHyp-DBS. As no patient-specific functional or diffusion-weighted imaging scans were available, these analyses were performed using high-resolution, high signal-to-noise ratio images derived from healthy individuals that create an average atlas of the functional and connectivity profiles of the human brain <xref ref-type="bibr" rid="bib46">Gouveia et al., 2021c</xref>; <xref ref-type="bibr" rid="bib40">Germann et al., 2021a</xref>; <xref ref-type="bibr" rid="bib27">Elias et al., 2021</xref>; <xref ref-type="bibr" rid="bib41">Germann et al., 2021b</xref>; <xref ref-type="bibr" rid="bib98">Wang et al., 2021</xref>; <xref ref-type="bibr" rid="bib28">Elias, 2022</xref>. The analysis of functional and structural connectivity via normative datasets is an opportunity to investigate possible underlying mechanisms based on the current knowledge of the typical human brain. Unlike patient-specific studies, where functional MRI and diffusion-weighted images are acquired from a single patient, normative analyses rely on high-quality atlases derived from very large cohorts of healthy subjects (around 1000 brain scans). Thus, these exploratory data-driven approaches are intended to investigate the pattern of brain activity and structural connectivity related to a specific region of interest (i.e. individual VAT) and correlate these data with clinical outcomes to simulate the presumed brain changes associated with DBS treatment. This approach allows for the expansion of the investigation to a large, previously inaccessible cohort of patients whose individual data are available, generating knowledge that can help optimize treatment in future patient populations. Although normative connectivity data may not fully capture patient- or pathology-specific variations, they have been previously shown to generate results that are comparable to patient-specific imaging data <xref ref-type="bibr" rid="bib28">Elias, 2022</xref>; <xref ref-type="bibr" rid="bib98">Wang et al., 2021</xref>.</p><p>Structural connectivity analysis in our study implicated fiber tracts involved in somatosensation (e.g. medial lemniscus and spinothalamic tract), emotional regulation (e.g. amygdalofugal pathway and medial forebrain bundle), and motor signaling (e.g. motor projections and central tegmental tract) in the amelioration of aggressive behavior. Previous studies have shown a significant correlation between aggressive behavior and motor agitation <xref ref-type="bibr" rid="bib43">Gouveia et al., 2020</xref>; <xref ref-type="bibr" rid="bib45">Gouveia et al., 2021b</xref>, with a concomitant reduction in both following neuromodulatory treatments targeting the posterior hypothalamus <xref ref-type="bibr" rid="bib46">Gouveia et al., 2021c</xref>; <xref ref-type="bibr" rid="bib68">López Ríos et al., 2023</xref>. Indeed, patients with neurodevelopmental disorders, especially those presenting with self-injurious behavior, are known to frequently have altered sensory perception (including reduced pain sensitivity), which can contribute to the chronicity and severity of the behaviour <xref ref-type="bibr" rid="bib44">Gouveia et al., 2021a</xref>; <xref ref-type="bibr" rid="bib61">Koenig et al., 2017</xref>. Furthermore, self-injurious behaviors in this patient population are considered to be a type of repetitive/stereotypic behavior that results in physical injury to the patient’s own body <xref ref-type="bibr" rid="bib49">Hagopian et al., 2015</xref>; <xref ref-type="bibr" rid="bib101">Yan et al., 2022</xref>, highlighting the relevance of the motor system in the network subserving aggressive behavior. As such, modulation of somatosensory and motor pathways – perhaps leading to increased pain perception or awareness, and reduction in repetitive/stereotypic behaviors – could help reduce self-injurious behaviors.</p><p>More generally, aggressive behaviors and motor agitation are believed to occur as a result of a decreased tolerance to provocative stimuli caused by reduced serotonergic transmission in the prefrontal cortex, resulting in an ineffective top-down inhibitory control over a consequently hyper-activated amygdala. The amygdala, in turn, sends alert signs to the periaqueductal gray and hypothalamus for motor activation and hormonal production, preparing the organism for a response <xref ref-type="bibr" rid="bib44">Gouveia et al., 2021a</xref>; <xref ref-type="bibr" rid="bib42">Gouveia et al., 2019</xref>; <xref ref-type="bibr" rid="bib43">Gouveia et al., 2020</xref>; <xref ref-type="bibr" rid="bib45">Gouveia et al., 2021b</xref>; <xref ref-type="bibr" rid="bib11">Blair, 2016</xref>. Thus, it is conceivable that stimulation of fiber tracts involved in emotional regulation and motor outputs could mediate clinical improvement by reducing motor agitation, improving concentration and learning, and increasing tolerance to provocative external stimuli. The functional connectivity mapping showed that the successful VATs were functionally connected to several key areas within the neurocircuitry of aggressive behavior, including the amygdala, nucleus accumbens, hypothalamus, periaqueductal gray, and cingulate cortex. To further explore these results, we investigated the relationship between the functional connectivity of each of these brain structures and individual treatment outcomes and observed that functional connectivity with the PAG is the most relevant. In addition, when modeling the functional connectivity of any two brain areas identified in the functional connectivity analysis, we observed that the most relevant connections involved the PAG and limbic structures believed to be at the core of the neurocircuitry of aggressive behavior, such as the amygdala, anterior cingulate cortex, and nucleus accumbens. In line with our findings, previous studies have shown positive outcomes following ablative and neuromodulation treatments targeting the amygdala, hypothalamus, and nucleus accumbens for the control of aggressive behavior <xref ref-type="bibr" rid="bib44">Gouveia et al., 2021a</xref>; <xref ref-type="bibr" rid="bib42">Gouveia et al., 2019</xref>; <xref ref-type="bibr" rid="bib45">Gouveia et al., 2021b</xref>; <xref ref-type="bibr" rid="bib101">Yan et al., 2022</xref>. Moreover, PAG DBS – primarily performed to treat neuropathic pain <xref ref-type="bibr" rid="bib60">Knotkova et al., 2021</xref> – has been reported to induce changes in mood and anxiety <xref ref-type="bibr" rid="bib48">Gray et al., 2014</xref>.</p><p>Another aspect detected by the functional connectivity analysis was the involvement of areas responsible for the production of serotonin (i.e. raphe nuclei) and dopamine (i.e. substantia nigra). Both these monoamines are thought to be directly involved in the initiation and maintenance of aggressive behaviors due to their role in facilitating top-down inhibitory controls, regulating mood, and mediating social behaviors <xref ref-type="bibr" rid="bib42">Gouveia et al., 2019</xref>; <xref ref-type="bibr" rid="bib46">Gouveia et al., 2021c</xref>; <xref ref-type="bibr" rid="bib76">Miczek et al., 2002</xref>. Antipsychotics (both typical and atypical) and selective serotonin reuptake inhibitors – the most commonly used drugs to control of aggressive behaviors – act on the dopaminergic and serotonergic neurotransmission systems <xref ref-type="bibr" rid="bib44">Gouveia et al., 2021a</xref>; <xref ref-type="bibr" rid="bib42">Gouveia et al., 2019</xref>. In a mouse model of escalated aggression, pHyp-DBS increased the density of serotonin receptors type 1A (5-HT1<sub>A</sub>) in the orbitofrontal cortex and amygdala, while pretreatment with a 5-HT1<sub>A</sub> antagonist blocked the anti-aggressive effect of stimulation <xref ref-type="bibr" rid="bib47">Gouveia et al., 2023</xref>.</p><p>To further explore the dataset pooled in our study, we performed a spatial imaging transcriptomic analysis. Our goal was to investigate spatial correlations between gene expression patterns (i.e. microarray data from the Allen Human Brain Atlas) and imaging characteristics (i.e. functional connectivity map derived from the patient’s VATs) and possible molecular characteristics associated with symptom improvement (for a review on imaging transcriptomics see <xref ref-type="bibr" rid="bib35">Fornito et al., 2019</xref>). Imaging transcriptomics is a powerful non-invasive method to measure neural phenotypes and investigate neurobiological mechanisms of disease or treatments <xref ref-type="bibr" rid="bib5">Arnatkeviciute et al., 2022</xref>. Genes whose spatial pattern correlates with brain changes in imaging transcriptomics are also found in post-mortem and large-scale GWAS studies of specific patient populations <xref ref-type="bibr" rid="bib5">Arnatkeviciute et al., 2022</xref>. In fact, several studies have demonstrated associations between the spatial distribution of genes and neurodevelopmental changes <xref ref-type="bibr" rid="bib99">Xie et al., 2020</xref>; <xref ref-type="bibr" rid="bib86">Romero-Garcia et al., 2019</xref> as well as psychiatric disorders <xref ref-type="bibr" rid="bib87">Romero-Garcia et al., 2020</xref>. In this study, we identified a number of genes with similar spatial distribution to brain regions that showed clinically important functional connectivity with the stimulation target. The biological processes associated with these genes were investigated using several gene ontology analysis tools. The Jensen Tissues library revealed a list of brain structures classically associated with aggressive behavior, including those associated with the limbic system (e.g. amygdala and hypothalamus) and those involved in higher-order cognitive centers (e.g. prefrontal cortex). As described above, dysregulation in the top-down inhibitory control of the prefrontal cortex over the limbic system is thought to subserve aggressive behaviors. Additionally, the KEGG 2021 Human Library identified genes implicated in the oxytocin signaling pathway, a peptide hormone critically implicated in aggressive behavior <xref ref-type="bibr" rid="bib82">Neumann, 2008</xref>. It has been shown that intranasal administration of oxytocin increases human aggressive responses when subjects are evaluated in a social orientation paradigm <xref ref-type="bibr" rid="bib81">Ne’eman et al., 2016</xref>. Moreover, single-nucleotide polymorphisms in the oxytocin gene have been associated with childhood-onset aggressive behaviors <xref ref-type="bibr" rid="bib72">Malik et al., 2012</xref> and with aggressive behaviors in men intoxicated with alcohol <xref ref-type="bibr" rid="bib58">Johansson et al., 2012</xref>.</p><p>A large number of genes identified by the Jensen Compartments and KEGG 2021 Human Libraries are part of biological processes associated with neuronal communication and plasticity, thus possibly linked to the intrinsic mechanism of action of DBS <xref ref-type="bibr" rid="bib50">Hamani and Temel, 2012</xref>; <xref ref-type="bibr" rid="bib34">Florence et al., 2016</xref>. As a neuromodulation therapy, DBS induces long-lasting changes in cellular and molecular aspects of neurons belonging to dysfunctional neurocircuitries in order to restore functional normality <xref ref-type="bibr" rid="bib57">Jakobs et al., 2019</xref>; <xref ref-type="bibr" rid="bib59">Karas et al., 2013</xref>; <xref ref-type="bibr" rid="bib71">Lozano et al., 2019</xref>. Although its neurobiological mechanisms are not fully understood, DBS is believed to exert its effects by altering the cellular membrane potential, resulting in either an increase or a decrease in action potentials <xref ref-type="bibr" rid="bib57">Jakobs et al., 2019</xref>; <xref ref-type="bibr" rid="bib59">Karas et al., 2013</xref>; <xref ref-type="bibr" rid="bib71">Lozano et al., 2019</xref>. These changes are then propagated throughout neural networks, changing neurotransmitter dynamics, protein expression, and membrane receptor availability <xref ref-type="bibr" rid="bib57">Jakobs et al., 2019</xref>; <xref ref-type="bibr" rid="bib59">Karas et al., 2013</xref>; <xref ref-type="bibr" rid="bib71">Lozano et al., 2019</xref>. In fact, a previous study using imaging transcriptomics to investigate brain changes after functional neurosurgery of the amygdala in patients with refractory aggressive behavior has also identified several genes related to neuronal communication and plasticity <xref ref-type="bibr" rid="bib44">Gouveia et al., 2021a</xref>. Preclinical studies have also found significant increases in neural precursor cells, plasticity, and precursor cell markers in animals implanted with DBS, along with significant reductions in the number of activated microglia and astrocytes <xref ref-type="bibr" rid="bib97">Vedam-Mai et al., 2016</xref>; <xref ref-type="bibr" rid="bib65">Leplus et al., 2019</xref>; <xref ref-type="bibr" rid="bib14">Chan et al., 2018</xref>; <xref ref-type="bibr" rid="bib8">Bambico et al., 2015</xref>; <xref ref-type="bibr" rid="bib31">Encinas et al., 2011</xref>. This is in line with the cell type investigation, where a significant reduction in the ratio of genes per cell type was observed for astrocytes and microglia when compared to the expected distribution. Both astrocytes and microglia are highly implicated in mechanisms of neuroinflammation <xref ref-type="bibr" rid="bib13">Carson et al., 2006</xref>, which in turn is associated with several psychiatric disorders <xref ref-type="bibr" rid="bib80">Najjar et al., 2013</xref>. The reduction of neuroinflammatory markers (such as glial activation and interleukin levels) has been described in several preclinical DBS studies and is thought to be involved in the mechanism of action of DBS <xref ref-type="bibr" rid="bib14">Chan et al., 2018</xref>; <xref ref-type="bibr" rid="bib15">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib2">Amorim et al., 2015</xref>.</p><p>Some limitations of this study are of note; with the exception of the analysis of the most efficacious location of stimulation (i.e. voxel efficacy map), which is fully derived from patient data, the remaining exploratory analyses were performed using normative datasets. This methodology was chosen as neither patient-specific functional nor diffusion-weighted imaging was available. Sophisticated imaging acquisitions, such as the ones necessary for the connectivity analysis, are not frequently acquired in patients with implanted DBS, as many devices have not been considered safe for MRI use. Additionally, it is frequent for health centers to have a ‘no-MRI’ policy for patients with implanted DBS, only allowing for the acquisition of CTs following surgery. It is important to highlight that previous studies showed that normative datasets could be used to create probabilistic models of optimal connectivity associated with patients’ outcomes that are meaningful to predict outcomes in patient-specific connectivity data <xref ref-type="bibr" rid="bib98">Wang et al., 2021</xref>. Similarly, individual brain genetic profiles were not available for this patient population. The imaging transcriptomic analysis performed here was based on the Allen Human Brain Atlas, which is derived from post-mortem biopsies of multiple adult control brains <xref ref-type="bibr" rid="bib53">Hawrylycz et al., 2012</xref>; <xref ref-type="bibr" rid="bib4">Arnatkeviciute et al., 2019</xref>; <xref ref-type="bibr" rid="bib6">Arnatkeviciute et al., 2023</xref>; <xref ref-type="bibr" rid="bib74">Markello et al., 2021</xref>, and has been shown to be relevant to large-scale GWAS studies of specific patient populations <xref ref-type="bibr" rid="bib5">Arnatkeviciute et al., 2022</xref>.</p><p>The structural connectivity analysis performed here provides a detailed overview of the relevant tracts that are related to symptom alleviation in this patient population. However, for precise segregation of these fiber tracts and the determination of those that are necessary for symptom improvement, it would be necessary to perform preclinical experiments to selectively activate/inactivate specific fiber tracts and investigate the impact of these changes on behavior and network dynamics. Nevertheless, understanding how the location of the most efficacious area of stimulation correlates with these tracts is important for refining the surgical planning of future patients, as one could use individual patient tractography to determine the optimal location of the electrodes based on how it would impact individual fiber tracts.</p><sec id="s3-1"><title>Conclusion</title><p>This integrated imaging analysis of the largest multi-center international dataset of patients treated with posterior hypothalamus deep brain stimulation (pHyp-DBS) for refractory and severe aggressive behavior showed that treatment efficacy is high, with over 90% of patients presenting significant symptom improvement. The probabilistic sweet-spot mapping revealed an optimized surgical target where maximal symptom alleviation could be achieved, and the stereotaxic coordinates of this optimal stimulation site are provided, allowing for direct clinical application. The connectomics analysis performed here expands our understanding of the neurocircuitry of aggressive behavior and suggests that engagement of specific brain areas within the neurocircuitry is key for symptom alleviation. Further studies are necessary to investigate if neurostimulation of these deep brain structures with non-invasive neuromodulatory treatments, such as deep transcranial magnetic stimulation (dTMS) or low-intensity focused ultrasound (LIFUS), would result in beneficial outcomes for patients.</p></sec></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Patients included</title><p>Thirty-three patients from five international centers were included in this study: Hospital Universitario San Vicente Fundación, Colombia; University Hospital La Princesa, Spain; International Misericordia Clinic, Colombia; Universidad Autónoma de Bucaramanga and FOSCAL Clinic, Colombia; Sírio-Libanês Hospital, Brazil. Detailed demographics, medical history, surgical procedure, and relevant information regarding institutional ethical review board and informed consent can be found in previous publications <xref ref-type="bibr" rid="bib46">Gouveia et al., 2021c</xref>; <xref ref-type="bibr" rid="bib17">Contreras Lopez et al., 2021</xref>; <xref ref-type="bibr" rid="bib10">Benedetti-Isaac et al., 2015</xref>; <xref ref-type="bibr" rid="bib96">Torres et al., 2020</xref>; <xref ref-type="bibr" rid="bib75">Micieli et al., 2017</xref>. All patients had pre-operative T1w MRI images as well as postoperative imaging (CT or MRI) that allowed for the precise determination of individual electrode placement (imaging parameters may be found in the original publications of the individual centers) <xref ref-type="bibr" rid="bib46">Gouveia et al., 2021c</xref>; <xref ref-type="bibr" rid="bib17">Contreras Lopez et al., 2021</xref>; <xref ref-type="bibr" rid="bib10">Benedetti-Isaac et al., 2015</xref>; <xref ref-type="bibr" rid="bib96">Torres et al., 2020</xref>; <xref ref-type="bibr" rid="bib75">Micieli et al., 2017</xref>.</p></sec><sec id="s4-2"><title>Electrode localization and volume of activated tissue (VAT) modeling</title><p>Lead-DBS software (<ext-link ext-link-type="uri" xlink:href="https://www.lead-dbs.org/">https://www.lead-dbs.org/</ext-link>) was used for electrode localization and modeling of the volume of activated tissue, as previously described <xref ref-type="bibr" rid="bib56">Horn and Kühn, 2015</xref>. Following intensity inhomogeneity correction, the postoperative MRI or CT and the preoperative MRI scans were rigidly co-registered using SPM12 (<ext-link ext-link-type="uri" xlink:href="https://www.fil.ion.ucl.ac.uk/spm/software/spm12/">https://www.fil.ion.ucl.ac.uk/spm/software/spm12/</ext-link> <xref ref-type="bibr" rid="bib85">Penny et al., 2011</xref>). Images were non-linearly normalized to standard space (ICBM 2009b NLIN asymmetric) using Effective Low Variance ANTS (<ext-link ext-link-type="uri" xlink:href="http://stnava.github.io/ANTs">http://stnava.github.io/ANTs</ext-link>), and an additional subcortical affine transformation was implemented to correct for post-operative brain shift <xref ref-type="bibr" rid="bib7">Avants et al., 2011</xref>. Electrodes located in the right and/or left hemispheres were manually localized using the post-operative scan and then warped to standard space using the previously generated transforms. The patient’s unilateral or bilateral VATs associated with individual stimulation parameters at the last follow-up (individual stimulation parameters are described in <xref ref-type="table" rid="table1">Table 1</xref>) were modeled by first constructing a four-compartment volume conductor model (<ext-link ext-link-type="uri" xlink:href="http://iso2mesh.sourceforge.net/cgi-bin/index.cgi">http://iso2mesh.sourceforge.net/cgi-bin/index.cgi</ext-link>) that segregated peri-electrode tissue by tissue type <xref ref-type="bibr" rid="bib32">Ewert et al., 2018</xref>. Next, the FieldTrip-SimBio finite element model pipeline was used to simulate the potential electric field distribution around each active contact (<ext-link ext-link-type="uri" xlink:href="https://www.mrt.uni-jena.de/simbio/index.php/">https://www.mrt.uni-jena.de/simbio/index.php/</ext-link>; <ext-link ext-link-type="uri" xlink:href="http://fieldtriptoolbox.org">http://fieldtriptoolbox.org</ext-link>) and binary VATs were generated by thresholding the gradient of this distribution at 0.2 V/mm. Considering that increased pulse width increases the effective range of stimulation (thus translating to a larger VAT) by lowering the activation threshold of nearby axons <xref ref-type="bibr" rid="bib24">Duffley et al., 2019</xref>, and given that our patient cohort included a small number of patients who received higher pulse widths than the ones assumed by the FieldTripSimBio model in Lead-DBS, we performed a supplementary analysis to investigate changes in VAT volumes by also modeling the pulse width observed in these patients. To this aim, we used a simpler heuristic model <xref ref-type="bibr" rid="bib20">Dembek et al., 2017</xref> that takes pulse width into account to compute additional VATs using pulse width values ranging from 90μs up to the patient’s actual pulse width values. As expected, this analysis yielded larger VATs when higher pulse width values were used, with an absolute difference in VAT diameter between 90 μs and 450 μs (the highest pulse width observed in this cohort) of 2 mm. Then, we investigated whether or not these larger VATs could have potentially impacted our results by performing a new probabilistic mapping analysis using the newly generated VATs (specifically, the largest VATs that were enlarged by 2 mm in diameter) for the patients with higher pulse width values. This new analysis yielded a very similar average map to the original analysis, with the overall map pattern and location/values of the peak corresponding to the most efficacious area for maximal symptom alleviation remaining unaltered with only a few voxels on the periphery of the map changing in value by a couple of percentage points (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). As such, this supplementary analysis indicates that our results were not meaningfully altered by the unusual pulse width observed in these patients.</p></sec><sec id="s4-3"><title>Voxel efficacy mapping</title><p>Probabilistic maps of efficacious voxels were generated to provide insight into spatial patterns of response to pHyp-DBS, as previously described <xref ref-type="bibr" rid="bib27">Elias et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Dembek et al., 2017</xref>; <xref ref-type="bibr" rid="bib41">Germann et al., 2021b</xref>. All VATs were flipped to the right hemisphere, and each VAT was weighted by the percentage of improvement from the baseline. Mean improvement at each voxel was computed by averaging the normalized weighting values. The resultant raw average map was then masked by a frequency map thresholded at 10% in order to exclude outlier voxels. Finally, a statistical map thresholded at p&lt;0.05 was calculated using the Wilcoxon signed-rank test to determine whether pHyp-DBS was associated with a significant difference in clinical change at each voxel. The validity of the voxel efficacy map was confirmed using a non-parametric permutation analysis, in which each clinical score was randomly assigned to a random VAT. The voxel map was determined to be significant (p<sub>permute</sub> &lt;0.01). The coordinates relative to the most efficacious area of stimulation were extracted in MNI space and converted to Talairach space using the MNI-Talairach Converter from BioImage Suite Web (<ext-link ext-link-type="uri" xlink:href="https://bioimagesuiteweb.github.io/webapp/mni2tal.html">https://bioimagesuiteweb.github.io/webapp/mni2tal.html</ext-link>) <xref ref-type="bibr" rid="bib63">Lacadie et al., 2008</xref>. All imaging analyses were performed using the MNI152 non-linear template (<ext-link ext-link-type="uri" xlink:href="https://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009">https://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009</ext-link>).</p></sec><sec id="s4-4"><title>Imaging connectomics analyses - structural and functional connectivity mapping</title><p>The brain-wide imaging connectomics analyses of the patient’s unilateral or bilateral VATs were explored using high-quality Structural (diffusion MRI-based tractography derived streamlines) and Functional (resting-state functional MRI-derived voxel-wise functional pattern) normative connectomes, as previously described <xref ref-type="bibr" rid="bib27">Elias et al., 2021</xref>; <xref ref-type="bibr" rid="bib26">Elias et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Germann et al., 2021b</xref>; <xref ref-type="bibr" rid="bib16">Coblentz et al., 2021</xref>. Briefly, for each patient’s individual VAT(s), a whole-brain r-map was computed based on the resting-state functional MRI BOLD time course-dependent correlations between the seed region and the remaining voxels in the brain (the processed rsfMRI connectome data and script are freely available through lead-DBS <ext-link ext-link-type="uri" xlink:href="https://www.lead-dbs.org">https://www.lead-dbs.org</ext-link>. In-house MATLAB script, The MathWorks, Inc, Version R2017b. Natick, MA, USA) across 1000 healthy subjects (Brain Genomics Superstruct Project dataset, age range: 18–35 years; 57% female, <ext-link ext-link-type="uri" xlink:href="http://neuroinformatics.harvard.edu/gsp">http://neuroinformatics.harvard.edu/gsp</ext-link>) <xref ref-type="bibr" rid="bib36">Fox et al., 2014</xref>. To exclude voxels with potentially spurious correlations, all individual r-map were corrected for multiple comparisons by converting them to a t-map and thresholded at p<sub>corrected</sub> &lt;0.05 (whole-brain voxel-wise Bonferroni correction) using the known p-distribution <xref ref-type="bibr" rid="bib37">Fox, 2018</xref>; <xref ref-type="bibr" rid="bib73">Mansouri et al., 2020</xref>. Thus, only voxels significantly functionally connected to each patient’s VATs were used for the subsequent analysis. For generating group-level maps, a voxel-wise linear regression analysis investigating the relationship between the functional connectivity of the VATs and the individual clinical outcome was then performed, followed by non-parametric permutation analysis. The individual improvement scores were randomly assigned to a functional connectivity map, and the analysis was repeated 1000 times. At each voxel, p<sub>permute</sub> &lt;0.05 was used as a significance threshold for the final functional connectivity analysis. <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> illustrates this process.</p><p>Structural connectivity outputs were obtained by identifying all streamlines that touched the uni or bilateral VATs (used as seeds) out of an approximately 12 million-fibers whole-brain tractography template (the processed dMRI connectome data and script are also freely available through lead-DBS <ext-link ext-link-type="uri" xlink:href="https://www.lead-dbs.org">https://www.lead-dbs.org</ext-link>. In-house MATLAB script, The MathWorks, Inc, Version R2017b. Natick, MA, USA). This template was assembled from a 985-subject multi-shell diffusion-weighted MRI Human Connectome Project dataset (<ext-link ext-link-type="uri" xlink:href="http://www.humanconnectomeproject.org">http://www.humanconnectomeproject.org</ext-link>) using generalized q-sampling imaging (<ext-link ext-link-type="uri" xlink:href="http://dsi-41studio.labsolver.org/">http://dsi-41studio.labsolver.org/</ext-link>). To determine what streamlines are significantly associated with the outcome, a t-test of symptom improvement comparing subjects whose VAT touched a given streamline and individuals who did not was performed as previously described <xref ref-type="bibr" rid="bib66">Li et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Germann et al., 2021b</xref>. The results were corrected for multiple comparisons using False Discovery Rate (FDR) at q<sub>FDRcor</sub> &lt;0.001.</p></sec><sec id="s4-5"><title>Imaging transcriptomics - gene set analysis</title><p>We performed a gene set analysis using the abagen toolbox (<ext-link ext-link-type="uri" xlink:href="https://abagen.readthedocs.io/en/stable/index.html">https://abagen.readthedocs.io/en/stable/index.html</ext-link>) to investigate genes whose spatial pattern distribution is similar to the pattern of clinically relevant functional connectivity. For this analysis, we used the Allen Human Brain Atlas (<ext-link ext-link-type="uri" xlink:href="https://alleninstitute.org/">https://alleninstitute.org/</ext-link>) microarray data describing the cortical, subcortical, brainstem and cerebellar localization of over 20,000 genes in the human brain (3702 anatomical locations from 6 neurotypical adult brains) <xref ref-type="bibr" rid="bib53">Hawrylycz et al., 2012</xref>; <xref ref-type="bibr" rid="bib4">Arnatkeviciute et al., 2019</xref>; <xref ref-type="bibr" rid="bib6">Arnatkeviciute et al., 2023</xref>; <xref ref-type="bibr" rid="bib74">Markello et al., 2021</xref>, along with a cell-specific aggregate gene set <xref ref-type="bibr" rid="bib92">Seidlitz et al., 2020</xref>. These data are provided preprocessed, with gene expression values normalized across all donors’ brains, and registered to standard MNI space allowing for the direct comparison between the spatial pattern of gene expression and the functional connectivity map (<ext-link ext-link-type="uri" xlink:href="https://human.brain-map.org/microarray/search">https://human.brain-map.org/microarray/search</ext-link>) <xref ref-type="bibr" rid="bib4">Arnatkeviciute et al., 2019</xref>. To achieve this spatial mapping, we first applied Threshold Free Cluster Enhancement (TFCE) to the functional connectivity map to generate clusters of significant functional connectivity with a spatial extent that overlaps with the anatomical locations where microarray data was obtained. Then, based on the Harvard-Oxford Atlas (<ext-link ext-link-type="uri" xlink:href="http://www.cma.mgh.harvard.edu/">http://www.cma.mgh.harvard.edu/</ext-link>), a regional parcellation covering 48 cortical and 21 subcortical areas in each hemisphere (a total of 138 parcellations) was applied to both datasets. A direct correlation between the spatial distribution of gene expression and functional connectivity analysis in each specific brain area was performed and corrected for multiple comparisons using FDR at q<sub>FDAcor</sub> &lt;0.005, resulting in a gene list composed of 1734 genes associated with biological processes and ratios of genes per cell type. This list was used as input for gene ontology analyses using the EnRichr Gene Ontology tool (<ext-link ext-link-type="uri" xlink:href="https://maayanlab.cloud/Enrichr/">https://maayanlab.cloud/Enrichr/</ext-link>), along with the Jensen Gene Ontology enrichment tool (<ext-link ext-link-type="uri" xlink:href="https://jensenlab.org/resources/proteomics/">https://jensenlab.org/resources/proteomics/</ext-link>) and the Kyoto Encyclopedia of Genes and Genomes (KEGG pathway enrichment; <ext-link ext-link-type="uri" xlink:href="https://www.genome.jp/kegg/kegg1b.html">https://www.genome.jp/kegg/kegg1b.html</ext-link>), resulting in an extensive list of associated biological terms that were corrected for multiple comparisons using FDR at q<sub>FDAcor</sub> &lt; 0.005.</p></sec><sec id="s4-6"><title>Statistical analysis</title><p>R (version 3.4.4; <ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/">https://www.r-project.org/</ext-link>) was used for statistical analysis. The RMINC package (<ext-link ext-link-type="uri" xlink:href="https://github.com/Mouse-Imaging-Centre/RMINC">https://github.com/Mouse-Imaging-Centre/RMINC</ext-link>; <xref ref-type="bibr" rid="bib78">Mouse Imaging Centre, Hospital for Sick Children, Toronto Canada, 2022</xref>) was used for the analysis of imaging data. Linear models were used to investigate the percentage of improvement by age, and t-tests were performed to investigate possible differences in symptom improvement comparing male and female patients. Additive linear models were used to test our ability to estimate the percentage of improvement from baseline using age and the functional connectivity of all brain areas functionally connected with the VATs. The level of significance for all analyses was set at a minimum of p&lt;0.05.</p></sec><sec id="s4-7"><title>Study approval</title><p>Individual trials and cases were evaluated by the corresponding local ethics committees. Written informed consent was obtained. Five international centers shared clinical data for this study. 1. Comité de Ética de la Investigación of Hospital Universitario San Vicente Fundación (#08–2022). 2. Comité de Ética de la Investigación con Medicamentos of Hospital Universitario La Princesa. 3. Comité de Ética de los Estudios Clínicos of La Misericordia Clínica Internacional (2012). 4. Comité Institucional de Ética of Universidad Autónoma de Bucaramanga. 5. Comitê de Ética em Pesquisa of Sociedade Beneficente de Senhoras Hospital Sírio-Libanês (#27470619.8.0000.5461).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Funding acquisition, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Individual trials and cases were evaluated by the corresponding local ethics committees. Written informed consent was obtained. Five international centers shared clinical data for this study. 1. Comité de Ética de la Investigación of Hospital Universitario San Vicente Fundación (#08-2022). 2. Comité de Ética de la Investigación con Medicamentos of Hospital Universitario La Princesa. 3. Comité de Ética de los Estudios Clínicos of La Misericordia Clínica Internacional (2012). 4. Comité Institucional de Ética of Universidad Autónoma de Bucaramanga. 5. Comitê de Ética em Pesquisa of Sociedade Beneficente de Senhoras Hospital Sírio-Libanês (#27470619.8.0000.5461).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Matrix of the correlations between estimated symptom improvement (i.e. linear model of age and functional connectivity of the two areas) and the measured improvement.</title></caption><media xlink:href="elife-84566-supp1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-84566-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The codes for electrode localization, modelling of the volume of activated tissue, and imaging connectomics (i.e. functional and structural connectivity) are freely available in Lead-DBS (<ext-link ext-link-type="uri" xlink:href="https://www.lead-dbs.org/">https://www.lead-dbs.org/</ext-link>). The codes, along with the Allen Human Brain Atlas (AHBA) microarray dataset, for the analysis of spatial transcriptomics are freely available in abagen (<ext-link ext-link-type="uri" xlink:href="https://abagen.readthedocs.io/en/stable/">https://abagen.readthedocs.io/en/stable/</ext-link>). Along with the codes, the websites for these two toolboxes provide manuals describing the step-by-step procedure for successful analysis. The dataset accompanying this study is freely available at Zenodo (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.7344268">https://doi.org/10.5281/zenodo.7344268</ext-link>).</p><p>The following previously published dataset was used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset1"><person-group person-group-type="author"><name><surname>Gouveia</surname><given-names>FV</given-names></name><name><surname>Jurgen</surname><given-names>G</given-names></name></person-group><source>Zenodo</source><year iso-8601-date="2022">2022</year><data-title>Dataset accompanying this study</data-title><pub-id pub-id-type="doi">10.5281/zenodo.7344268</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by funds from the Harquail Center for Neuromodulation, Canadian Institutes of Health Research (CIHR) Postdoctoral Fellowship #472484 (FVG), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) #13/20602–5 (FVG), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) #17/10466–8 (FVG), Canadian Institutes of Health Research (CIHR) Banting fellowship #471913 (JG), and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) #11/08575–7 (RCRM). The authors wish to thank the research assistants and staff of Hospital Sirio-Libanes, Brazil; Hospital Universitario San Vicente Fundación, Colombia; University Hospital La Princesa, Spain; International Misericordia Clinic, Colombia; Universidad Autónoma de Bucaramanga and FOSCAL Clinic, Colombia.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adler</surname><given-names>BA</given-names></name><name><surname>Wink</surname><given-names>LK</given-names></name><name><surname>Early</surname><given-names>M</given-names></name><name><surname>Shaffer</surname><given-names>R</given-names></name><name><surname>Minshawi</surname><given-names>N</given-names></name><name><surname>McDougle</surname><given-names>CJ</given-names></name><name><surname>Erickson</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: a chart review study</article-title><source>Autism</source><volume>19</volume><fpage>102</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1177/1362361314524641</pub-id><pub-id pub-id-type="pmid">24571823</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amorim</surname><given-names>BO</given-names></name><name><surname>Covolan</surname><given-names>L</given-names></name><name><surname>Ferreira</surname><given-names>E</given-names></name><name><surname>Brito</surname><given-names>JG</given-names></name><name><surname>Nunes</surname><given-names>DP</given-names></name><name><surname>de Morais</surname><given-names>DG</given-names></name><name><surname>Nobrega</surname><given-names>JN</given-names></name><name><surname>Rodrigues</surname><given-names>AM</given-names></name><name><surname>deAlmeida</surname><given-names>ACG</given-names></name><name><surname>Hamani</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Deep brain stimulation induces Antiapoptotic and anti-inflammatory effects in epileptic rats</article-title><source>Journal of Neuroinflammation</source><volume>12</volume><elocation-id>162</elocation-id><pub-id pub-id-type="doi">10.1186/s12974-015-0384-7</pub-id><pub-id pub-id-type="pmid">26337974</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amorim</surname><given-names>L</given-names></name><name><surname>Gouveia</surname><given-names>FV</given-names></name><name><surname>Germann</surname><given-names>J</given-names></name><name><surname>Zambori</surname><given-names>D</given-names></name><name><surname>Morais</surname><given-names>R</given-names></name><name><surname>Sato</surname><given-names>FM</given-names></name><name><surname>Fongaro</surname><given-names>C</given-names></name><name><surname>Portolese</surname><given-names>J</given-names></name><name><surname>Brentani</surname><given-names>H</given-names></name><name><surname>Martinez</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Oxytocin and Gynecomastia: correlation or causality</article-title><source>Cureus</source><volume>10</volume><elocation-id>e2661</elocation-id><pub-id pub-id-type="doi">10.7759/cureus.2661</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnatkeviciute</surname><given-names>A</given-names></name><name><surname>Fulcher</surname><given-names>BD</given-names></name><name><surname>Fornito</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A practical guide to linking brain-wide gene expression and neuroimaging data</article-title><source>NeuroImage</source><volume>189</volume><fpage>353</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2019.01.011</pub-id><pub-id pub-id-type="pmid">30648605</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Arnatkeviciute</surname><given-names>A</given-names></name><name><surname>Fulcher</surname><given-names>BD</given-names></name><name><surname>Bellgrove</surname><given-names>MA</given-names></name><name><surname>Fornito</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Imaging transcriptomics of brain disorders</article-title><source>PsyArXiv</source><pub-id pub-id-type="doi">10.1016/j.bpsgos.2021.10.002</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnatkeviciute</surname><given-names>A</given-names></name><name><surname>Markello</surname><given-names>RD</given-names></name><name><surname>Fulcher</surname><given-names>BD</given-names></name><name><surname>Misic</surname><given-names>B</given-names></name><name><surname>Fornito</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Toward best practices for imaging Transcriptomics of the human brain</article-title><source>Biological Psychiatry</source><volume>93</volume><fpage>391</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2022.10.016</pub-id><pub-id pub-id-type="pmid">36725139</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avants</surname><given-names>BB</given-names></name><name><surname>Tustison</surname><given-names>NJ</given-names></name><name><surname>Song</surname><given-names>G</given-names></name><name><surname>Cook</surname><given-names>PA</given-names></name><name><surname>Klein</surname><given-names>A</given-names></name><name><surname>Gee</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A reproducible evaluation of ants similarity metric performance in brain image registration</article-title><source>NeuroImage</source><volume>54</volume><fpage>2033</fpage><lpage>2044</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2010.09.025</pub-id><pub-id pub-id-type="pmid">20851191</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bambico</surname><given-names>FR</given-names></name><name><surname>Bregman</surname><given-names>T</given-names></name><name><surname>Diwan</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Darvish-Ghane</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Laver</surname><given-names>B</given-names></name><name><surname>Amorim</surname><given-names>BO</given-names></name><name><surname>Covolan</surname><given-names>L</given-names></name><name><surname>Nobrega</surname><given-names>JN</given-names></name><name><surname>Hamani</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Neuroplasticity-dependent and -Independent mechanisms of chronic deep brain stimulation in stressed rats</article-title><source>Translational Psychiatry</source><volume>5</volume><elocation-id>e674</elocation-id><pub-id pub-id-type="doi">10.1038/tp.2015.166</pub-id><pub-id pub-id-type="pmid">26529427</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beattie</surname><given-names>J</given-names></name><name><surname>Brow</surname><given-names>GR</given-names></name><name><surname>Long</surname><given-names>CNH</given-names></name></person-group><year iso-8601-date="1930">1930</year><article-title>Physiological and anatomical evidence for the existence of nerve tracts connecting the hypothalamus with spinal sympathetic centres</article-title><source>Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character</source><volume>106</volume><fpage>253</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1098/rspb.1930.0027</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benedetti-Isaac</surname><given-names>JC</given-names></name><name><surname>Torres-Zambrano</surname><given-names>M</given-names></name><name><surname>Vargas-Toscano</surname><given-names>A</given-names></name><name><surname>Perea-Castro</surname><given-names>E</given-names></name><name><surname>Alcalá-Cerra</surname><given-names>G</given-names></name><name><surname>Furlanetti</surname><given-names>LL</given-names></name><name><surname>Reithmeier</surname><given-names>T</given-names></name><name><surname>Tierney</surname><given-names>TS</given-names></name><name><surname>Anastasopoulos</surname><given-names>C</given-names></name><name><surname>Fonoff</surname><given-names>ET</given-names></name><name><surname>Contreras Lopez</surname><given-names>WO</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Seizure frequency reduction after Posteromedial hypothalamus deep brain stimulation in drug-resistant epilepsy associated with intractable aggressive behavior</article-title><source>Epilepsia</source><volume>56</volume><fpage>1152</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1111/epi.13025</pub-id><pub-id pub-id-type="pmid">26146753</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blair</surname><given-names>RJR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The Neurobiology of impulsive aggression</article-title><source>Journal of Child and Adolescent Psychopharmacology</source><volume>26</volume><fpage>4</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1089/cap.2015.0088</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brentani</surname><given-names>H</given-names></name><name><surname>Paula</surname><given-names>CSD</given-names></name><name><surname>Bordini</surname><given-names>D</given-names></name><name><surname>Rolim</surname><given-names>D</given-names></name><name><surname>Sato</surname><given-names>F</given-names></name><name><surname>Portolese</surname><given-names>J</given-names></name><name><surname>Pacifico</surname><given-names>MC</given-names></name><name><surname>McCracken</surname><given-names>JT</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Autism spectrum disorders: an overview on diagnosis and treatment</article-title><source>Revista Brasileira de Psiquiatria</source><volume>35 Suppl 1</volume><fpage>S62</fpage><lpage>S72</lpage><pub-id pub-id-type="doi">10.1590/1516-4446-2013-S104</pub-id><pub-id pub-id-type="pmid">24142129</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carson</surname><given-names>MJ</given-names></name><name><surname>Thrash</surname><given-names>JC</given-names></name><name><surname>Walter</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The cellular response in Neuroinflammation: the role of leukocytes, Microglia and Astrocytes in neuronal death and survival</article-title><source>Clinical Neuroscience Research</source><volume>6</volume><fpage>237</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/j.cnr.2006.09.004</pub-id><pub-id pub-id-type="pmid">19169437</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>HH</given-names></name><name><surname>Wathen</surname><given-names>CA</given-names></name><name><surname>Mathews</surname><given-names>ND</given-names></name><name><surname>Hogue</surname><given-names>O</given-names></name><name><surname>Modic</surname><given-names>JP</given-names></name><name><surname>Kundalia</surname><given-names>R</given-names></name><name><surname>Wyant</surname><given-names>C</given-names></name><name><surname>Park</surname><given-names>H-J</given-names></name><name><surname>Najm</surname><given-names>IM</given-names></name><name><surname>Trapp</surname><given-names>BD</given-names></name><name><surname>Machado</surname><given-names>AG</given-names></name><name><surname>Baker</surname><given-names>KB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Lateral cerebellar nucleus stimulation promotes motor recovery and suppresses Neuroinflammation in a fluid percussion injury rodent model</article-title><source>Brain Stimulation</source><volume>11</volume><fpage>1356</fpage><lpage>1367</lpage><pub-id pub-id-type="doi">10.1016/j.brs.2018.07.051</pub-id><pub-id pub-id-type="pmid">30061053</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Subthalamic nucleus deep brain stimulation suppresses Neuroinflammation by Fractalkine pathway in Parkinson’s disease rat model</article-title><source>Brain, Behavior, and Immunity</source><volume>90</volume><fpage>16</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2020.07.035</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coblentz</surname><given-names>A</given-names></name><name><surname>Elias</surname><given-names>GJB</given-names></name><name><surname>Boutet</surname><given-names>A</given-names></name><name><surname>Germann</surname><given-names>J</given-names></name><name><surname>Algarni</surname><given-names>M</given-names></name><name><surname>Oliveira</surname><given-names>LM</given-names></name><name><surname>Neudorfer</surname><given-names>C</given-names></name><name><surname>Widjaja</surname><given-names>E</given-names></name><name><surname>Ibrahim</surname><given-names>GM</given-names></name><name><surname>Kalia</surname><given-names>SK</given-names></name><name><surname>Jain</surname><given-names>M</given-names></name><name><surname>Lozano</surname><given-names>AM</given-names></name><name><surname>Fasano</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mapping efficacious deep brain stimulation for pediatric dystonia</article-title><source>Journal of Neurosurgery. Pediatrics</source><volume>27</volume><fpage>346</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.3171/2020.7.PEDS20322</pub-id><pub-id pub-id-type="pmid">33385998</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Contreras Lopez</surname><given-names>WO</given-names></name><name><surname>Navarro</surname><given-names>PA</given-names></name><name><surname>Gouveia</surname><given-names>FV</given-names></name><name><surname>Fonoff</surname><given-names>ET</given-names></name><name><surname>Lebrun</surname><given-names>I</given-names></name><name><surname>Auada</surname><given-names>AVV</given-names></name><name><surname>Lopes Alho</surname><given-names>EJ</given-names></name><name><surname>Martinez</surname><given-names>RCR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Directional deep brain stimulation of the Posteromedial hypothalamus for refractory intermittent explosive disorder: A case series using a novel Neurostimulation device and intraoperative Microdialysis</article-title><source>World Neurosurgery</source><volume>155</volume><fpage>e19</fpage><lpage>e33</lpage><pub-id pub-id-type="doi">10.1016/j.wneu.2021.07.086</pub-id><pub-id pub-id-type="pmid">34325026</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coulombe</surname><given-names>M-A</given-names></name><name><surname>Elkaim</surname><given-names>LM</given-names></name><name><surname>Alotaibi</surname><given-names>NM</given-names></name><name><surname>Gorman</surname><given-names>DA</given-names></name><name><surname>Weil</surname><given-names>AG</given-names></name><name><surname>Fallah</surname><given-names>A</given-names></name><name><surname>Kalia</surname><given-names>SK</given-names></name><name><surname>Lipsman</surname><given-names>N</given-names></name><name><surname>Lozano</surname><given-names>AM</given-names></name><name><surname>Ibrahim</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Deep brain stimulation for Gilles de la Tourette syndrome in children and youth: a meta-analysis with individual participant data</article-title><source>Journal of Neurosurgery. Pediatrics</source><volume>23</volume><fpage>236</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.3171/2018.7.PEDS18300</pub-id><pub-id pub-id-type="pmid">30497215</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>B</given-names></name><name><surname>Giacobbe</surname><given-names>P</given-names></name><name><surname>George</surname><given-names>TP</given-names></name><name><surname>Nestor</surname><given-names>SM</given-names></name><name><surname>Rabin</surname><given-names>JS</given-names></name><name><surname>Goubran</surname><given-names>M</given-names></name><name><surname>Nyman</surname><given-names>AJ</given-names></name><name><surname>Baskaran</surname><given-names>A</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name><name><surname>Pople</surname><given-names>CB</given-names></name><name><surname>Graham</surname><given-names>SJ</given-names></name><name><surname>Tam</surname><given-names>F</given-names></name><name><surname>Hamani</surname><given-names>C</given-names></name><name><surname>Lipsman</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Deep brain stimulation of the nucleus accumbens in the treatment of severe alcohol use disorder: a phase I pilot trial</article-title><source>Molecular Psychiatry</source><volume>27</volume><fpage>3992</fpage><lpage>4000</lpage><pub-id pub-id-type="doi">10.1038/s41380-022-01677-6</pub-id><pub-id pub-id-type="pmid">35858989</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dembek</surname><given-names>TA</given-names></name><name><surname>Barbe</surname><given-names>MT</given-names></name><name><surname>Åström</surname><given-names>M</given-names></name><name><surname>Hoevels</surname><given-names>M</given-names></name><name><surname>Visser-Vandewalle</surname><given-names>V</given-names></name><name><surname>Fink</surname><given-names>GR</given-names></name><name><surname>Timmermann</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Probabilistic mapping of deep brain stimulation effects in essential tremor</article-title><source>NeuroImage. Clinical</source><volume>13</volume><fpage>164</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.nicl.2016.11.019</pub-id><pub-id pub-id-type="pmid">27981031</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dembek</surname><given-names>TA</given-names></name><name><surname>Roediger</surname><given-names>J</given-names></name><name><surname>Horn</surname><given-names>A</given-names></name><name><surname>Reker</surname><given-names>P</given-names></name><name><surname>Oehrn</surname><given-names>C</given-names></name><name><surname>Dafsari</surname><given-names>HS</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Kühn</surname><given-names>AA</given-names></name><name><surname>Fink</surname><given-names>GR</given-names></name><name><surname>Visser-Vandewalle</surname><given-names>V</given-names></name><name><surname>Barbe</surname><given-names>MT</given-names></name><name><surname>Timmermann</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Probabilistic sweet spots predict motor outcome for deep brain stimulation in Parkinson disease</article-title><source>Annals of Neurology</source><volume>86</volume><fpage>527</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1002/ana.25567</pub-id><pub-id pub-id-type="pmid">31376171</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Vloo</surname><given-names>P</given-names></name><name><surname>Lam</surname><given-names>E</given-names></name><name><surname>Elias</surname><given-names>GJ</given-names></name><name><surname>Boutet</surname><given-names>A</given-names></name><name><surname>Sutandar</surname><given-names>K</given-names></name><name><surname>Giacobbe</surname><given-names>P</given-names></name><name><surname>Woodside</surname><given-names>DB</given-names></name><name><surname>Lipsman</surname><given-names>N</given-names></name><name><surname>Lozano</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Long-term follow-up of deep brain stimulation for anorexia Nervosa</article-title><source>Journal of Neurology, Neurosurgery, and Psychiatry</source><volume>92</volume><fpage>1135</fpage><lpage>1136</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2020-325711</pub-id><pub-id pub-id-type="pmid">33687970</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Dudás</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2013">2013</year><source>The Human Hypothalamus: Anatomy, Functions and Disorders</source><publisher-name>Nova Science Publishers</publisher-name></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffley</surname><given-names>G</given-names></name><name><surname>Anderson</surname><given-names>DN</given-names></name><name><surname>Vorwerk</surname><given-names>J</given-names></name><name><surname>Dorval</surname><given-names>AD</given-names></name><name><surname>Butson</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Evaluation of Methodologies for computing the deep brain stimulation volume of tissue activated</article-title><source>Journal of Neural Engineering</source><volume>16</volume><elocation-id>066024</elocation-id><pub-id pub-id-type="doi">10.1088/1741-2552/ab3c95</pub-id><pub-id pub-id-type="pmid">31426036</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenstein</surname><given-names>SA</given-names></name><name><surname>Koller</surname><given-names>JM</given-names></name><name><surname>Black</surname><given-names>KD</given-names></name><name><surname>Campbell</surname><given-names>MC</given-names></name><name><surname>Lugar</surname><given-names>HM</given-names></name><name><surname>Ushe</surname><given-names>M</given-names></name><name><surname>Tabbal</surname><given-names>SD</given-names></name><name><surname>Karimi</surname><given-names>M</given-names></name><name><surname>Hershey</surname><given-names>T</given-names></name><name><surname>Perlmutter</surname><given-names>JS</given-names></name><name><surname>Black</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Functional anatomy of Subthalamic nucleus stimulation in Parkinson disease</article-title><source>Annals of Neurology</source><volume>76</volume><fpage>279</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1002/ana.24204</pub-id><pub-id pub-id-type="pmid">24953991</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elias</surname><given-names>GJB</given-names></name><name><surname>Giacobbe</surname><given-names>P</given-names></name><name><surname>Boutet</surname><given-names>A</given-names></name><name><surname>Germann</surname><given-names>J</given-names></name><name><surname>Beyn</surname><given-names>ME</given-names></name><name><surname>Gramer</surname><given-names>RM</given-names></name><name><surname>Pancholi</surname><given-names>A</given-names></name><name><surname>Joel</surname><given-names>SE</given-names></name><name><surname>Lozano</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Probing the circuitry of panic with deep brain stimulation: Connectomic analysis and review of the literature</article-title><source>Brain Stimulation</source><volume>13</volume><fpage>10</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.brs.2019.09.010</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elias</surname><given-names>GJB</given-names></name><name><surname>Boutet</surname><given-names>A</given-names></name><name><surname>Joel</surname><given-names>SE</given-names></name><name><surname>Germann</surname><given-names>J</given-names></name><name><surname>Gwun</surname><given-names>D</given-names></name><name><surname>Neudorfer</surname><given-names>C</given-names></name><name><surname>Gramer</surname><given-names>RM</given-names></name><name><surname>Algarni</surname><given-names>M</given-names></name><name><surname>Paramanandam</surname><given-names>V</given-names></name><name><surname>Prasad</surname><given-names>S</given-names></name><name><surname>Beyn</surname><given-names>ME</given-names></name><name><surname>Horn</surname><given-names>A</given-names></name><name><surname>Madhavan</surname><given-names>R</given-names></name><name><surname>Ranjan</surname><given-names>M</given-names></name><name><surname>Lozano</surname><given-names>CS</given-names></name><name><surname>Kühn</surname><given-names>AA</given-names></name><name><surname>Ashe</surname><given-names>J</given-names></name><name><surname>Kucharczyk</surname><given-names>W</given-names></name><name><surname>Munhoz</surname><given-names>RP</given-names></name><name><surname>Giacobbe</surname><given-names>P</given-names></name><name><surname>Kennedy</surname><given-names>SH</given-names></name><name><surname>Woodside</surname><given-names>DB</given-names></name><name><surname>Kalia</surname><given-names>SK</given-names></name><name><surname>Fasano</surname><given-names>A</given-names></name><name><surname>Hodaie</surname><given-names>M</given-names></name><name><surname>Lozano</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Probabilistic mapping of deep brain stimulation: insights from 15 years of therapy</article-title><source>Annals of Neurology</source><volume>89</volume><fpage>426</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1002/ana.25975</pub-id><pub-id pub-id-type="pmid">33252146</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Elias</surname><given-names>GJB</given-names></name></person-group><year iso-8601-date="2022">2022</year><chapter-title>Normative Connectomes and their use in DBS</chapter-title><person-group person-group-type="editor"><name><surname>Horn</surname><given-names>A</given-names></name></person-group><source>In Connectomic Deep Brain Stimulation</source><publisher-name>Elsevier</publisher-name><fpage>245</fpage><lpage>274</lpage></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elias</surname><given-names>GJB</given-names></name><name><surname>Germann</surname><given-names>J</given-names></name><name><surname>Boutet</surname><given-names>A</given-names></name><name><surname>Pancholi</surname><given-names>A</given-names></name><name><surname>Beyn</surname><given-names>ME</given-names></name><name><surname>Bhatia</surname><given-names>K</given-names></name><name><surname>Neudorfer</surname><given-names>C</given-names></name><name><surname>Loh</surname><given-names>A</given-names></name><name><surname>Rizvi</surname><given-names>SJ</given-names></name><name><surname>Bhat</surname><given-names>V</given-names></name><name><surname>Giacobbe</surname><given-names>P</given-names></name><name><surname>Woodside</surname><given-names>DB</given-names></name><name><surname>Kennedy</surname><given-names>SH</given-names></name><name><surname>Lozano</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Structuro-functional Surrogates of response to Subcallosal cingulate deep brain stimulation for depression</article-title><source>Brain</source><volume>145</volume><fpage>362</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1093/brain/awab284</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elkaim</surname><given-names>LM</given-names></name><name><surname>De Vloo</surname><given-names>P</given-names></name><name><surname>Kalia</surname><given-names>SK</given-names></name><name><surname>Lozano</surname><given-names>AM</given-names></name><name><surname>Ibrahim</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Deep brain stimulation for childhood dystonia: Current evidence and emerging practice</article-title><source>Expert Review of Neurotherapeutics</source><volume>18</volume><fpage>773</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1080/14737175.2018.1523721</pub-id><pub-id pub-id-type="pmid">30221558</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Encinas</surname><given-names>JM</given-names></name><name><surname>Hamani</surname><given-names>C</given-names></name><name><surname>Lozano</surname><given-names>AM</given-names></name><name><surname>Enikolopov</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Neurogenic hippocampal targets of deep brain stimulation</article-title><source>The Journal of Comparative Neurology</source><volume>519</volume><fpage>6</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1002/cne.22503</pub-id><pub-id pub-id-type="pmid">21120924</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ewert</surname><given-names>S</given-names></name><name><surname>Plettig</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Chakravarty</surname><given-names>MM</given-names></name><name><surname>Collins</surname><given-names>DL</given-names></name><name><surname>Herrington</surname><given-names>TM</given-names></name><name><surname>Kühn</surname><given-names>AA</given-names></name><name><surname>Horn</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Toward defining deep brain stimulation targets in MNI space: A subcortical Atlas based on Multimodal MRI, Histology and structural Connectivity</article-title><source>NeuroImage</source><volume>170</volume><fpage>271</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2017.05.015</pub-id><pub-id pub-id-type="pmid">28536045</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flament-Durand</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1980">1980</year><article-title>The hypothalamus: anatomy and functions</article-title><source>Acta Psychiatrica Belgica</source><volume>80</volume><fpage>364</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">7025580</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Florence</surname><given-names>G</given-names></name><name><surname>Sameshima</surname><given-names>K</given-names></name><name><surname>Fonoff</surname><given-names>ET</given-names></name><name><surname>Hamani</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Deep brain stimulation: more complex than the inhibition of cells and Excitation of fibers</article-title><source>The Neuroscientist</source><volume>22</volume><fpage>332</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1177/1073858415591964</pub-id><pub-id pub-id-type="pmid">26150316</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fornito</surname><given-names>A</given-names></name><name><surname>Arnatkevičiūtė</surname><given-names>A</given-names></name><name><surname>Fulcher</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Bridging the gap between Connectome and Transcriptome</article-title><source>Trends in Cognitive Sciences</source><volume>23</volume><fpage>34</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.tics.2018.10.005</pub-id><pub-id pub-id-type="pmid">30455082</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>MD</given-names></name><name><surname>Buckner</surname><given-names>RL</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Chakravarty</surname><given-names>MM</given-names></name><name><surname>Lozano</surname><given-names>AM</given-names></name><name><surname>Pascual-Leone</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Resting-state networks link invasive and noninvasive brain stimulation across diverse psychiatric and neurological diseases</article-title><source>PNAS</source><volume>111</volume><fpage>E4367</fpage><lpage>E4375</lpage><pub-id pub-id-type="doi">10.1073/pnas.1405003111</pub-id><pub-id pub-id-type="pmid">25267639</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mapping symptoms to brain networks with the human Connectome</article-title><source>The New England Journal of Medicine</source><volume>379</volume><fpage>2237</fpage><lpage>2245</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1706158</pub-id><pub-id pub-id-type="pmid">30575457</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franzini</surname><given-names>A</given-names></name><name><surname>Messina</surname><given-names>G</given-names></name><name><surname>Cordella</surname><given-names>R</given-names></name><name><surname>Marras</surname><given-names>C</given-names></name><name><surname>Broggi</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Deep brain stimulation of the Posteromedial hypothalamus: indications, long-term results, and neurophysiological considerations</article-title><source>Neurosurgical Focus</source><volume>29</volume><elocation-id>E13</elocation-id><pub-id pub-id-type="doi">10.3171/2010.5.FOCUS1094</pub-id><pub-id pub-id-type="pmid">20672915</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>A</given-names></name><name><surname>Bulteau</surname><given-names>C</given-names></name><name><surname>Cohen</surname><given-names>D</given-names></name><name><surname>Michaud</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2019">2019</year><source>Neurocognitive Development: Normative Development</source><publisher-name>Elsevier Science</publisher-name></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Germann</surname><given-names>J</given-names></name><name><surname>Elias</surname><given-names>GJB</given-names></name><name><surname>Boutet</surname><given-names>A</given-names></name><name><surname>Narang</surname><given-names>K</given-names></name><name><surname>Neudorfer</surname><given-names>C</given-names></name><name><surname>Horn</surname><given-names>A</given-names></name><name><surname>Loh</surname><given-names>A</given-names></name><name><surname>Deeb</surname><given-names>W</given-names></name><name><surname>Salvato</surname><given-names>B</given-names></name><name><surname>Almeida</surname><given-names>L</given-names></name><name><surname>Foote</surname><given-names>KD</given-names></name><name><surname>Rosenberg</surname><given-names>PB</given-names></name><name><surname>Tang-Wai</surname><given-names>DF</given-names></name><name><surname>Wolk</surname><given-names>DA</given-names></name><name><surname>Burke</surname><given-names>AD</given-names></name><name><surname>Salloway</surname><given-names>S</given-names></name><name><surname>Sabbagh</surname><given-names>MN</given-names></name><name><surname>Chakravarty</surname><given-names>MM</given-names></name><name><surname>Smith</surname><given-names>GS</given-names></name><name><surname>Lyketsos</surname><given-names>CG</given-names></name><name><surname>Okun</surname><given-names>MS</given-names></name><name><surname>Lozano</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Brain structures and networks responsible for stimulation-induced memory flashbacks during Forniceal deep brain stimulation for Alzheimer’s disease</article-title><source>Alzheimer’s &amp; Dementia</source><volume>17</volume><fpage>777</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1002/alz.12238</pub-id><pub-id pub-id-type="pmid">33480187</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Germann</surname><given-names>J</given-names></name><name><surname>Elias</surname><given-names>GJB</given-names></name><name><surname>Neudorfer</surname><given-names>C</given-names></name><name><surname>Boutet</surname><given-names>A</given-names></name><name><surname>Chow</surname><given-names>CT</given-names></name><name><surname>Wong</surname><given-names>EHY</given-names></name><name><surname>Parmar</surname><given-names>R</given-names></name><name><surname>Gouveia</surname><given-names>FV</given-names></name><name><surname>Loh</surname><given-names>A</given-names></name><name><surname>Giacobbe</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Jung</surname><given-names>HH</given-names></name><name><surname>Bhat</surname><given-names>V</given-names></name><name><surname>Kucharczyk</surname><given-names>W</given-names></name><name><surname>Chang</surname><given-names>JW</given-names></name><name><surname>Lozano</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Potential optimization of focused ultrasound Capsulotomy for obsessive compulsive disorder</article-title><source>Brain</source><volume>144</volume><fpage>3529</fpage><lpage>3540</lpage><pub-id pub-id-type="doi">10.1093/brain/awab232</pub-id><pub-id pub-id-type="pmid">34145884</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gouveia</surname><given-names>FV</given-names></name><name><surname>Hamani</surname><given-names>C</given-names></name><name><surname>Fonoff</surname><given-names>ET</given-names></name><name><surname>Brentani</surname><given-names>H</given-names></name><name><surname>Alho</surname><given-names>EJL</given-names></name><name><surname>de Morais</surname><given-names>RMCB</given-names></name><name><surname>de Souza</surname><given-names>AL</given-names></name><name><surname>Rigonatti</surname><given-names>SP</given-names></name><name><surname>Martinez</surname><given-names>RCR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Amygdala and hypothalamus: historical overview with focus on aggression</article-title><source>Neurosurgery</source><volume>85</volume><fpage>11</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1093/neuros/nyy635</pub-id><pub-id pub-id-type="pmid">30690521</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gouveia</surname><given-names>FV</given-names></name><name><surname>Germann</surname><given-names>J</given-names></name><name><surname>Devenyi</surname><given-names>GA</given-names></name><name><surname>Morais</surname><given-names>RMCB</given-names></name><name><surname>Santos</surname><given-names>APM</given-names></name><name><surname>Fonoff</surname><given-names>ET</given-names></name><name><surname>Hamani</surname><given-names>C</given-names></name><name><surname>Brentani</surname><given-names>H</given-names></name><name><surname>Chakravarty</surname><given-names>MM</given-names></name><name><surname>Martinez</surname><given-names>RCR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Refractoriness of aggressive behaviour to pharmacological treatment: cortical thickness analysis in autism spectrum disorder</article-title><source>BJPsych Open</source><volume>6</volume><elocation-id>e96</elocation-id><pub-id pub-id-type="doi">10.1192/bjo.2020.91</pub-id><pub-id pub-id-type="pmid">32873365</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gouveia</surname><given-names>FV</given-names></name><name><surname>Germann</surname><given-names>J</given-names></name><name><surname>de Morais</surname><given-names>R</given-names></name><name><surname>Fonoff</surname><given-names>ET</given-names></name><name><surname>Hamani</surname><given-names>C</given-names></name><name><surname>Alho</surname><given-names>EJ</given-names></name><name><surname>Brentani</surname><given-names>H</given-names></name><name><surname>Martins</surname><given-names>AP</given-names></name><name><surname>Devenyi</surname><given-names>G</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name><name><surname>Steele</surname><given-names>C</given-names></name><name><surname>Gramer</surname><given-names>R</given-names></name><name><surname>Chakravarty</surname><given-names>M</given-names></name><name><surname>Martinez</surname><given-names>RCR</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Longitudinal changes after amygdala surgery for intractable aggressive behavior: clinical, imaging Genetics, and deformation-based Morphometry study-A case series</article-title><source>Neurosurgery</source><volume>88</volume><fpage>E158</fpage><lpage>E169</lpage><pub-id pub-id-type="doi">10.1093/neuros/nyaa378</pub-id><pub-id pub-id-type="pmid">33026432</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gouveia</surname><given-names>FV</given-names></name><name><surname>Germann</surname><given-names>J</given-names></name><name><surname>Devenyi</surname><given-names>GA</given-names></name><name><surname>Fonoff</surname><given-names>ET</given-names></name><name><surname>Morais</surname><given-names>RMCB</given-names></name><name><surname>Brentani</surname><given-names>H</given-names></name><name><surname>Chakravarty</surname><given-names>MM</given-names></name><name><surname>Martinez</surname><given-names>RCR</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Bilateral amygdala radio-frequency ablation for refractory aggressive behavior alters local cortical thickness to a pattern found in non-refractory patients</article-title><source>Frontiers in Human Neuroscience</source><volume>15</volume><elocation-id>653631</elocation-id><pub-id pub-id-type="doi">10.3389/fnhum.2021.653631</pub-id><pub-id pub-id-type="pmid">34177490</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gouveia</surname><given-names>FV</given-names></name><name><surname>Germann</surname><given-names>J</given-names></name><name><surname>Elias</surname><given-names>GJB</given-names></name><name><surname>Hamani</surname><given-names>C</given-names></name><name><surname>Fonoff</surname><given-names>ET</given-names></name><name><surname>Martinez</surname><given-names>RCR</given-names></name></person-group><year iso-8601-date="2021">2021c</year><article-title>Case report: 5 years follow-up on posterior hypothalamus deep brain stimulation for intractable aggressive behaviour associated with drug-resistant epilepsy</article-title><source>Brain Stimulation</source><volume>14</volume><fpage>1201</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1016/j.brs.2021.07.062</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Gouveia</surname><given-names>FV</given-names></name><name><surname>Diwan</surname><given-names>M</given-names></name><name><surname>Martinez</surname><given-names>RC</given-names></name><name><surname>Giacobbe</surname><given-names>P</given-names></name><name><surname>Lipsman</surname><given-names>N</given-names></name><name><surname>Hamani</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Reduction of Aggressive Behaviour Following Hypothalamic Deep Brain Stimulation: Involvement of 5-HT <sub>1A</sub> and Testosterone</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2023.03.20.533520</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>AM</given-names></name><name><surname>Pounds-Cornish</surname><given-names>E</given-names></name><name><surname>Eccles</surname><given-names>FJR</given-names></name><name><surname>Aziz</surname><given-names>TZ</given-names></name><name><surname>Green</surname><given-names>AL</given-names></name><name><surname>Scott</surname><given-names>RB</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Deep brain stimulation as a treatment for neuropathic pain: a longitudinal study addressing neuropsychological outcomes</article-title><source>The Journal of Pain</source><volume>15</volume><fpage>283</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.jpain.2013.11.003</pub-id><pub-id pub-id-type="pmid">24333399</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagopian</surname><given-names>LP</given-names></name><name><surname>Rooker</surname><given-names>GW</given-names></name><name><surname>Zarcone</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Delineating subtypes of self-injurious behavior maintained by automatic reinforcement</article-title><source>Journal of Applied Behavior Analysis</source><volume>48</volume><fpage>523</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1002/jaba.236</pub-id><pub-id pub-id-type="pmid">26223959</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamani</surname><given-names>C</given-names></name><name><surname>Temel</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Deep brain stimulation for psychiatric disease: contributions and validity of animal models</article-title><source>Science Translational Medicine</source><volume>4</volume><elocation-id>142rv8</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3003722</pub-id><pub-id pub-id-type="pmid">22786683</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamani</surname><given-names>C</given-names></name><name><surname>Pilitsis</surname><given-names>J</given-names></name><name><surname>Rughani</surname><given-names>AI</given-names></name><name><surname>Rosenow</surname><given-names>JM</given-names></name><name><surname>Patil</surname><given-names>PG</given-names></name><name><surname>Slavin</surname><given-names>KS</given-names></name><name><surname>Abosch</surname><given-names>A</given-names></name><name><surname>Eskandar</surname><given-names>E</given-names></name><name><surname>Mitchell</surname><given-names>LS</given-names></name><name><surname>Kalkanis</surname><given-names>S</given-names></name><collab>American Society for Stereotactic and Functional Neurosurgery</collab><collab>Congress of Neurological Surgeons</collab><collab>CNS and American Association of Neurological Surgeons</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Deep brain stimulation for obsessive-compulsive disorder: Systematic review and evidence-based guideline sponsored by the American society for stereotactic and functional Neurosurgery and the Congress of neurological Surgeons (CNS) and endorsed by the CNS and American Association of neurological Surgeons</article-title><source>Neurosurgery</source><volume>75</volume><fpage>327</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1227/NEU.0000000000000499</pub-id><pub-id pub-id-type="pmid">25050579</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamani</surname><given-names>C</given-names></name><name><surname>Davidson</surname><given-names>B</given-names></name><name><surname>Corchs</surname><given-names>F</given-names></name><name><surname>Abrahao</surname><given-names>A</given-names></name><name><surname>Nestor</surname><given-names>SM</given-names></name><name><surname>Rabin</surname><given-names>JS</given-names></name><name><surname>Nyman</surname><given-names>AJ</given-names></name><name><surname>Phung</surname><given-names>L</given-names></name><name><surname>Goubran</surname><given-names>M</given-names></name><name><surname>Levitt</surname><given-names>A</given-names></name><name><surname>Talakoub</surname><given-names>O</given-names></name><name><surname>Giacobbe</surname><given-names>P</given-names></name><name><surname>Lipsman</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Deep brain stimulation of the Subgenual Cingulum and Uncinate Fasciculus for the treatment of Posttraumatic stress disorder</article-title><source>Science Advances</source><volume>8</volume><elocation-id>eadc9970</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.adc9970</pub-id><pub-id pub-id-type="pmid">36459550</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawrylycz</surname><given-names>MJ</given-names></name><name><surname>Lein</surname><given-names>ES</given-names></name><name><surname>Guillozet-Bongaarts</surname><given-names>AL</given-names></name><name><surname>Shen</surname><given-names>EH</given-names></name><name><surname>Ng</surname><given-names>L</given-names></name><name><surname>Miller</surname><given-names>JA</given-names></name><name><surname>van de Lagemaat</surname><given-names>LN</given-names></name><name><surname>Smith</surname><given-names>KA</given-names></name><name><surname>Ebbert</surname><given-names>A</given-names></name><name><surname>Riley</surname><given-names>ZL</given-names></name><name><surname>Abajian</surname><given-names>C</given-names></name><name><surname>Beckmann</surname><given-names>CF</given-names></name><name><surname>Bernard</surname><given-names>A</given-names></name><name><surname>Bertagnolli</surname><given-names>D</given-names></name><name><surname>Boe</surname><given-names>AF</given-names></name><name><surname>Cartagena</surname><given-names>PM</given-names></name><name><surname>Chakravarty</surname><given-names>MM</given-names></name><name><surname>Chapin</surname><given-names>M</given-names></name><name><surname>Chong</surname><given-names>J</given-names></name><name><surname>Dalley</surname><given-names>RA</given-names></name><name><surname>David Daly</surname><given-names>B</given-names></name><name><surname>Dang</surname><given-names>C</given-names></name><name><surname>Datta</surname><given-names>S</given-names></name><name><surname>Dee</surname><given-names>N</given-names></name><name><surname>Dolbeare</surname><given-names>TA</given-names></name><name><surname>Faber</surname><given-names>V</given-names></name><name><surname>Feng</surname><given-names>D</given-names></name><name><surname>Fowler</surname><given-names>DR</given-names></name><name><surname>Goldy</surname><given-names>J</given-names></name><name><surname>Gregor</surname><given-names>BW</given-names></name><name><surname>Haradon</surname><given-names>Z</given-names></name><name><surname>Haynor</surname><given-names>DR</given-names></name><name><surname>Hohmann</surname><given-names>JG</given-names></name><name><surname>Horvath</surname><given-names>S</given-names></name><name><surname>Howard</surname><given-names>RE</given-names></name><name><surname>Jeromin</surname><given-names>A</given-names></name><name><surname>Jochim</surname><given-names>JM</given-names></name><name><surname>Kinnunen</surname><given-names>M</given-names></name><name><surname>Lau</surname><given-names>C</given-names></name><name><surname>Lazarz</surname><given-names>ET</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Lemon</surname><given-names>TA</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Morris</surname><given-names>JA</given-names></name><name><surname>Overly</surname><given-names>CC</given-names></name><name><surname>Parker</surname><given-names>PD</given-names></name><name><surname>Parry</surname><given-names>SE</given-names></name><name><surname>Reding</surname><given-names>M</given-names></name><name><surname>Royall</surname><given-names>JJ</given-names></name><name><surname>Schulkin</surname><given-names>J</given-names></name><name><surname>Sequeira</surname><given-names>PA</given-names></name><name><surname>Slaughterbeck</surname><given-names>CR</given-names></name><name><surname>Smith</surname><given-names>SC</given-names></name><name><surname>Sodt</surname><given-names>AJ</given-names></name><name><surname>Sunkin</surname><given-names>SM</given-names></name><name><surname>Swanson</surname><given-names>BE</given-names></name><name><surname>Vawter</surname><given-names>MP</given-names></name><name><surname>Williams</surname><given-names>D</given-names></name><name><surname>Wohnoutka</surname><given-names>P</given-names></name><name><surname>Zielke</surname><given-names>HR</given-names></name><name><surname>Geschwind</surname><given-names>DH</given-names></name><name><surname>Hof</surname><given-names>PR</given-names></name><name><surname>Smith</surname><given-names>SM</given-names></name><name><surname>Koch</surname><given-names>C</given-names></name><name><surname>Grant</surname><given-names>SGN</given-names></name><name><surname>Jones</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>An Anatomically comprehensive Atlas of the adult human brain Transcriptome</article-title><source>Nature</source><volume>489</volume><fpage>391</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1038/nature11405</pub-id><pub-id pub-id-type="pmid">22996553</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="report"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>WR</given-names></name></person-group><year iso-8601-date="1945">1945</year><source>Von DEN Höheren Zentren des Vegetativen Funktionssystemes</source><publisher-name>Von DEN</publisher-name><pub-id pub-id-type="doi">10.5169/SEALS-306728</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoff</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1950">1950</year><article-title>The hypothalamus, its anatomy, physiology and pathology</article-title><source>Acta Neuroveg</source><volume>1</volume><fpage>123</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1007/BF01226522</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horn</surname><given-names>A</given-names></name><name><surname>Kühn</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Lead-DBS: A Toolbox for deep brain stimulation electrode Localizations and Visualizations</article-title><source>NeuroImage</source><volume>107</volume><fpage>127</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2014.12.002</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakobs</surname><given-names>M</given-names></name><name><surname>Fomenko</surname><given-names>A</given-names></name><name><surname>Lozano</surname><given-names>AM</given-names></name><name><surname>Kiening</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cellular, molecular, and clinical mechanisms of action of deep brain stimulation-a systematic review on established indications and outlook on future developments</article-title><source>EMBO Molecular Medicine</source><volume>11</volume><elocation-id>e9575</elocation-id><pub-id pub-id-type="doi">10.15252/emmm.201809575</pub-id><pub-id pub-id-type="pmid">30862663</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>A</given-names></name><name><surname>Bergman</surname><given-names>H</given-names></name><name><surname>Corander</surname><given-names>J</given-names></name><name><surname>Waldman</surname><given-names>ID</given-names></name><name><surname>Karrani</surname><given-names>N</given-names></name><name><surname>Salo</surname><given-names>B</given-names></name><name><surname>Jern</surname><given-names>P</given-names></name><name><surname>Ålgars</surname><given-names>M</given-names></name><name><surname>Sandnabba</surname><given-names>K</given-names></name><name><surname>Santtila</surname><given-names>P</given-names></name><name><surname>Westberg</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Alcohol and aggressive behavior in men--moderating effects of oxytocin receptor gene (OXTR) Polymorphisms</article-title><source>Genes, Brain and Behavior</source><volume>11</volume><fpage>214</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1111/j.1601-183X.2011.00744.x</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karas</surname><given-names>PJ</given-names></name><name><surname>Mikell</surname><given-names>CB</given-names></name><name><surname>Christian</surname><given-names>E</given-names></name><name><surname>Liker</surname><given-names>MA</given-names></name><name><surname>Sheth</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Deep brain stimulation: a mechanistic and clinical update</article-title><source>Neurosurgical Focus</source><volume>35</volume><elocation-id>E1</elocation-id><pub-id pub-id-type="doi">10.3171/2013.9.FOCUS13383</pub-id><pub-id pub-id-type="pmid">24175861</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knotkova</surname><given-names>H</given-names></name><name><surname>Hamani</surname><given-names>C</given-names></name><name><surname>Sivanesan</surname><given-names>E</given-names></name><name><surname>Le Beuffe</surname><given-names>MFE</given-names></name><name><surname>Moon</surname><given-names>JY</given-names></name><name><surname>Cohen</surname><given-names>SP</given-names></name><name><surname>Huntoon</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Neuromodulation for chronic pain</article-title><source>Lancet</source><volume>397</volume><fpage>2111</fpage><lpage>2124</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00794-7</pub-id><pub-id pub-id-type="pmid">34062145</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koenig</surname><given-names>J</given-names></name><name><surname>Rinnewitz</surname><given-names>L</given-names></name><name><surname>Warth</surname><given-names>M</given-names></name><name><surname>Hillecke</surname><given-names>TK</given-names></name><name><surname>Brunner</surname><given-names>R</given-names></name><name><surname>Resch</surname><given-names>F</given-names></name><name><surname>Kaess</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Psychobiological response to pain in female adolescents with Nonsuicidal self-injury</article-title><source>Journal of Psychiatry &amp; Neuroscience</source><volume>42</volume><fpage>189</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1503/jpn.160074</pub-id><pub-id pub-id-type="pmid">28234208</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuleshov</surname><given-names>MV</given-names></name><name><surname>Jones</surname><given-names>MR</given-names></name><name><surname>Rouillard</surname><given-names>AD</given-names></name><name><surname>Fernandez</surname><given-names>NF</given-names></name><name><surname>Duan</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Koplev</surname><given-names>S</given-names></name><name><surname>Jenkins</surname><given-names>SL</given-names></name><name><surname>Jagodnik</surname><given-names>KM</given-names></name><name><surname>Lachmann</surname><given-names>A</given-names></name><name><surname>McDermott</surname><given-names>MG</given-names></name><name><surname>Monteiro</surname><given-names>CD</given-names></name><name><surname>Gundersen</surname><given-names>GW</given-names></name><name><surname>Ma’ayan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Enrichr: a comprehensive Gene set enrichment analysis web server 2016 update</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>W90</fpage><lpage>W97</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw377</pub-id><pub-id pub-id-type="pmid">27141961</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacadie</surname><given-names>CM</given-names></name><name><surname>Fulbright</surname><given-names>RK</given-names></name><name><surname>Rajeevan</surname><given-names>N</given-names></name><name><surname>Constable</surname><given-names>RT</given-names></name><name><surname>Papademetris</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>More accurate Talairach coordinates for neuroimaging using non-linear registration</article-title><source>NeuroImage</source><volume>42</volume><fpage>717</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2008.04.240</pub-id><pub-id pub-id-type="pmid">18572418</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lechan</surname><given-names>RM</given-names></name><name><surname>Toni</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><chapter-title>Endotext</chapter-title><person-group person-group-type="editor"><name><surname>Feingold,</surname><given-names>KR</given-names></name></person-group><source>Functional Anatomy of the Hypothalamus and Pituitary</source><publisher-loc>MDText.com</publisher-loc><publisher-name>Inc</publisher-name></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leplus</surname><given-names>A</given-names></name><name><surname>Lauritzen</surname><given-names>I</given-names></name><name><surname>Melon</surname><given-names>C</given-names></name><name><surname>Kerkerian-Le Goff</surname><given-names>L</given-names></name><name><surname>Fontaine</surname><given-names>D</given-names></name><name><surname>Checler</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Chronic Fornix deep brain stimulation in a transgenic Alzheimer’s rat model reduces Amyloid burden, inflammation, and neuronal loss</article-title><source>Brain Structure &amp; Function</source><volume>224</volume><fpage>363</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1007/s00429-018-1779-x</pub-id><pub-id pub-id-type="pmid">30341742</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Baldermann</surname><given-names>JC</given-names></name><name><surname>Kibleur</surname><given-names>A</given-names></name><name><surname>Treu</surname><given-names>S</given-names></name><name><surname>Akram</surname><given-names>H</given-names></name><name><surname>Elias</surname><given-names>GJB</given-names></name><name><surname>Boutet</surname><given-names>A</given-names></name><name><surname>Lozano</surname><given-names>AM</given-names></name><name><surname>Al-Fatly</surname><given-names>B</given-names></name><name><surname>Strange</surname><given-names>B</given-names></name><name><surname>Barcia</surname><given-names>JA</given-names></name><name><surname>Zrinzo</surname><given-names>L</given-names></name><name><surname>Joyce</surname><given-names>E</given-names></name><name><surname>Chabardes</surname><given-names>S</given-names></name><name><surname>Visser-Vandewalle</surname><given-names>V</given-names></name><name><surname>Polosan</surname><given-names>M</given-names></name><name><surname>Kuhn</surname><given-names>J</given-names></name><name><surname>Kühn</surname><given-names>AA</given-names></name><name><surname>Horn</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A unified Connectomic target for deep brain stimulation in obsessive-compulsive disorder</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>3364</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-16734-3</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipsman</surname><given-names>N</given-names></name><name><surname>Ellis</surname><given-names>M</given-names></name><name><surname>Lozano</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Current and future indications for deep brain stimulation in pediatric populations</article-title><source>Neurosurgical Focus</source><volume>29</volume><elocation-id>E2</elocation-id><pub-id pub-id-type="doi">10.3171/2010.5.FOCUS1095</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>López Ríos</surname><given-names>AL</given-names></name><name><surname>Germann</surname><given-names>J</given-names></name><name><surname>Hutchison</surname><given-names>WD</given-names></name><name><surname>Botero Posada</surname><given-names>LF</given-names></name><name><surname>Ahunca Velasquez</surname><given-names>LF</given-names></name><name><surname>Garcia Jimenez</surname><given-names>FA</given-names></name><name><surname>Gloria Escobar</surname><given-names>JM</given-names></name><name><surname>Chacon Ruiz Martinez</surname><given-names>R</given-names></name><name><surname>Hamani</surname><given-names>C</given-names></name><name><surname>Lebrun</surname><given-names>I</given-names></name><name><surname>Auada</surname><given-names>AVV</given-names></name><name><surname>Restrepo Bravo</surname><given-names>CA</given-names></name><name><surname>Gouveia</surname><given-names>FV</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Long-term follow-up on bilateral posterior hypothalamic deep brain stimulation for treating refractory aggressive behavior in a patient with CRI Du chat syndrome: analysis of clinical data</article-title><source>Stereotactic and Functional Neurosurgery</source><volume>100</volume><fpage>275</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1159/000526871</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lozano</surname><given-names>AM</given-names></name><name><surname>Mayberg</surname><given-names>HS</given-names></name><name><surname>Giacobbe</surname><given-names>P</given-names></name><name><surname>Hamani</surname><given-names>C</given-names></name><name><surname>Craddock</surname><given-names>RC</given-names></name><name><surname>Kennedy</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression</article-title><source>Biological Psychiatry</source><volume>64</volume><fpage>461</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2008.05.034</pub-id><pub-id pub-id-type="pmid">18639234</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lozano</surname><given-names>AM</given-names></name><name><surname>Fosdick</surname><given-names>L</given-names></name><name><surname>Chakravarty</surname><given-names>MM</given-names></name><name><surname>Leoutsakos</surname><given-names>J-M</given-names></name><name><surname>Munro</surname><given-names>C</given-names></name><name><surname>Oh</surname><given-names>E</given-names></name><name><surname>Drake</surname><given-names>KE</given-names></name><name><surname>Lyman</surname><given-names>CH</given-names></name><name><surname>Rosenberg</surname><given-names>PB</given-names></name><name><surname>Anderson</surname><given-names>WS</given-names></name><name><surname>Tang-Wai</surname><given-names>DF</given-names></name><name><surname>Pendergrass</surname><given-names>JC</given-names></name><name><surname>Salloway</surname><given-names>S</given-names></name><name><surname>Asaad</surname><given-names>WF</given-names></name><name><surname>Ponce</surname><given-names>FA</given-names></name><name><surname>Burke</surname><given-names>A</given-names></name><name><surname>Sabbagh</surname><given-names>M</given-names></name><name><surname>Wolk</surname><given-names>DA</given-names></name><name><surname>Baltuch</surname><given-names>G</given-names></name><name><surname>Okun</surname><given-names>MS</given-names></name><name><surname>Foote</surname><given-names>KD</given-names></name><name><surname>McAndrews</surname><given-names>MP</given-names></name><name><surname>Giacobbe</surname><given-names>P</given-names></name><name><surname>Targum</surname><given-names>SD</given-names></name><name><surname>Lyketsos</surname><given-names>CG</given-names></name><name><surname>Smith</surname><given-names>GS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A phase II study of Fornix deep brain stimulation in mild Alzheimer’s disease</article-title><source>Journal of Alzheimer’s Disease</source><volume>54</volume><fpage>777</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.3233/JAD-160017</pub-id><pub-id pub-id-type="pmid">27567810</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lozano</surname><given-names>AM</given-names></name><name><surname>Lipsman</surname><given-names>N</given-names></name><name><surname>Bergman</surname><given-names>H</given-names></name><name><surname>Brown</surname><given-names>P</given-names></name><name><surname>Chabardes</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>JW</given-names></name><name><surname>Matthews</surname><given-names>K</given-names></name><name><surname>McIntyre</surname><given-names>CC</given-names></name><name><surname>Schlaepfer</surname><given-names>TE</given-names></name><name><surname>Schulder</surname><given-names>M</given-names></name><name><surname>Temel</surname><given-names>Y</given-names></name><name><surname>Volkmann</surname><given-names>J</given-names></name><name><surname>Krauss</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Deep brain stimulation: Current challenges and future directions</article-title><source>Nature Reviews. Neurology</source><volume>15</volume><fpage>148</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1038/s41582-018-0128-2</pub-id><pub-id pub-id-type="pmid">30683913</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>AI</given-names></name><name><surname>Zai</surname><given-names>CC</given-names></name><name><surname>Abu</surname><given-names>Z</given-names></name><name><surname>Nowrouzi</surname><given-names>B</given-names></name><name><surname>Beitchman</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The role of oxytocin and oxytocin receptor gene variants in childhood-onset aggression</article-title><source>Genes, Brain, and Behavior</source><volume>11</volume><fpage>545</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1111/j.1601-183X.2012.00776.x</pub-id><pub-id pub-id-type="pmid">22372486</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansouri</surname><given-names>AM</given-names></name><name><surname>Germann</surname><given-names>J</given-names></name><name><surname>Boutet</surname><given-names>A</given-names></name><name><surname>Elias</surname><given-names>GJB</given-names></name><name><surname>Mithani</surname><given-names>K</given-names></name><name><surname>Chow</surname><given-names>CT</given-names></name><name><surname>Karmur</surname><given-names>B</given-names></name><name><surname>Ibrahim</surname><given-names>GM</given-names></name><name><surname>McAndrews</surname><given-names>MP</given-names></name><name><surname>Lozano</surname><given-names>AM</given-names></name><name><surname>Zadeh</surname><given-names>G</given-names></name><name><surname>Valiante</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Identification of neural networks preferentially engaged by epileptogenic mass lesions through lesion network mapping analysis</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>10989</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-67626-x</pub-id><pub-id pub-id-type="pmid">32620922</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markello</surname><given-names>RD</given-names></name><name><surname>Arnatkeviciute</surname><given-names>A</given-names></name><name><surname>Poline</surname><given-names>J-B</given-names></name><name><surname>Fulcher</surname><given-names>BD</given-names></name><name><surname>Fornito</surname><given-names>A</given-names></name><name><surname>Misic</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Standardizing workflows in imaging transcriptomics with the abagen toolbox</article-title><source>eLife</source><volume>10</volume><elocation-id>e72129</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.72129</pub-id><pub-id pub-id-type="pmid">34783653</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Micieli</surname><given-names>R</given-names></name><name><surname>Rios</surname><given-names>ALL</given-names></name><name><surname>Aguilar</surname><given-names>RP</given-names></name><name><surname>Posada</surname><given-names>LFB</given-names></name><name><surname>Hutchison</surname><given-names>WD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Single-unit analysis of the human posterior hypothalamus and red nucleus during deep brain stimulation for Aggressivity</article-title><source>Journal of Neurosurgery</source><volume>126</volume><fpage>1158</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.3171/2016.4.JNS141704</pub-id><pub-id pub-id-type="pmid">27341042</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miczek</surname><given-names>KA</given-names></name><name><surname>Fish</surname><given-names>EW</given-names></name><name><surname>De Bold</surname><given-names>JF</given-names></name><name><surname>De Almeida</surname><given-names>RMM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Social and neural determinants of aggressive behavior: Pharmacotherapeutic targets at serotonin, dopamine and gamma-aminobutyric acid systems</article-title><source>Psychopharmacology</source><volume>163</volume><fpage>434</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1007/s00213-002-1139-6</pub-id><pub-id pub-id-type="pmid">12373445</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miczek</surname><given-names>KA</given-names></name><name><surname>de Almeida</surname><given-names>RMM</given-names></name><name><surname>Kravitz</surname><given-names>EA</given-names></name><name><surname>Rissman</surname><given-names>EF</given-names></name><name><surname>de Boer</surname><given-names>SF</given-names></name><name><surname>Raine</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Neurobiology of escalated aggression and violence</article-title><source>The Journal of Neuroscience</source><volume>27</volume><fpage>11803</fpage><lpage>11806</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3500-07.2007</pub-id><pub-id pub-id-type="pmid">17978016</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="software"><person-group person-group-type="author"><collab>Mouse Imaging Centre, Hospital for Sick Children, Toronto Canada</collab></person-group><year iso-8601-date="2022">2022</year><data-title>Rminc</data-title><version designator="edfa0f4">edfa0f4</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/Mouse-Imaging-Centre/RMINC">https://github.com/Mouse-Imaging-Centre/RMINC</ext-link></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mroczek</surname><given-names>M</given-names></name><name><surname>Desouky</surname><given-names>A</given-names></name><name><surname>Sirry</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Imaging Transcriptomics in neurodegenerative diseases</article-title><source>Journal of Neuroimaging</source><volume>31</volume><fpage>244</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1111/jon.12827</pub-id><pub-id pub-id-type="pmid">33368775</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Najjar</surname><given-names>S</given-names></name><name><surname>Pearlman</surname><given-names>DM</given-names></name><name><surname>Alper</surname><given-names>K</given-names></name><name><surname>Najjar</surname><given-names>A</given-names></name><name><surname>Devinsky</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Neuroinflammation and psychiatric illness</article-title><source>Journal of Neuroinflammation</source><volume>10</volume><elocation-id>43</elocation-id><pub-id pub-id-type="doi">10.1186/1742-2094-10-43</pub-id><pub-id pub-id-type="pmid">23547920</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ne’eman</surname><given-names>R</given-names></name><name><surname>Perach-Barzilay</surname><given-names>N</given-names></name><name><surname>Fischer-Shofty</surname><given-names>M</given-names></name><name><surname>Atias</surname><given-names>A</given-names></name><name><surname>Shamay-Tsoory</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Intranasal administration of oxytocin increases human aggressive behavior</article-title><source>Hormones and Behavior</source><volume>80</volume><fpage>125</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.yhbeh.2016.01.015</pub-id><pub-id pub-id-type="pmid">26862988</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>ID</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Brain oxytocin: a key regulator of emotional and social Behaviours in both females and males</article-title><source>Journal of Neuroendocrinology</source><volume>20</volume><fpage>858</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2826.2008.01726.x</pub-id><pub-id pub-id-type="pmid">18601710</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieuwenhuys</surname><given-names>R</given-names></name><name><surname>Geeraedts</surname><given-names>LM</given-names></name><name><surname>Veening</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>The medial forebrain bundle of the rat. I. general introduction</article-title><source>The Journal of Comparative Neurology</source><volume>206</volume><fpage>49</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1002/cne.902060106</pub-id><pub-id pub-id-type="pmid">6124562</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Nieuwenhuys</surname><given-names>R</given-names></name><name><surname>Voogd</surname><given-names>J</given-names></name><name><surname>van</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2007">2007</year><source>The Human Central Nervous System: A Synopsis and Atlas</source><publisher-name>Springer</publisher-name></element-citation></ref><ref id="bib85"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Penny</surname><given-names>WD</given-names></name><name><surname>Friston</surname><given-names>KJ</given-names></name><name><surname>Ashburner</surname><given-names>JT</given-names></name><name><surname>Kiebel</surname><given-names>SJ</given-names></name><name><surname>Nichols</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2011">2011</year><source>Statistical Parametric Mapping: The Analysis of Functional Brain Images</source><publisher-name>Elsevier</publisher-name></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero-Garcia</surname><given-names>R</given-names></name><name><surname>Warrier</surname><given-names>V</given-names></name><name><surname>Bullmore</surname><given-names>ET</given-names></name><name><surname>Baron-Cohen</surname><given-names>S</given-names></name><name><surname>Bethlehem</surname><given-names>RAI</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Synaptic and Transcriptionally downregulated genes are associated with cortical thickness differences in autism</article-title><source>Molecular Psychiatry</source><volume>24</volume><fpage>1053</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1038/s41380-018-0023-7</pub-id><pub-id pub-id-type="pmid">29483624</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero-Garcia</surname><given-names>R</given-names></name><name><surname>Seidlitz</surname><given-names>J</given-names></name><name><surname>Whitaker</surname><given-names>KJ</given-names></name><name><surname>Morgan</surname><given-names>SE</given-names></name><name><surname>Fonagy</surname><given-names>P</given-names></name><name><surname>Dolan</surname><given-names>RJ</given-names></name><name><surname>Jones</surname><given-names>PB</given-names></name><name><surname>Goodyer</surname><given-names>IM</given-names></name><name><surname>Suckling</surname><given-names>J</given-names></name><name><surname>Vértes</surname><given-names>PE</given-names></name><name><surname>Bullmore</surname><given-names>ET</given-names></name><collab>NSPN Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Schizotypy-related Magnetization of cortex in healthy adolescence is Colocated with expression of schizophrenia-related genes</article-title><source>Biological Psychiatry</source><volume>88</volume><fpage>248</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2019.12.005</pub-id><pub-id pub-id-type="pmid">32029217</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salanova</surname><given-names>V</given-names></name><name><surname>Sperling</surname><given-names>MR</given-names></name><name><surname>Gross</surname><given-names>RE</given-names></name><name><surname>Irwin</surname><given-names>CP</given-names></name><name><surname>Vollhaber</surname><given-names>JA</given-names></name><name><surname>Giftakis</surname><given-names>JE</given-names></name><name><surname>Fisher</surname><given-names>RS</given-names></name><collab>SANTÉ Study Group</collab></person-group><year iso-8601-date="2021">2021</year><article-title>The SANTé study at 10 years of follow-up: effectiveness, safety, and sudden unexpected death in epilepsy</article-title><source>Epilepsia</source><volume>62</volume><fpage>1306</fpage><lpage>1317</lpage><pub-id pub-id-type="doi">10.1111/epi.16895</pub-id><pub-id pub-id-type="pmid">33830503</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sano</surname><given-names>K</given-names></name><name><surname>Yoshioka</surname><given-names>M</given-names></name><name><surname>Ogashiwa</surname><given-names>M</given-names></name><name><surname>Ishijima</surname><given-names>B</given-names></name><name><surname>Ohye</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1966">1966</year><article-title>Postero-medial Hypothalamotomy in the treatment of aggressive behaviors</article-title><source>Confinia Neurologica</source><volume>27</volume><fpage>164</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1159/000103949</pub-id><pub-id pub-id-type="pmid">5955970</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sano</surname><given-names>K</given-names></name><name><surname>Mayanagi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Posteromedial Hypothalamotomy in the treatment of violent, aggressive behaviour</article-title><source>Acta Neurochirurgica. Supplementum</source><volume>44</volume><fpage>145</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1007/978-3-7091-9005-0_28</pub-id><pub-id pub-id-type="pmid">3066130</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saper</surname><given-names>CB</given-names></name><name><surname>Lowell</surname><given-names>BB</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The hypothalamus</article-title><source>Current Biology</source><volume>24</volume><fpage>R1111</fpage><lpage>R1116</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2014.10.023</pub-id><pub-id pub-id-type="pmid">25465326</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seidlitz</surname><given-names>J</given-names></name><name><surname>Nadig</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Bethlehem</surname><given-names>RAI</given-names></name><name><surname>Vértes</surname><given-names>PE</given-names></name><name><surname>Morgan</surname><given-names>SE</given-names></name><name><surname>Váša</surname><given-names>F</given-names></name><name><surname>Romero-Garcia</surname><given-names>R</given-names></name><name><surname>Lalonde</surname><given-names>FM</given-names></name><name><surname>Clasen</surname><given-names>LS</given-names></name><name><surname>Blumenthal</surname><given-names>JD</given-names></name><name><surname>Paquola</surname><given-names>C</given-names></name><name><surname>Bernhardt</surname><given-names>B</given-names></name><name><surname>Wagstyl</surname><given-names>K</given-names></name><name><surname>Polioudakis</surname><given-names>D</given-names></name><name><surname>de la Torre-Ubieta</surname><given-names>L</given-names></name><name><surname>Geschwind</surname><given-names>DH</given-names></name><name><surname>Han</surname><given-names>JC</given-names></name><name><surname>Lee</surname><given-names>NR</given-names></name><name><surname>Murphy</surname><given-names>DG</given-names></name><name><surname>Bullmore</surname><given-names>ET</given-names></name><name><surname>Raznahan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Transcriptomic and cellular decoding of regional brain vulnerability to Neurogenetic disorders</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>5936</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-19362-z</pub-id><pub-id pub-id-type="pmid">33203864</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>EH</given-names></name><name><surname>Overly</surname><given-names>CC</given-names></name><name><surname>Jones</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The Allen human brain Atlas: comprehensive gene expression mapping of the human brain</article-title><source>Trends in Neurosciences</source><volume>35</volume><fpage>711</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2012.09.005</pub-id><pub-id pub-id-type="pmid">23041053</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sunkin</surname><given-names>SM</given-names></name><name><surname>Ng</surname><given-names>L</given-names></name><name><surname>Lau</surname><given-names>C</given-names></name><name><surname>Dolbeare</surname><given-names>T</given-names></name><name><surname>Gilbert</surname><given-names>TL</given-names></name><name><surname>Thompson</surname><given-names>CL</given-names></name><name><surname>Hawrylycz</surname><given-names>M</given-names></name><name><surname>Dang</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Allen brain Atlas: an integrated Spatio-temporal portal for exploring the central nervous system</article-title><source>Nucleic Acids Research</source><volume>41</volume><fpage>D996</fpage><lpage>D1008</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1042</pub-id><pub-id pub-id-type="pmid">23193282</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres</surname><given-names>CV</given-names></name><name><surname>Sola</surname><given-names>RG</given-names></name><name><surname>Pastor</surname><given-names>J</given-names></name><name><surname>Pedrosa</surname><given-names>M</given-names></name><name><surname>Navas</surname><given-names>M</given-names></name><name><surname>García-Navarrete</surname><given-names>E</given-names></name><name><surname>Ezquiaga</surname><given-names>E</given-names></name><name><surname>García-Camba</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Long-term results of Posteromedial hypothalamic deep brain stimulation for patients with resistant aggressiveness</article-title><source>Journal of Neurosurgery</source><volume>119</volume><fpage>277</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.3171/2013.4.JNS121639</pub-id><pub-id pub-id-type="pmid">23746102</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres</surname><given-names>CV</given-names></name><name><surname>Blasco</surname><given-names>G</given-names></name><name><surname>Navas García</surname><given-names>M</given-names></name><name><surname>Ezquiaga</surname><given-names>E</given-names></name><name><surname>Pastor</surname><given-names>J</given-names></name><name><surname>Vega-Zelaya</surname><given-names>L</given-names></name><name><surname>Pulido Rivas</surname><given-names>P</given-names></name><name><surname>Pérez Rodrigo</surname><given-names>S</given-names></name><name><surname>Manzanares</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Deep brain stimulation for aggressiveness: long-term follow-up and Tractography study of the stimulated brain areas</article-title><source>Journal of Neurosurgery</source><volume>1</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.3171/2019.11.JNS192608</pub-id><pub-id pub-id-type="pmid">32032944</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vedam-Mai</surname><given-names>V</given-names></name><name><surname>Baradaran-Shoraka</surname><given-names>M</given-names></name><name><surname>Reynolds</surname><given-names>BA</given-names></name><name><surname>Okun</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tissue response to deep brain stimulation and Microlesion: A comparative study</article-title><source>Neuromodulation</source><volume>19</volume><fpage>451</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1111/ner.12406</pub-id><pub-id pub-id-type="pmid">27018335</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Akram</surname><given-names>H</given-names></name><name><surname>Muthuraman</surname><given-names>M</given-names></name><name><surname>Gonzalez-Escamilla</surname><given-names>G</given-names></name><name><surname>Sheth</surname><given-names>SA</given-names></name><name><surname>Oxenford</surname><given-names>S</given-names></name><name><surname>Yeh</surname><given-names>F-C</given-names></name><name><surname>Groppa</surname><given-names>S</given-names></name><name><surname>Vanegas-Arroyave</surname><given-names>N</given-names></name><name><surname>Zrinzo</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Kühn</surname><given-names>A</given-names></name><name><surname>Horn</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Normative vs. patient-specific brain Connectivity in deep brain stimulation</article-title><source>NeuroImage</source><volume>224</volume><elocation-id>117307</elocation-id><pub-id pub-id-type="doi">10.1016/j.neuroimage.2020.117307</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Qin</surname><given-names>W</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Xue</surname><given-names>K</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Brain mRNA expression associated with cortical volume alterations in autism spectrum disorder</article-title><source>Cell Reports</source><volume>32</volume><elocation-id>108137</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108137</pub-id><pub-id pub-id-type="pmid">32937121</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Toyota</surname><given-names>E</given-names></name><name><surname>Anderson</surname><given-names>M</given-names></name><name><surname>Abel</surname><given-names>TJ</given-names></name><name><surname>Donner</surname><given-names>E</given-names></name><name><surname>Kalia</surname><given-names>SK</given-names></name><name><surname>Drake</surname><given-names>J</given-names></name><name><surname>Rutka</surname><given-names>JT</given-names></name><name><surname>Ibrahim</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A systematic review of deep brain stimulation for the treatment of drug-resistant epilepsy in childhood</article-title><source>Journal of Neurosurgery</source><volume>23</volume><fpage>274</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.3171/2018.9.PEDS18417</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Elkaim</surname><given-names>LM</given-names></name><name><surname>Venetucci Gouveia</surname><given-names>F</given-names></name><name><surname>Huber</surname><given-names>JF</given-names></name><name><surname>Germann</surname><given-names>J</given-names></name><name><surname>Loh</surname><given-names>A</given-names></name><name><surname>Benedetti-Isaac</surname><given-names>JC</given-names></name><name><surname>Doshi</surname><given-names>PK</given-names></name><name><surname>Torres</surname><given-names>CV</given-names></name><name><surname>Segar</surname><given-names>DJ</given-names></name><name><surname>Elias</surname><given-names>GJB</given-names></name><name><surname>Boutet</surname><given-names>A</given-names></name><name><surname>Cosgrove</surname><given-names>GR</given-names></name><name><surname>Fasano</surname><given-names>A</given-names></name><name><surname>Lozano</surname><given-names>AM</given-names></name><name><surname>Kulkarni</surname><given-names>AV</given-names></name><name><surname>Ibrahim</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Deep brain stimulation for extreme behaviors associated with autism spectrum disorder Converges on a common pathway: a systematic review and Connectomic analysis</article-title><source>Journal of Neurosurgery</source><volume>1</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.3171/2021.11.JNS21928</pub-id><pub-id pub-id-type="pmid">35061980</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84566.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Forstmann</surname><given-names>Birte U</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04dkp9463</institution-id><institution>University of Amsterdam</institution></institution-wrap><country>Netherlands</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.10.29.22281666" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.10.29.22281666"/></front-stub><body><p>This study presents useful structural and functional connectivity profiles of patients receiving deep brain stimulation in the posterior hypothalamus for severe and refractory aggressive behavior. The inclusion of data from multiple centers is compelling. This study will be important for a broad readership including basic and clinical neuroscientists.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84566.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Forstmann</surname><given-names>Birte U</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04dkp9463</institution-id><institution>University of Amsterdam</institution></institution-wrap><country>Netherlands</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.10.29.22281666">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2022.10.29.22281666v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Networks and genes modulated by posterior hypothalamic stimulation in patients with aggressive behaviours: Analysis of probabilistic mapping, normative connectomics, and atlas-derived transcriptomics of the largest international multi-centre dataset&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Michael Frank as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. The validation of findings is heterogeneous and inconsistent across analysis pipelines. While the authors performed non-parametric permutation testing during sweet-spot mapping, structural and functional connectivity were validated using a 'four-fold consistency analysis'. The latter consists of a visual representation of streamlines and peak intensities after randomly dividing data into four groups, the findings were not validated quantitatively. If possible, the authors should apply permutation analysis in alignment with sweet-spot mapping and demonstrate the predictive ability of their identified networks in a LOO or k-fold cross-validation paradigm as carried out by similar studies. Given that the data has been derived from multiple centers, the prediction of left-out cohorts based on models generated by the remaining cohorts could be another means of validation. If validation is not possible, the authors should clearly state the limitations of their approach.</p><p>2. In addition to a 'four-fold consistency analysis', functional connectivity was evaluated using LOOCV in a-priori-identified ROIs. Their network analysis, however, revealed a far more extensive network encompassing cortical, subcortical, and cerebellar structures. To avoid selection bias the authors should incorporate identified structures into their analysis and apply appropriate means of validation.</p><p>3. Functional connectivity mapping: how were R-maps generated? The authors mention that patient-specific R-maps were p-thresholded and corrected for multiple comparisons, but it is not clear how group-level maps were generated. How did the authors perform regression on these maps? Were voxels that did not survive thresholding excluded?</p><p>4. The authors determined that age was a significant prédictor of the outcome, but it is unclear whether certain age groups presented with distinct etiologies underlying their aggressiveness. For example, aggression in epilepsy may show a better response to DBS as opposed to schizophrenia. How does patient outcome change when stratifying according to etiology? How does model performance change when controlling for etiology? The authors should include the etiology of aggressiveness in Table 1.</p><p>5. Stimulation parameters. The authors report average pulse widths of 219 µs and 142µs respectively, which is up to 4-fold higher as compared to DBS settings used conventionally in movement disorders and will significantly alter the volume of activated tissue. Did the authors account for the drastic increases in pulse width during VAT modeling?</p><p>6. Imaging transcriptomics. The methods described lack detail: How did the authors account for differences in expression across donors, samples, and regions during preprocessing of the Allen Human Brain Atlas? How was expression data collapsed into regions of interest? Did the authors apply any normalization? Recent publications have introduced reproducible workflows for processing and preparing the AHBA expression data for analysis that is publicly available.</p><p>7. 'genes with similar patterns of spatial distribution to the TFCE map were compiled in an extensive list'. It is unclear why authors used TFCE maps for spatial transcriptomics as opposed to the functional connectivity map featured in Figure 5. How was similarity measured between the TFCE map and the AHBA? How were candidate genes identified? Please provide a more comprehensive description of the analysis pipeline.</p><p>8. What do the bar plots in Figure 7 (left) represent? P-values? The authors should label the axes to make this clear to the reader.</p><p>9. Interprétation of imaging transcriptomics: The authors identify a therapeutic circuit associated with deep brain stimulation of the posterior hypothalamic area, however, it is unclear how to reconcile genes associated with hormones, inflammation, and plasticity in this context. The authors mention and discuss genes implicated in hormonal processing, specifically oxytocin. The results provided in Figure 7, however, do not support this finding and it is unclear how the authors identified genes linked to oxytocin. In addition, the authors identified reductions in the number of microglia and astrocytes, while oligodendrocytes were overexpressed relative to the expected distribution of genes per cell type. These findings were attributed to DBS effects, however, both connectomic and transcriptomic data are acquired from healthy subjects, which suggests a physiological deficit/enrichment in a therapeutic circuit. How do the authors interpret findings given that no electrode implantation and stimulation were performed?</p><p>10. Data availability. Code used for data processing should be made openly available or shared as source data along with the Figures that were generated using the code. Sweet-spot, structural, and functional connectivity maps should be shared openly.</p><p>11. Methods: Given the small number of patients over 5 centers, the authors should better address the similarities and differences of data collection across the sites.</p><p>12. Results: Clinically relevant bundles included somatosensory, emotions, and motor connections. This is pretty much a summary of connections through the hypothalamus and surrounding regions. Do the authors suggest that the effectiveness of DBS in this region is this nonspecific?</p><p>13. Indeed, it appears that the motor system is most involved based on the tractography. This is consistent with figure 3 in which the 'sweet spot' appears to be lateral to the hypothalamus and more centered in the red nucleus/STN region (Figures 1 and 3).</p><p>14. The emphasis on connections on monoamine connections (P. 7) is unwarranted, given the stronger connections to motor regions. Moreover, both DBS and tractography favor myelinated fibers over unmyelinated ones. The monoamines are unmyelinated. Finally, the MFB is a relatively small bundle compared to others in the region that carry motor and sensory information to and from the brainstem. The resolution of tractography is unlikely to distinguish the MFB and favor other fiber tracts.</p><p>15. In this regard, the paragraph on P. 9, &quot;functional connectivity…&quot; is confusing. (My understanding is that the authors are linking connections to the amygdala, etc.) via the monoamines. Is that correct? If so, that's a discussion point and not well supported by the connectivity data.</p><p>16. Other comments: The introduction lacks clear text referring to the organization and connections of the hypothalamus based on classic literature.</p><p>17. Examples. First, the authors described the division into 3 regions: anterior, medial, and posterior (reference is the author's article in neurosurgery). Then, without reference to these three regions, describe preclinical studies of the lateral and ventromedial hypothalamus. How do these two areas relate to the three regions?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84566.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The validation of findings is heterogeneous and inconsistent across analysis pipelines. While the authors performed non-parametric permutation testing during sweet-spot mapping, structural and functional connectivity were validated using a 'four-fold consistency analysis'. The latter consists of a visual representation of streamlines and peak intensities after randomly dividing data into four groups, the findings were not validated quantitatively. If possible, the authors should apply permutation analysis in alignment with sweet-spot mapping and demonstrate the predictive ability of their identified networks in a LOO or k-fold cross-validation paradigm as carried out by similar studies. Given that the data has been derived from multiple centers, the prediction of left-out cohorts based on models generated by the remaining cohorts could be another means of validation. If validation is not possible, the authors should clearly state the limitations of their approach.</p></disp-quote><p>We agree with the reviewer, and have now improved the validation of our connectomics analyses and removed the four-fold consistency analysis. As for the functional connectivity analysis, we performed a 1000 permutation test (p&lt;0.05), which resulted in an extremely similar map, with the same main brain areas being detected in the corrected and uncorrected maps. Regarding the structural connectivity analysis, we used False Discovery Rate (FDR) correction at a significant level of p&lt;0.001, as it is not feasible to perform a 1000 permutation test with this data. The structural connectome is composed of 12 million fibres, and every single permutation takes approximately 4 hours to be completed using our most powerful computational system. To perform 1000 permutations, it would take at least 4000 hours (i.e. 167 days or 5.5 months) of uninterrupted analysis to complete the test. However, it is important to highlight that an FDR correction at the level of p&lt;0.001 is an extremely stringent method. This means that of the 23,000 fibres detected as being touched by the VATs, only 23 could be incorrect, while the remaining 22,977 are correct. Here again, we observed many similarities between the uncorrected and corrected maps, with the main anatomical structures being detected in both.</p><p>We replaced the brain slices in Figures 4 and 5 to demonstrate the new corrected maps and added the information to the Methods section as follows:</p><p>Methods, section: Imaging Connectomics Analyses – Structural and Functional Connectivity Mapping. pg 15, 2nd paragraph:</p><p>“For generating group-level maps, a voxel-wise linear regression analysis investigating the relationship between the functional connectivity of the VATs and the individual clinical outcome was then performed, followed by non-parametric permutation analysis. The individual improvement scores were randomly assigned to a functional connectivity map, and the analysis was repeated 1000 times. At each voxel, p<sub>permute</sub>&lt;0.05 was used as a significance threshold for the final functional connectivity analysis. Figure 1—figure supplement 1 illustrates this process.”</p><p>Methods, section: Imaging Connectomics Analyses – Structural and Functional Connectivity Mapping. pg 17, 1st paragraph:</p><p>“The results were corrected for multiple comparisons using False Discovery Rate (FDR) at q<sub>FDRcor</sub>&lt;0.001.”</p><disp-quote content-type="editor-comment"><p>2) In addition to a 'four-fold consistency analysis', functional connectivity was evaluated using LOOCV in a-priori-identified ROIs. Their network analysis, however, revealed a far more extensive network encompassing cortical, subcortical, and cerebellar structures. To avoid selection bias the authors should incorporate identified structures into their analysis and apply appropriate means of validation.</p></disp-quote><p>We would like to thank the reviewer for this valuable suggestion. We originally did not explore the various significant areas but performed a more focused analysis intended to demonstrate that regions of the known ‘aggression network’ are indeed implicated in our findings. We performed a new analysis exploring the correlation between symptom improvement and the functional connectivity of all the areas described in Figure 5 (i.e. functional connectivity map). To this aim, we extracted individual connectivity values from the peak within each significant region and performed the same additive linear model as before, incorporating the functional connectivity of each area, as well as patient age, to estimate individual symptom improvement. In addition, we performed a complete exploratory analysis considering the connectivity of any 2 brain structures and age. The resulting matrix shows to what extent functional connectivity to any two areas can be used to estimate clinical outcomes. Interestingly, this new analysis revealed the Periaqueductal Grey matter (PAG) to be the most important functionally connected area when investigated alone or in combination with brain structures critically involved in the regulation of emotional responses, namely the amygdala, anterior cingulate cortex, bed nucleus of the stria terminalis, nucleus accumbens, orbitofrontal cortex and fusiform gyrus. Also, PAG significance was retained during leave-one-out cross-validation (LOOCV). We added a new Table 2 and Supplementary File 1 showing the results of these analyses, revised Figure 6 and adjusted the text to describe the new analysis and results in the Results, Methods and Discussion sections, as follows:</p><p>Results, section: Estimation of Clinical Outcome, pg 8, 2nd paragraph:</p><p>“To investigate whether individual functional connectivity to particular hubs within the neurocircuitry of aggressive behaviour could be used to estimate symptom improvement following pHyp-DBS, additive linear models were created. For this, we extracted individual connectivity values from the peak within each brain area where functional connectivity with the VATs was found to be significantly related to outcomes at the group level (as described in the Normative Connectomics Analyses, Figure 6A). The best-performing parsimonious model, which incorporated patient age as well as individual VAT functional connectivity, revealed the Periaqueductal Grey Matter (PAG) to be the only structure that, together with age, significantly predicted more than half of the variance in individual symptom improvement (R=0.72, R2=0.52, p=1.86e-05, Figure 6B, Table 2), retaining significance during leave-one-out cross-validation (LOOCV) (R=0.65, R2=0.42, p=4.406e-5; Figure 6C). Additionally, we investigated if functional connectivity of the VATs with any 2 brain areas, in addition to patient age, would improve the estimation of clinical outcome (Supplementary File 1). Indeed, connectivity with PAG and limbic structures, namely the amygdala (R=0.75, R2=0.57, p=4.20e-07), anterior cingulate cortex (rostral: R=0.76, R2=0.58, p=2.75e-07; dorsal: R=0.75, R2=0.57, p=3.96e-07), bed nucleus of the stria terminallis ( R=0.76, R2=0.58, p=2.75e07), left nucleus accumbens (R=0.76, R2=0.58, p=8.51e-07), right orbitofrontal cortex (R=0.76, R2=0.58, p=2.75e-07) and right fusiform gyrus (R=0.75, R2=0.56, p=4.67e-07) was superior in predicting outcome.”</p><p>Methods, section: Statistical Analysis, pg 18, 2nd paragraph:</p><p>“Additive linear models were used to test our ability to estimate the percentage of improvement from baseline using age and the functional connectivity of all brain areas functionally connected with the VATs.”</p><p>Discussion, pg 11, 2nd paragraph:</p><p>“The functional connectivity mapping showed that the successful VATs were functionally connected to several key areas within the neurocircuitry of aggressive behaviour, including the amygdala, nucleus accumbens, hypothalamus, periaqueductal gray, and cingulate cortex. To further explore these results, we investigated the relationship between the functional connectivity of each of these brain structures and individual treatment outcomes and observed that functional connectivity with the PAG is the most relevant. In addition, when modelling the functional connectivity of any two brain areas identified in the functional connectivity analysis, we observed that the most relevant connections involved the PAG and limbic structures believed to be at the core of the neurocircuitry of aggressive behaviour, such as the amygdala, anterior cingulate cortex, and nucleus accumbens. In line with our findings, previous studies have shown positive outcomes following ablative and neuromodulation treatments targeting the amygdala, hypothalamus, and nucleus accumbens for the control of aggressive behaviour 1,3,6,67. Moreover, PAG DBS – primarily performed to treat neuropathic pain 68 – has been reported to modulate mood and anxiety 69.”</p><disp-quote content-type="editor-comment"><p>3) Functional connectivity mapping: how were R-maps generated? The authors mention that patient-specific R-maps were p-thresholded and corrected for multiple comparisons, but it is not clear how group-level maps were generated. How did the authors perform regression on these maps? Were voxels that did not survive thresholding excluded?</p></disp-quote><p>This is a multiple-step analysis. First, it is necessary to localize the electrodes in each patient’s brain and estimate the volume of activated tissue (VAT) with the stimulation parameters associated with a symptomatic improvement. The VATs are then used as seeds for the next steps, during which we investigate how much functional influence the VTAs have on the other areas of the brain (i.e. individual r-map). This is done by correlating the BOLD time course of the VATs seed with the BOLD time course of all other voxels in the brain. The individual r-maps are then corrected for multiple comparisons to exclude voxels with potentially spurious correlations, resulting in an individual r-map that only included voxels surviving Bonferroni correction at the level of p&lt;0.05. Finally, to create group-level maps, a voxel-wise linear regression analysis is performed to investigate for each voxel of the map if more or less influence (corrected individual r-map with the functional connectivity of the patient’s VAT) is more or less related to the clinical outcome (i.e. individual improvement). The last step is permutation correction resulting in a significant group-level functional connectivity map (p<sub>permute</sub>&lt;0.05). We improved the text in the methods section to better describe the generation of the group-level maps and added a new Figure 1—figure supplement 1 illustrating this analysis.</p><p>Methods, section: Imaging Connectomics Analyses – Structural and Functional Connectivity Mapping, pg 16, 2nd paragraph:</p><p>“For generating group-level maps, a voxel-wise linear regression analysis investigating the relationship between the functional connectivity of the VATs and the individual clinical outcome was then performed, followed by non-parametric permutation analysis. The individual improvement scores were randomly assigned to a functional connectivity map, and the analysis was repeated 1000 times. At each voxel, p<sub>permute</sub>&lt;0.05 was used as a significance threshold for the final functional connectivity analysis.Figure 1—figure supplement 1 illustrates this process.”</p><disp-quote content-type="editor-comment"><p>4) The authors determined that age was a significant predictor of the outcome, but it is unclear whether certain age groups presented with distinct etiologies underlying their aggressiveness. For example, aggression in epilepsy may show a better response to DBS as opposed to schizophrenia. How does patient outcome change when stratifying according to etiology? How does model performance change when controlling for etiology? The authors should include the etiology of aggressiveness in Table 1.</p></disp-quote><p>This is a very interesting point. We observed a similar distribution between the pediatric and adult populations in relation to the most common etiologies. Epilepsy was the most frequent diagnosis in both populations (pediatric: 50%, adult: 62%), followed by autism spectrum disorder (pediatric: 34%, adult: 24%). The remaining etiologies were mostly composed of single cases. The percentage of intellectual disability was also similar in pediatric and adult populations. Severe deficits were observed in 75% of pediatric and 85% of adult patients, while moderate disability was present in 25% of pediatric and 15% of adult patients. The different diagnoses presented by the patient are reported in the legend of Table 1. This strategy was adopted, rather than presenting specific diagnoses in each patient’s row to preserve anonymity. In the end of Table 1, the diagnoses are reported from more to less frequent. We have added a sentence to the Results and Discussion sections as follows:</p><p>Results, section: Patients Included, pg 5, 3rd paragraph:</p><p>“The most frequent diagnoses were epilepsy (pediatric: 50%, adult: 62%) and ASD (pediatric: 34%, adult: 24%). Intellectual disability was observed in all cases. This was described as severe in 82% of patients (pediatric: 75%, adult: 85%) and moderate in 18% of patients (pediatric: 25%, adult: 15%). Table 1 presents demographic data.“</p><p>Discussion, pg 9, 3rd paragraph:</p><p>“Although we did not observe a difference in the main diagnosis between the pediatric and adult populations, the former presented the highest percentage of symptom improvement following pHyp-DBS treatment.”</p><disp-quote content-type="editor-comment"><p>5) Stimulation parameters. The authors report average pulse widths of 219 µs and 142µs respectively, which is up to 4-fold higher as compared to DBS settings used conventionally in movement disorders and will significantly alter the volume of activated tissue. Did the authors account for the drastic increases in pulse width during VAT modeling?</p></disp-quote><p>We thank the reviewer for raising this important point about the volume of activated tissue (VAT) modelled and the unusual pulse width observed in some patients in this cohort. These patients presented sympathetic side effects of stimulation when DBS was set with higher frequencies (e.g. increased heart rate and blood pressure). The final parameters selected were the ones that would lead to clinical benefits without generating side effects.</p><p>A multitude of models exists for estimating VATs, ranging from advanced axon cable models – the gold standard, which simulate axon membrane dynamics and require patient-specific diffusion-weighted imaging and tremendous computing power <sup>1</sup> – to simple heuristics-based models that estimate the rough extent of a VAT based on stimulation parameters without constructing an actual spatial model <sup>2–4</sup>. The model employed in the current paper (and a number of previous publications by our group <sup>5–10</sup>) is the FieldTripSimBio ‘E-field norm’ finite element method (FEM) model. This model, which was first described by Horn et al. <sup>11</sup> and is freely available in Lead-DBS (https://www.lead-dbs.org/), strikes a balance between the sophisticated axon cable models and the simpler heuristic models. In particular, this model constructs an electric field (E-field, by applying an electric field strength threshold, or activation threshold) and calculates a VAT associated with specific voltage settings and contact configurations, taking into account the conductivity of surrounding brain tissue and electrode components. Notably, studies comparing VAT modelling techniques <sup>12</sup> showed that ‘E-field norm’ FEM models closely approximate (&lt;0.1 mm difference) the gold standard axon cable models in terms of the size of VATs constructed for monopolar stimulation settings. However, it should be acknowledged that the FieldTripSimBio model in Lead-DBS does not allow the user to specifically enter values for stimulation pulse width, instead employing a standard activation/electric field strength threshold (0.2 V/mm) that reflects a combination of commonly modelled axon diameters (roughly 3.5 μm) and commonly used pulse width values (i.e., 60-90 μs). This threshold is based on work by researchers such as Astrom et al. <sup>13</sup> and reflects a ‘middle ground’ value reflective of the fact that any VAT model will necessarily be an imperfect approximation of how electrical stimulation interfaces with brain tissue, depending heavily on aspects such as the diameter of local axons. Nonetheless, it is understood that increased pulse width does meaningfully increase the effective range of stimulation (thus translating to a larger VAT) by lowering the activation threshold of nearby axons <sup>12</sup>.</p><p>Given that our patient cohort included a small number of patients who were stimulated with notably higher pulse widths than the pulse width value assumed by our model (90 μs), it is reasonable to consider whether we underestimated the VAT in these patients. To address this, we experimented by modelling these patients’ VATs using a simpler heuristic model <sup>2</sup> that does allow specific pulse width values to be selected by the user; specifically, we computed a range of VATs for these patients using varied pulse width values (ranging from 90 μs up to their actual pulse width values). Not surprisingly, this endeavour did yield larger VATs when higher pulse width values were used: on average, the absolute difference in VAT diameter between 90 μs and 450 μs (the largest pulse width observed in this cohort) versions of these patients’ VATs was 2 mm. To check whether this difference could have potentially impacted our results, we next repeated our probabilistic mapping analysis using altered VATs (specifically, VATs that were enlarged by 2 mm in diameter) for the patients with notably higher pulse width values. This new repeat analysis yielded a very similar average map to the original analysis: the overall map pattern and location/values of the peak corresponding to the most efficacious area for maximal symptom alleviation remaining unaltered, and only a few voxels on the periphery of the map changing in value by a couple of percentage points. As such, this new supplementary analysis indicates that our results are not meaningfully altered by the unusual pulse width observed in these patients.</p><p>We improved the Methods section of the manuscript and added a new Figure 3—figure supplement 2 illustrating both voxel efficacy maps.</p><p>Methods, section: Electrode localization and Volume of Activated Tissue (VAT) modelling, pg 15, 1st paragraph:</p><p>“Considering that increased pulse width increases the effective range of stimulation (thus translating to a larger VAT) by lowering the activation threshold of nearby axons 97, and given that our patient cohort included a small number of patients who received higher pulse widths than the ones assumed by the FieldTripSimBio model in Lead-DBS, we performed a supplementary analysis to investigate changes in VAT volumes by also modelling the pulse width observed in these patients. To this aim, we used a simpler heuristic model 38 that takes pulse width into account to compute additional VATs using pulse width values ranging from 90μs up to the patient’s actual pulse width values. As expected, this analysis yielded larger VATs when higher pulse width values were used, with an absolute difference in VAT diameter between 90 μs and 450 μs (the highest pulse width observed in this cohort) of 2 mm. Then, we investigated whether or not these larger VATs could have potentially impacted our results by performing a new probabilistic mapping analysis using the newly generated VATs (specifically, the largest VATs that were enlarged by 2 mm in diameter) for the patients with higher pulse width values. This new analysis yielded a very similar average map to the original analysis, with the overall map pattern and location/values of the peak corresponding to the most efficacious area for maximal symptom alleviation remaining unaltered with only a few voxels on the periphery of the map changing in value by a couple of percentage points (Figure 3—figure supplement 2). As such, this supplementary analysis indicates that our results were not meaningfully altered by the unusual pulse width observed in these patients.”</p><disp-quote content-type="editor-comment"><p>6 &amp; 7. Imaging transcriptomics. The methods described lack detail: How did the authors account for differences in expression across donors, samples, and regions during preprocessing of the Allen Human Brain Atlas? How was expression data collapsed into regions of interest? Did the authors apply any normalization? Recent publications have introduced reproducible workflows for processing and preparing the AHBA expression data for analysis that is publicly available. 'genes with similar patterns of spatial distribution to the TFCE map were compiled in an extensive list'. It is unclear why authors used TFCE maps for spatial transcriptomics as opposed to the functional connectivity map featured in Figure 5. How was similarity measured between the TFCE map and the AHBA? How were candidate genes identified? Please provide a more comprehensive description of the analysis pipeline.</p></disp-quote><p>We would like to apologize for the short description of this analysis. We performed a gene set analysis using the abagen toolbox (https://abagen.readthedocs.io/en/stable/index.html) to investigate genes whose spatial pattern is similar to the pattern observed for clinically relevant functional connectivity. For this analysis, we used the Allen Human Brain Atlas (https://alleninstitute.org/) microarray data describing the cortical, subcortical, brainstem and cerebellar localization of over 20,000 genes in the human brain (3702 anatomical locations from 6 neurotypical adult brains) <sup>14–17</sup>, along with a cell-specific aggregate gene set <sup>18</sup>. These data are provided preprocessed, with gene expression values, normalized across all donors’ brains, and registered to standard MNI space, allowing for the direct comparison between the spatial pattern of gene expression and the functional connectivity map (https://human.brain-map.org/microarray/search) <sup>15</sup>. The TFCE maps were used to create clusters of clinically relevant functional connectivity that have a spatial extent that overlaps with the anatomical locations where microarray data was obtained. We parcellated both datasets (results of functional connectivity analysis and Allen Gene Atlas) according to the Harvard-Oxford brain atlas and correlated the spatial distribution of gene expression with the spatial distribution of the results of the functional connectivity mapping. The resulting list of candidate genes was used as input in gene ontology tools to investigate the associated biological processes and cell types. It is important to highlight that this process involves 2 corrections for multiple comparisons using FDR at q&lt;0.005; one correction occurs at the level of the gene list to include only the most significant genes in the gene ontology analysis; and a second correction at the level of the gene ontology analysis to consider only the most significant biological processes. We improved the Methods section as follows:</p><p>Results, section: Imaging Transcriptomics – Gene set analysis, pg 8, 3rd paragraph:</p><p>“Finally, to investigate neural phenotypes and possible neurobiological mechanisms of treatments, we performed imaging transcriptomics analysis using the abagen toolbox (https://abagen.readthedocs.io/en/stable/index.html) and the human gene expression data from the Allen Human Brain Atlas (https://alleninstitute.org/). We investigated genes with a spatial distribution of expression that resembled the pattern of brain regions with clinically relevant (following TFCE correction) functional connectivity to the stimulation locus (qFDRcor&lt;0.0001).”</p><p>Discussion, page 12, 2nd paragraph:</p><p>“To further explore the dataset pooled in our study, we performed a spatial imaging transcriptomic analysis. Our goal was to investigate spatial correlations between gene expression patterns (i.e. microarray data from the Allen Human Brain Atlas) and imaging characteristics (i.e. functional connectivity map derived from the patient’s VATs) and possible molecular characteristics associated with symptom improvement (for a review on imaging transcriptomics see Fomito et al., 2019 70)”</p><p>Methods, section Imaging Transcriptomics – Gene Set Analysis, pg. 17, 2nd paragraph:</p><p>“We performed a gene set analysis using the abagen toolbox (https://abagen.readthedocs.io/en/stable/index.html) to investigate genes whose spatial pattern distribution is similar to the pattern of clinically relevant functional connectivity. For this analysis, we used the Allen Human Brain Atlas (https://alleninstitute.org/) microarray data describing the cortical, subcortical, brainstem and cerebellar localization of over 20,000 genes in the human brain (3702 anatomical locations from 6 neurotypical adult brains) 89–92, along with a cell-specific aggregate gene set 49. These data are provided preprocessed, with gene expression values normalized across all donors’ brains, and registered to standard MNI space allowing for the direct comparison between the spatial pattern of gene expression and the functional connectivity map (https://human.brain-map.org/microarray/search) 90. To achieve this spatial mapping, we first applied Threshold Free Cluster Enhancement (TFCE) to the functional connectivity map to generate clusters of significant functional connectivity with a spatial extent that overlaps with the anatomical locations where microarray data was obtained. Then, based on the Harvard-Oxford Atlas (http://www.cma.mgh.harvard.edu/), a regional parcellation covering 48 cortical and 21 subcortical areas in each hemisphere (a total of 138 parcellations) was applied to both datasets. A direct correlation between the spatial distribution of gene expression and functional connectivity analysis in each specific brain area was performed and corrected for multiple comparisons using FDR at qFDAcor&lt;0.005, resulting in a gene list composed of 1734 genes associated with biological processes and ratios of genes per cell type. This list was used as input for gene ontology analyses using the EnRichr Gene Ontology tool (https://maayanlab.cloud/Enrichr/), along with the Jensen Gene Ontology enrichment tool (https://jensenlab.org/resources/proteomics/) and the Kyoto Encyclopedia of Genes and Genomes (KEGG pathway enrichment; https://www.genome.jp/kegg/kegg1b.html), resulting in an extensive list of associated biological terms that were corrected for multiple comparisons using FDR at q<sub>FDAcor</sub>&lt;0.005.”</p><disp-quote content-type="editor-comment"><p>(8 &amp; 9) What do the bar plots in Figure 7 (left) represent? P-values? The authors should label the axes to make this clear to the reader. Interprétation of imaging transcriptomics: The authors identify a therapeutic circuit associated with deep brain stimulation of the posterior hypothalamic area, however, it is unclear how to reconcile genes associated with hormones, inflammation, and plasticity in this context. The authors mention and discuss genes implicated in hormonal processing, specifically oxytocin. The results provided in Figure 7, however, do not support this finding and it is unclear how the authors identified genes linked to oxytocin. In addition, the authors identified reductions in the number of microglia and astrocytes, while oligodendrocytes were overexpressed relative to the expected distribution of genes per cell type. These findings were attributed to DBS effects, however, both connectomic and transcriptomic data are acquired from healthy subjects, which suggests a physiological deficit/enrichment in a therapeutic circuit. How do the authors interpret findings given that no electrode implantation and stimulation were performed?</p></disp-quote><p>The analysis of normative datasets (functional and structural connectomics and spatial transcriptomics) is based on the idea of understanding underlying mechanisms of treatment considering our current knowledge of the average human brain. Unlike patient-specific studies where imaging is acquired from a single patient or genetic profiles are extracted from tissue samples, these normative analyses rely on high-quality “atlases” derived from healthy subjects, and, in the case of the functional and structural connectivity, atlases that are calculated from very large cohorts of subjects (around 1000 brain scans). Thus, imaging connectomics investigates the pattern of brain activity and structural connectivity related to a specific area of the brain (in this case, the volume of tissue activated (VATs) with DBS) and correlates the acquired data with clinical outcomes to shed light on potential mechanisms of action. Similarly, the spatial transcriptomic analysis was used to identify spatial correlations between gene expression patterns and brain characteristics detected by MRI <sup>19</sup> (in this case, the spatial pattern of functional connectivity) and investigate possible genetic underlying mechanisms. It is important to highlight that previous studies have shown that normative analyses yield results that are similar to the ones observed in patient-specific data <sup>20–22</sup>. In the case of imaging connectomics, normative datasets have been used to create probabilistic models of optimal connectivity associated with patients’ outcomes that are meaningful to predict outcomes in patient-specific connectivity data <sup>21</sup>. Thus, these exploratory data-driven approaches strive to simulate the presumed fingerprint that a particular patient’s individualized DBS intervention might modulate and allows for the investigation of possible mechanisms of action in a large, previously inaccessible cohort of patients whose individual data are available. We improved the Discussion section of the manuscript. We also would like to apologize for the previous Figure 7, which was incorrect. We included the label for the bar plots in the left panel to facilitate the reading of the graph and added the missing result from the KEGG 2021 Human Library that shows the oxytocin signalling pathway.</p><p>Discussion, pg 10, 2nd paragraph:</p><p>“The analysis of functional and structural connectivity via normative datasets is an opportunity to investigate possible underlying mechanisms based on the current knowledge of the typical human brain. Unlike patient-specific studies, where functional MRI and diffusion-weighted images are acquired from a single patient, normative analyses rely on high-quality atlases derived from very large cohorts of healthy subjects (around 1000 brain scans). Thus, these exploratory data-driven approaches are intended to investigate the pattern of brain activity and structural connectivity related to a specific region of interest (i.e. individual VAT) and correlate these data with clinical outcomes to simulate the presumed brain changes associated with DBS treatment. This approach allows for the expansion of the investigation to a large, previously inaccessible cohort of patients whose individual data are available, generating knowledge that can help optimize treatment in future patient populations. Although normative connectivity data may not fully capture patient- or pathology-specific variations, they have been previously shown to generate results that are comparable to patient-specific imaging data 62,63.”</p><p>Discussion, pg 11, 2nd paragraph:</p><p>“The functional connectivity mapping showed that the successful VATs were functionally connected to several key areas within the neurocircuitry of aggressive behaviour, including the amygdala, nucleus accumbens, hypothalamus, periaqueductal gray, and cingulate cortex. To further explore these results, we investigated the relationship between the functional connectivity of each of these brain structures and individual treatment outcomes and observed that functional connectivity with the PAG is the most relevant. In addition, when modelling the functional connectivity of any two brain areas identified in the functional connectivity analysis, we observed that the most relevant connections involved the PAG and limbic structures believed to be at the core of the neurocircuitry of aggressive behaviour, such as the amygdala, anterior cingulate cortex, and nucleus accumbens. In line with our findings, previous studies have shown positive outcomes following ablative and neuromodulation treatments targeting the amygdala, hypothalamus, and nucleus accumbens for the control of aggressive behaviour 1,3,6,67. Moreover, PAG DBS – primarily performed to treat neuropathic pain 68 – has been reported to modulate mood and anxiety 69.</p><p>Discussion, pg 12, 3rd paragraph:</p><p>“A large number of genes identified by the Jensen Compartments and KEGG 2021 Human Libraries are part of biological processes associated with neuronal communication and plasticity, thus possibly linked to the intrinsic mechanism of action of DBS 76,77. As a neuromodulation therapy, DBS induces long-lasting changes in cellular and molecular aspects of neurons belonging to dysfunctional neurocircuitries in order to restore functional normality 12,78,79. Although its neurobiological mechanisms are not fully understood, DBS is believed to exert its effects by altering the cellular membrane potential, resulting in either an increase or a decrease in action potentials 12,78,79. These changes are then propagated throughout neural networks, changing neurotransmitter dynamics, protein expression, and membrane receptor availability 12,78,79. In fact, a previous study using imaging transcriptomics to investigate brain changes after functional neurosurgery of the amygdala in patients with refractory aggressive behaviour has also identified several genes related to neuronal communication and plasticity 1. Preclinical studies have also found significant increases in neural precursor cells, plasticity, and precursor cell markers in animals implanted with DBS, along with significant reductions in the number of activated microglia and astrocytes 80–84. This is in line with the cell type investigation, where a significant reduction in the ratio of genes per cell type was observed for astrocytes and microglia when compared to the expected distribution. Both astrocytes and microglia are highly implicated in mechanisms of neuroinflammation 85, which in turn is associated with several psychiatric disorders 86. The reduction of neuroinflammatory markers (such as glial activation and interleukin levels) has been described in several preclinical DBS studies and is thought to be involved in the mechanism of action of DBS 82,87,88.”</p><disp-quote content-type="editor-comment"><p>10) Data availability. Code used for data processing should be made openly available or shared as source data along with the Figures that were generated using the code. Sweet-spot, structural, and functional connectivity maps should be shared openly.</p></disp-quote><p>All tools and codes necessary for localizing the electrodes, the estimation of the volume of activated tissues, and imaging connectomics analyses are freely available in Lead-DBS (https://www.lead-dbs.org/), a toolbox designed for DBS electrode reconstructions and computer simulations based on postoperative imaging. All codes for spatial transcriptomics are freely available in abagen (https://abagen.readthedocs.io/en/stable/), a toolbox designed for analyzing the Allen Brain Atlas genetics data. Along with the codes, the websites for these tools provide manuals describing the step-by-step procedure for successful analysis. The datasets are freely available at Zenodo (doi: 10.5281/zenodo.7344268). We improved our Data Availability Statement to address this concern.</p><p>Data availability statement, pg 18, 4th paragraph:</p><p>“The codes for electrode localization, modelling of the volume of activated tissue, and imaging connectomics (i.e. functional and structural connectivity) are freely available in Lead-DBS (https://www.lead-dbs.org/). The codes, along with the Allen Human Brain Atlas (AHBA) microarray dataset, for the analysis of spatial transcriptomics are freely available in abagen (https://abagen.readthedocs.io/en/stable/). Along with the codes, the websites for these two toolboxes provide manuals describing the step-by-step procedure for successful analysis. The dataset accompanying this study is freely available at Zenodo (doi: 10.5281/zenodo.7344268).”</p><disp-quote content-type="editor-comment"><p>11) Methods: Given the small number of patients over 5 centers, the authors should better address the similarities and differences of data collection across the sites.</p></disp-quote><p>We added the similarities and differences across sites in the first paragraph of the Results section, as follows:</p><p>Results, section Patients Included, pg 6, 1st paragraph:</p><p>“In all centres, patients were evaluated by a multidisciplinary healthcare team that reviewed all clinical and medication history. Patients were only considered for surgery when a consensus was reached that they indeed presented severe medication-resistant aggressive behaviour (i.e., persistent severe symptomatology despite using multiple medications at well-established doses and duration). Whole-brain T1-weighted MRI was acquired preoperatively for surgical planning (1.5T MRI used in 14 cases at 3 centres, and 3T MRI used in 19 cases at 2 centres). Postoperative brain MRI and/or CT were obtained for electrode localization. Aggressive behaviour was assessed using standard questionnaires conducted by a neuropsychologist and answered by the parents/caregivers in all centres (i.e., Overt Aggressive Behaviour [OAS] used in 3 centres; Modified Overt Aggressive Behaviour [MOAS] used in 1 centre; Inventory for Client and Agency Planning [ICAP] used in 1 centre). Treatment response is reported as the percentage of improvement at the last follow-up relative to baseline (preoperative). Patients presenting more than 30% improvement were considered to be treatment responders.”</p><disp-quote content-type="editor-comment"><p>12) Results: Clinically relevant bundles included somatosensory, emotions, and motor connections. This is pretty much a summary of connections through the hypothalamus and surrounding regions. Do the authors suggest that the effectiveness of DBS in this region is this nonspecific?</p></disp-quote><p>This is a very interesting point. As the VATs are located in the posterior hypothalamus, the only fibres that could be touched by the VATs are the ones that cross the posterior hypothalamus. However, not all the fibres that cross the posterior hypothalamus are relevant for symptom improvement, as our statistical analysis only includes the most relevant fibre tracts. Understanding how symptom improvement and the location of the most efficacious stimulation region correlate with these tracts is important to refine surgical planning, as one could use individual patient tractography before surgery to determine the optimal location of the electrode based on individual fibre tracts. It is worth mentioning, however, that this analysis is excellent for segregating the fibre tracts as relevant or not relevant, but it is not capable of tearing apart the system to determine which of those are necessary for symptom alleviation. This could be done in preclinical settings using opto-or-chemogenetics to selectively inactivate specific fibre tracts and investigate the impact on behaviour and network dynamics. Thus, the structural connectivity analysis presented here contributes to the body of knowledge on the network of aggressive behaviour and provides clinically relevant data that can be useful to improve future patient outcomes. We added a sentence to the Discussion-limitations section of the manuscript addressing this concern, as follows:</p><p>Discussion, pg 13, 3rd paragraph:</p><p>“The structural connectivity analysis performed here provides a detailed overview of the relevant tracts that are related to symptom alleviation in this patient population. However, for precise segregation of these fibre tracts and the determination of those that are necessary for symptom improvement, it would be necessary to perform preclinical experiments to selectively activate/inactivate specific fibre tracts and investigate the impact of these changes on behaviour and network dynamics. Nevertheless, understanding how the location of the most efficacious area of stimulation correlates with these tracts is important for refining the surgical planning of future patients, as one could use individual patient tractography to determine the optimal location of the electrodes based on how it would impact individual fibre tracts.”</p><disp-quote content-type="editor-comment"><p>13) Indeed, it appears that the motor system is most involved based on the tractography. This is consistent with figure 3 in which the 'sweet spot' appears to be lateral to the hypothalamus and more centered in the red nucleus/STN region (Figures 1 and 3).</p></disp-quote><p>Although the structural connectivity mapping revealed tracts involved in motor and sensory information, it also showed tracts known to be involved in the regulation of emotions, such as the MFB, the Amygdalofugal Pathway and the ALIC. As discussed above, it is not possible to determine that motor projections are stronger or more relevant than others as we do not have the means to segregate the influence of each of these tracts in symptom improvement. However, we agree with the reviewer that the engagement of the motor system is indeed highly relevant for the reduction of aggressive behaviours, as we have previously shown that aggressive behaviour is highly correlated with motor agitation <sup>23,24</sup>. Additionally, in the context of ASD, self-injury behaviour is defined as a type of repetitive/stereotypic behaviour that results in physical injury to the patient’s own body. We added a sentence to the Discussion section highlighting the relevance of the motor system. The sweet spot is indeed located at the posterior-inferior-lateral region of the posterior hypothalamic area, reaching the most superior part of the red nucleus, however, not including the STN. It is important to highlight that the voxel-efficacy mapping only shows voxels that are associated with a minimum of 50% symptom improvement following treatment, thus, the areas not touching the red nucleus are also associated with excellent symptom alleviation. We added a new Figure 3—figure supplement 1, to show the localization of these areas in relation to the STN and red nucleus.</p><p>Discussion, pg 10, 3rd paragraph:</p><p>“Structural connectivity analysis in our study implicated fibre tracts involved in somatosensation (e.g. medial lemniscus and spinothalamic tract), emotional regulation (e.g., amygdalofugal pathway and medial forebrain bundle), and motor signalling (e.g., motor projections and central tegmental tract) in the amelioration of aggressive behaviour. Previous studies have shown a significant correlation between aggressive behaviour and motor agitation 5,64, with a concomitant reduction in both following neuromodulatory treatments targeting the posterior hypothalamus 7,37. Indeed, patients with neurodevelopmental disorders, especially those presenting with self-injurious behaviour, are known to frequently have altered sensory perception (including reduced pain sensitivity), which can contribute to the chronicity and severity of the behaviour 1,65. Furthermore, self-injurious behaviours in this patient population are considered to be a type of repetitive/stereotypic behaviour that results in physical injury to the patient’s own body 66,67, highlighting the relevance of the motor system in the network subserving aggressive behaviour. As such, modulation of somatosensory and motor pathways – perhaps leading to increased pain perception or awareness, and reduction in repetitive/stereotypic behaviours – could help reduce self-injurious behaviours. ”</p><p>Discussion section, pg. 10, 1st paragraph:</p><p>“One of the most commonly targeted areas in those series lies along the midpoint of the line between the anterior and posterior commissures (AC-PC line), in a region anterior to the rostral end of the aqueduct, posterior to the anterior border of the mammillary body and superior to the red nucleus 3,34 (Figure 3—figure supplement 1 shows the location of the sweet-spot in relation to the red nucleus and subthalamic nucleus)”</p><disp-quote content-type="editor-comment"><p>(14 &amp; 15) The emphasis on connections on monoamine connections (P. 7) is unwarranted, given the stronger connections to motor regions. Moreover, both DBS and tractography favor myelinated fibers over unmyelinated ones. The monoamines are unmyelinated. Finally, the MFB is a relatively small bundle compared to others in the region that carry motor and sensory information to and from the brainstem. The resolution of tractography is unlikely to distinguish the MFB and favor other fiber tracts. In this regard, the paragraph on P. 9, &quot;functional connectivity…&quot; is confusing. (My understanding is that the authors are linking connections to the amygdala, etc.) via the monoamines. Is that correct? If so, that's a discussion point and not well supported by the connectivity data.</p></disp-quote><p>We would like to apologize for not being clear in the discussion of our findings. Although functional and structural connectivity maps are related, they provide different means of exploring distinct aspects of the connectivity profile of each VAT. While the structural connectivity map may help to explain symptom improvement via direct fibre modulation (i.e. fibres that touch vs fibres that do not touch the VAT), the functional connectivity map investigates the functional dynamics of the network via BOLD signals (functional MRI). In this manuscript, we showed the functional connectivity (not fibre tracts) of the VATs with areas known to regulate monoamine production, such as the Raphe nuclei and the Substantia Nigra. Both serotonin and dopamine are critically involved in the control of aggressive behaviours being the target of the main classes of medications used to treat aggressive behaviours in different patient populations. We improved our Discussion section to address this concern as follows:</p><p>Discussion, pg 11, 2nd paragraph:</p><p>“The functional connectivity mapping showed that the successful VATs were functionally connected to several key areas within the neurocircuitry of aggressive behaviour, including the amygdala, nucleus accumbens, hypothalamus, periaqueductal gray, and cingulate cortex. To further explore these results, we investigated the relationship between the functional connectivity of each of these brain structures and individual treatment outcomes and observed that functional connectivity with the PAG is the most relevant. In addition, when modelling the functional connectivity of any two brain areas identified in the functional connectivity analysis, we observed that the most relevant connections involved the PAG and limbic structures believed to be at the core of the neurocircuitry of aggressive behaviour, such as the amygdala, anterior cingulate cortex, and nucleus accumbens. In line with our findings, previous studies have shown positive outcomes following ablative and neuromodulation treatments targeting the amygdala, hypothalamus, and nucleus accumbens for the control of aggressive behaviour 1,3,6,67. Moreover, PAG DBS – primarily performed to treat neuropathic pain 68 – has been reported to modulate mood and anxiety 69.</p><p>Another aspect detected by the functional connectivity analysis was the involvement of areas responsible for the production of serotonin (i.e., raphe nuclei) and dopamine (i.e., substantia nigra). Both these monoamines are thought to be directly involved in the initiation and maintenance of aggressive behaviours due to their role in facilitating top-down inhibitory controls, regulating mood, and mediating social behaviours 3,7,70. Antipsychotics (both typical and atypical) and selective serotonin reuptake inhibitors – the most commonly used drugs to control of aggressive behaviours – act on the dopaminergic and serotonergic neurotransmission systems 1,3. In a mouse model of escalated aggression, pHyp-DBS increased the density of serotonin receptors type 1A (5-HT1A) in the orbitofrontal cortex and amygdala, while pretreatment with a 5-HT1A antagonist countered the anti-aggressive effect of stimulation 71.”</p><disp-quote content-type="editor-comment"><p>16 &amp; 17) Other comments: The introduction lacks clear text referring to the organization and connections of the hypothalamus based on classic literature. Examples. First, the authors described the division into 3 regions: anterior, medial, and posterior (reference is the author's article in neurosurgery. Then, without reference to these three regions, describe preclinical studies of the lateral and ventromedial hypothalamus. How do these two areas relate to the three regions?</p></disp-quote><p>We improved the Introduction section to better describe the anterior-posterior subdivision of the hypothalamus, as follows:</p><p>Introduction, pg 4, 2nd paragraph:</p><p>“The hypothalamus is a diencephalic structure with well-established roles in the control of homeostasis and motivated behaviours and is a key area in a broader neurocircuitry regulating aggressive behaviour that also involves the orbitofrontal cortex, hippocampus, amygdala and periaqueductal gray 24–26. Along the anterior-posterior axis, the hypothalamus can be divided into three regions (i.e. supraoptic or anterior, tuber cinereum or medial and supramamillary or posterior) with distinct cell types, projections and functions 24,27. While the anterior region is mainly involved in thermoregulation and the control of circadian rhythms, the medial region regulates feeding and sexual behaviour and plays a critical role in several endocrine and autonomic processes 24,28,29. The posterior hypothalamus (pHyp) is an ergotropic area involved in the generation of sympathetic responses 30. It provides robust projections to the midbrain and reticular formation via the hypothalamotegmental tract, thus being critical in the regulation of wakefulness and stress responses 27,31,32. Indeed, lesions (e.g., hamartomas and gliomas) located at the pHyp have been reported to cause apathetic and somnolent symptoms, while the selective neurosurgical ablation of a small portion of the pHyp has been successfully used to treat patients with severe treatment-resistant aggressive behaviour (for a detailed review, see Gouveia et al. 2019 3,33,34). More recently, DBS of the pHyp (pHyp-DBS) has also been shown to reduce aggressive symptoms in humans, with variable outcomes 7–10,35–37.”</p><p>References:</p><p>1. Gunalan, K., Howell, B. &amp; McIntyre, C. C. Quantifying axonal responses in patient-specific models of subthalamic deep brain stimulation. Neuroimage 172, 263–277 (2018).</p><p>2. Dembek, T. A. et al. Probabilistic mapping of deep brain stimulation effects in essential tremor. Neuroimage Clin 13, 164–173 (2017).</p><p>3. Kuncel, A. M., Cooper, S. E. &amp; Grill, W. M. A method to estimate the spatial extent of activation in thalamic deep brain stimulation. Clin. Neurophysiol. 119, 2148–2158 (2008).</p><p>4. Mädler, B. &amp; Coenen, V. A. Explaining clinical effects of deep brain stimulation through simplified target-specific modeling of the volume of activated tissue. AJNR Am. J. Neuroradiol. 33, 1072–1080 (2012).</p><p>5. Elias, G. J. B. et al. Probabilistic Mapping of Deep Brain Stimulation: Insights from 15 Years of Therapy. Ann. Neurol. 89, 426–443 (2021).</p><p>6. Germann, J. et al. Brain structures and networks responsible for stimulation-induced memory flashbacks during forniceal deep brain stimulation for Alzheimer’s disease. Alzheimers. Dement. 17, 777–787 (2021).</p><p>7. Elias, G. J. B. et al. Mapping the network underpinnings of central poststroke pain and analgesic neuromodulation. Pain 161, 2805–2819 (2020).</p><p>8. Gouveia, F. V. et al. Case report: 5 Years follow-up on posterior hypothalamus deep brain stimulation for intractable aggressive behaviour associated with drug-resistant epilepsy. Brain Stimul. 14, 1201–1204 (2021).</p><p>9. Coblentz, A. et al. Mapping efficacious deep brain stimulation for pediatric dystonia. J. Neurosurg. Pediatr. 27, 346–356 (2021).</p><p>10. M Oliveira, L. et al. Probabilistic characterisation of deep brain stimulation in patients with tardive syndromes. J. Neurol. Neurosurg. Psychiatry (2021) doi:10.1136/jnnp-2020-324270.</p><p>11. Horn, A. et al. Connectivity Predicts deep brain stimulation outcome in Parkinson disease. Ann. Neurol. 82, 67–78 (2017).</p><p>12. Duffley, G., Anderson, D. N., Vorwerk, J., Dorval, A. D. &amp; Butson, C. R. Evaluation of methodologies for computing the deep brain stimulation volume of tissue activated. J. Neural Eng. 16, 066024 (2019).</p><p>13. Astrom, M., Diczfalusy, E., Martens, H. &amp; Wardell, K. Relationship between neural activation and electric field distribution during deep brain stimulation. IEEE Trans. Biomed. Eng. 62, 664–672 (2015).</p><p>14. Hawrylycz, M. J. et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 489, 391–399 (2012).</p><p>15. Arnatkeviciute, A., Fulcher, B. D. &amp; Fornito, A. A practical guide to linking brain-wide gene expression and neuroimaging data. Neuroimage 189, 353–367 (2019).</p><p>16. Arnatkeviciute, A., Markello, R. D., Fulcher, B. D., Misic, B. &amp; Fornito, A. Toward Best Practices for Imaging Transcriptomics of the Human Brain. Biol. Psychiatry 93, 391–404 (2023).</p><p>17. Markello, R. D. et al. Standardizing workflows in imaging transcriptomics with the abagen toolbox. e<italic>Life</italic> 10, (2021).</p><p>18. Seidlitz, J. et al. Transcriptomic and cellular decoding of regional brain vulnerability to neurogenetic disorders. Nat. Commun. 11, 3358 (2020).</p><p>19. Fornito, A., Arnatkevičiūtė, A. &amp; Fulcher, B. D. Bridging the Gap between Connectome and Transcriptome. Trends Cogn. Sci. 23, 34–50 (2019).</p><p>20. Arnatkeviciute, A., Fulcher, B. D., Bellgrove, M. A. &amp; Fornito, A. Imaging Transcriptomics of Brain Disorders. Biol Psychiatry Glob Open Sci 2, 319–331 (2022).</p><p>21. Wang, Q. et al. Normative vs. patient-specific brain connectivity in deep brain stimulation. Neuroimage 224, 117307 (2021).</p><p>22. Elias, G. J. B. et al. Normative connectomes and their use in DBS. in Connectomic Deep Brain Stimulation 245–274 (Elsevier, 2022).</p><p>23. Gouveia, F. V. et al. Bilateral Amygdala Radio-Frequency Ablation for Refractory Aggressive Behavior Alters Local Cortical Thickness to a Pattern Found in Non-refractory Patients. Front. Hum. Neurosci. 15, 653631 (2021).</p><p>24. Venetucci Gouveia, F. et al. Case report: 5 Years follow-up on posterior hypothalamus deep brain stimulation for intractable aggressive behaviour associated with drug-resistant epilepsy. Brain Stimul. (2021) doi:10.1016/j.brs.2021.07.062.</p><p>25. Gouveia, F. V. et al. Amygdala and Hypothalamus: Historical Overview With Focus on Aggression. Neurosurgery 85, 11–30 (2019).</p><p>26. Gouveia, F. V. et al. Longitudinal Changes After Amygdala Surgery for Intractable Aggressive Behavior: Clinical, Imaging Genetics, and Deformation-Based Morphometry Study-A Case Series. Neurosurgery 88, E158–E169 (2021).</p><p>27. Yan, H. et al. Deep brain stimulation for extreme behaviors associated with autism spectrum disorder converges on a common pathway: a systematic review and connectomic analysis. J. Neurosurg. 1–10 (2022).</p><p>28. Knotkova, H. et al. Neuromodulation for chronic pain. Lancet 397, 2111–2124 (2021).</p><p>29. Gray, A. M. et al. Deep brain stimulation as a treatment for neuropathic pain: a longitudinal study addressing neuropsychological outcomes. J. Pain 15, 283–292 (2014).</p><p>30. Miczek, K. A., Fish, E. W., De Bold, J. F. &amp; De Almeida, R. M. M. Social and neural determinants of aggressive behavior: pharmacotherapeutic targets at serotonin, dopamine and γ-aminobutyric acid systems. Psychopharmacology 163, 434–458 (2002).</p><p>31. Gouveia, F. V. et al. Reduction of aggressive behaviour following hypothalamic deep brain stimulation: involvement of 5-HT1Aand testosterone. bioRxiv (2023) doi:10.1101/2023.03.20.533520.</p></body></sub-article></article>